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ABSTRACT 
Mitochondria contain a 16.6 kb circular genome encoding 13 proteins as well as 
mitochondrial tRNAs and rRNAs. Copies of the genome are organized into nucleoids 
containing both DNA and proteins, including the machinery required for mtDNA 
replication and transcription. Although mtDNA integrity is essential for cellular and 
organismal viability, regulation of proliferation of the mitochondrial genome is poorly 
understood. To elucidate the mechanisms behind this, we chose to study the interplay 
between mtDNA copy number and the proteins involved in mitochondrial fusion, another 
required function in cells. Strikingly, we found that mouse embryonic fibroblasts lacking 
fusion also had a mtDNA copy number deficit. To understand this phenomenon further, we 
analyzed the binding of mitochondrial transcription factor A, whose role in transcription, 
replication, and packaging of the genome is well-established and crucial for cellular 
maintenance. Using ChIP-seq, we were able to detect largely uniform, non-specific binding 
across the genome, with no occupancy in the known specific binding sites in the regulatory 
region. We did detect a single binding site directly upstream of a known origin of 
replication, suggesting that TFAM may play a direct role in replication. Finally, although 
TFAM has been previously shown to localize to the nuclear genome, we found no evidence 
for such binding sites in our system. 
To further understand the regulation of mtDNA by other proteins, we analyzed 
publicly available ChIP-seq datasets from ENCODE, modENCODE, and mouseENCODE 
for evidence of nuclear transcription factor binding to the mitochondrial genome. We 
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identified eight human transcription factors and three mouse transcription factors that 
demonstrated binding events with the classical strand asymmetrical morphology of 
classical binding sites. ChIP-seq is a powerful tool for understanding the interactions 
between proteins and the mitochondrial genome, and future studies promise to further the 
understanding of how mtDNA is regulated within the nucleoid. 
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C h a p t e r  1  
INTRODUCTION 
I. Background 
Mitochondria most likely arose as a result of an endosymbiotic event (Sagan 1967) 
between the ancestor of modern eukaryotes and a member of the α-proteobacteria clade 
(Yang, Oyaizu et al. 1985), and are now present in all known species of eukaryotes. In 
modern eukaryotes, mitochondria serve as the epicenter of oxidative phosphorylation, 
which utilizes the ETC to create a proton gradient across the inner mitochondrial 
membrane to drive production of ATP using ATP synthase. Thus, mitochondria containing 
functional metabolic machinery are necessary for cellular survival. Interestingly, reflective 
of the organelle's prokaryotic ancestry, mitochondria retain their own circular DNA 
genome (Nass, Nass et al. 1965, van Bruggen, Borst et al. 1966), although its size has been 
greatly reduced in many eukaryotes through transfer of genes to the nucleus. In present-day 
eukaryotes, transcription and translation of the nuclear components of the mitochondrial 
proteome occurs in the nucleus and cytoplasm, respectively, and the components are then 
imported into the mitochondrial to modulate organellar function. These components 
include that of the separate mitochondrial transcription, replication and regulatory 
machineries, a number of which retain evidence of their prokaryotic origin (Szklarczyk and 
Huynen 2010). Given the relatively simple architecture as well as its importance for the 
cell, mtDNA has been extensively studied for much of the 50 years since its discovery. 
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However, although we now have some understanding of how some processes modulate 
mtDNA integrity, much still remains to be understood about the dynamics of the processes 
underlying these phenotypes. 
 
The mitochondrial genome is an essential component of eukaryotic cells 
mtDNA was first visualized by electron microscopy in chick embryos, a finding 
that was biochemically confirmed by the finding of DNA in the highly purified 
mitochondria in the eukaryotes Neurospora crassa and S. cerevisiae (Luck and Reich 1964, 
Schatz, Haslbrunner et al. 1964). In humans, the 16.6kb mitochondrial genome only 
encodes for 13 proteins, as well as the 22 mitochondrial tRNAs and 2 mitochondrial 
rRNAs (Anderson, Bankier et al. 1981). However, these products are necessary and 
required for the organelle’s bioenergetics functions because the proteins, translated using 
the encoded tRNAs and rRNAs, are essential components of the ETC. Remarkably, 
although the mitochondrial genome only encodes for 27 products, mass spectrometry 
analysis of the S. cerevisiae mitochondrial proteome has identified approximately 25% of 
the 1100 proteins that are imported into mitochondria as being involved in the maintenance 
of mtDNA (Sickmann, Reinders et al. 2003), highlighting the importance of the genome. 
It was clear from the first that there were many copies of mtDNA per cell, far 
beyond that of the nuclear genome. While some initial studies involved lengthy 
purification of mitochondria followed by quantification of DNA yield, at great risk of 
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nuclear contamination (Borst and Kroon 1969, Nass 1969), more successful quantitative 
analysis of copy number was performed utilizing thymidine kinase-negative HeLa cells, 
which selectively incorporate thymidine into mtDNA. This analysis yielded an estimate 
of 8800mtDNA/HeLa cell (Bogenhagen and Clayton 1974). Later experiments by Satoh 
and Kuroiwa in A2780 ovarian carcinoma cells first utilized visualization of mtDNA, 
through DAPI staining, to effect quantification, using a video-intensified photon counting 
microscope system, or VIM system. The VIM system was utilized to enhance the low 
signal intensity of the mtDNA staining, and also to allow for quantitation of the mtDNA 
by photon counting, using the T4 phage genome as a benchmark. Using this method, 
about 500 mtDNA copies per cell were counted (Satoh and Kuroiwa 1991). 
Quantification utilizing other techniques, such as Southern blot (Shmookler Reis and 
Goldstein 1983, Tang, Schon et al. 2000), ethidium bromide staining (Iborra, Kimura et 
al. 2004), and qPCR (Legros, Malka et al. 2004, Wai, Ao et al. 2010, Brown, Tkachuk et 
al. 2011), has resulted in a known range of copy numbers per human cell from the 
hundreds to hundreds of thousands (Garrido, Griparic et al.). 
Although cells exhibit a range of mtDNA levels, it is clear that mtDNA copy 
number is far in excess to that of nuclear DNA. In order to replicate the large number of 
copies required in time for cell division (as well as drive the closely linked transcription 
of the genome), while nuclear DNA replication is tightly timed via the cell cycle, mtDNA 
replication occurs constantly (Bogenhagen and Clayton 1977, Magnusson, Orth et al. 
2003), with some peaks at S and G2 (Lee, Kim et al. 2007, Chatre and Ricchetti 2013). 
However, mtDNA copy number within cells is tightly controlled, albeit by largely 
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uncharacterized mechanisms (Clay Montier, Deng et al. 2009). While cells requiring low 
amounts of energy, such as spleen and endothelial cells, consistently maintain a low copy 
number, cells requiring high levels of ATP, such as neurons and muscle cells, 
consistently exhibit relatively high levels of mtDNA (Williams 1986, Moyes, Battersby 
et al. 1998). Cells thus regulate mtDNA copy number in order to meet energy needs, and 
the requirement for such tight regulation becomes evident when observing the effects of 
loss of effective mtDNA copy number in cells and organisms. 
 
Pathologies of mtDNA instability 
When effective mtDNA copy number is perturbed, whether through mutation, 
depletion, or deletion, an expected phenotype is not always observed. This is due to a 
unique quality of mitochondrial disorders resulting from mutations or deletions in the 
genome: the phenotypic “threshold effect.” (Rossignol, Faustin et al. 2003) The number 
of genomes per cell can number between the hundreds and the thousands (Bogenhagen 
and Clayton 1974, Satoh and Kuroiwa 1991), leading to a large number of templates from 
which transcription and translation may take place. Furthermore, mitochondria constantly 
exchange their contents through fusion and fission. Thus, there is enough wild-type 
protein product distributed across mitochondria to maintain normal function until a 
certain threshold of mutated DNA is reached, upon which there is a precipitous decline in 
a number of measures of mitochondrial activity, such as respiration rates, ATP 
production, or phenotype of interest (Rossignol, Faustin et al. 2003, Chen, Chomyn et al. 
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2005). This threshold has been assayed in culture both by analysis of cybrids containing 
varying levels of mtDNA mutations as well as by analyzing primary patient samples. For 
example, in cells containing the A8344G tRNALeu mutation causing MERRF, respiration 
was found to be impacted only when mutant mtDNA levels were between 85-95% of the 
total mtDNA per cell (Shoffner, Lott et al. 1990, Zhou, Chomyn et al. 1997, Moslemi, 
Tulinius et al. 1998), values typical of that found with other mtDNA mutations, with the 
usual range being between 60-95% (Rossignol, Faustin et al. 2003). 
While the phenotypic threshold effect means that any single mtDNA mutation 
event does not lead to pathology, the accumulation of these mutations has significant 
phenotypic effects. Inherited mtDNA mutations lead to cellular respiratory defects, 
typically in the tissues with the highest rate of aerobic metabolism. This results in the 
phenotypes of neuromuscular impairment, movement disorders, myopathy, eye disorders, 
and other systemic manifestations, albeit often with high symptom variability between 
patients with the same mutation (Zeviani and Di Donato 2004). For example, a point 
mutation in tRNAleu (Goto, Nonaka et al. 1990, DiMauro and Schon 2003), A3243G, can 
cause the symptoms associated with multiple disorders, such as mitochondrial 
encephalomyopathy with lactic acidosis and stroke-like episodes, progressive external 
ophthalmoplegia, isolated myopathy, or cardiomyopathy (Chinnery and Turnbull 1999, 
Leonard and Schapira 2000). Such heterogeneity in phenotype of a single mutation is 
primarily postulated to be due to differential heteroplasmy between tissues in individuals 
resulting from unequal segregation upon mitosis (Lombes, Aure et al. 2014).  
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Damage or depletion of mtDNA may also causes numerous inherited disorders, 
including Alpers’ Disease, ataxia neuropathy spectrum, progressive external 
ophthalmoplegia, and mitochondrial depletion syndrome (Suomalainen and Isohanni 
2010, Stumpf, Saneto et al. 2013). Furthermore, loss and damage to mtDNA has been 
implicated in cardiovascular disease (Sugiyama, Hattori et al. 1991, Ide, Tsutsui et al. 
2001, Karamanlidis, Nascimben et al. 2010, Karamanlidis, Bautista-Hernandez et al. 
2011), diabetes (Maassen, LM et al. 2004, Simmons, Suponitsky-Kroyter et al. 2005, 
Gauthier, Wiederkehr et al. 2009), neurodegenerative disorders such as Alzheimer’s 
(Coskun, Beal et al. 2004, Coskun, Wyrembak et al. 2012, Rice, Keeney et al. 2014), and 
aging (Corral-Debrinski, Shoffner et al. 1992, Trifunovic and Larsson 2008). Strikingly, a 
~40% increase in mtDNA copy number in aging transgenic mice overexpressing human 
transcription factor A leads to significantly improved motor learning memory as assayed 
by latency to fall on the rotorod test, and to improved working memory as measured by 
the number of errors during the radial arm water maze (Ikeuchi, Matsusaka et al. 2005, 
Hayashi, Yoshida et al. 2008). Similar promotion of cell survival or function has been 
seen with increasing mtDNA copy number in other models of disease associated with 
decreased mtDNA abundance, such as diabetes (Suarez, Hu et al. 2008, Gauthier, 
Wiederkehr et al. 2009), Alzheimer’s (Xu, Zhong et al. 2009), and Parkinson’s (Keeney, 
Quigley et al. 2009, Piao, Kim et al. 2012), demonstrating the strong relationship between 
defective mtDNA copy number and pathology. Considering that loss of mtDNA leads to 
pathology, it is critical to understand how mtDNA copy number and integrity are 
maintained. 
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Organization of the Mitochondrial Genome 
Because mtDNA is relatively simply organized, the genome has been studied 
extensively. Mitochondrial genes are densely packed along the genome, with the notable 
exception of the non-coding D-loop (Tang, Schon et al. 2000), which is located within the 
~1kb NCR. Transcription initiates in the D-loop, is carried out by the mitochondrial-
specific RNA polymerase POLRMT, and results in long polycistronic transcripts on each 
strand (the H-strand and the L-strand), from the light strand promoter LSP and two heavy 
strand promoters, HSP1 and HSP2 (Cantatore and Attardi 1980, Montoya, Christianson et 
al. 1982). The D-loop also contains two putative origins of leading strand replication (OH 
and Ori-b), while another putative origin of replication, the lagging strand origin of 
replication (OL), is located downstream of the ND2 ORF (Crews, Ojala et al. 1979, 
Clayton 1982, Yasukawa, Yang et al. 2005). Thus, the D-loop is considered the primary 
regulatory region of the mitochondrial genome. 
Given the 16.6 kb size of the human mitochondrial genome, which translates to 
approximately 5µm in diameter, and that mitochondria are only ~2µm in diameter, it was 
predicted that mtDNA would be compacted by a specific mechanism in order to pack into 
the mitochondrial matrix, a task presumably performed by proteins. The first visualization 
of mtDNA localized to discrete loci within mitochondria was through DAPI staining of 
HeLa cells (Satoh and Kuroiwa 1991). Subsequent experiments utilizing PicoGreen, EtBr, 
BrdU, and FISH for detection of DNA have confirmed this finding (Davis and Clayton 
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1996, Bereiter-Hahn and Vöth 1997, Margineantu, Gregory Cox et al. 2002, Alam, Kanki 
et al. 2003, Garrido, Griparic et al. 2003, Magnusson, Orth et al. 2003, Gilkerson, Schon et 
al. 2008). Use of super-resolution microscopy, including STED, STORM, and PALM, has 
allowed for measurement of the nucleoid at ~100nm in mammals using fluorescently 
labeled TFAM, or anti-DNA, anti-TFAM, or anti-BrdU immunostaining (Brown, Tkachuk 
et al. 2011, Kukat, Wurm et al. 2011). Subtracting the volume of the antibodies used in 
labeling, the final diameter of each nucleoid is estimated to be ~70nm – amenable to the 
mitochondrial matrix. 
Quantification of mtDNA copy number as discussed previously, in conjunction 
with immunocytochemistry, has yielded estimates of 1 – 10 copies of nucleoids per cell in 
various cell types (Satoh and Kuroiwa 1991, Cavelier, Johannisson et al. 2000, Iborra, 
Kimura et al. 2004, Legros, Malka et al. 2004, Gilkerson, Schon et al. 2008). The first 
estimate of mtDNA/nucleoid in human cells, using DAPI staining in A2780 cells, used the 
assumption of a stepwise function of fluorescence intensity per mtDNA molecule to 
estimate copy number in each nucleoid, and found an average of 1.4 genomes per nucleoid, 
or about 4.6 mtDNA per organelle (Satoh and Kuroiwa 1991). However, this study, as well 
as subsequent papers using this technique as well as studies estimating by dividing average 
copy number per cell by average nucleoid number per cell, have all suffered from problems 
stemming from the detection limit for nucleoids in immunocytochemistry. Using STED, 
which detects ~1.6-fold more nucleoids due to increased sensitivity beyond that of the 
detection limit of conventional confocal microscopy, it has been estimated that there are an 
average of 1.4 genomes per nucleoid in human primary fibroblasts, meaning that the 
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majority of nucleoids contain only one genome (Kukat, Wurm et al. 2011). Calculations in 
3T3 mouse fibroblast cells have estimated that nucleoids occupy an average of 8.3 x 105 
nm3 (Brown, Tkachuk et al. 2011). Given that Brown et al. estimates that each nucleoid 
contains 3 mtDNAs, only 6.3% of the volume of each nucleoid is composed of DNA; the 
remainder is occupied by protein. Thus, the vast majority of the mitochondrial nucleoid is 
composed of the proteins that may modulate and interact with the mitochondrial genome. 
 
The Protein Components of the Mitochondrial Nucleoid 
Eukaryotic cellular viability is dependent upon the proliferation of mitochondria 
and of its essential genome, which must be replicated constantly so that the copy number 
per cell may roughly double in order to be ready for cell division (Magnusson, Orth et al. 
2003). It is safe to presume that such activities are effected by proteins that associate with 
the genome. Due to analogous paradigms of the yeast mtDNA as well as the ancestral 
bacterial nucleoid (Delius and Worcel 1974), it was long postulated that proteins would 
associate with the mammalian nucleoid. However, while mtDNA-protein complexes had 
been purified previously (Barat, Rickwood et al. 1985), it was only ten years after the first 
visualization of mtDNA puncta within cells that proteins were visually localized to the 
nucleoids, when an eGFP-tagged form of the mitochondrial helicase Twinkle was found to 
colocalize with an anti-DNA antibody (Spelbrink, Li et al. 2001). Soon afterward, TFAM, 
mtSSB, and POLG/POLG2 were also identified as components of the nucleoid via 
colocalization with Twinkle-eGFP and with BrdU incorporation (Garrido, Griparic et al. 
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2003). The particularly strong interactions between TFAM and mtSSB and mtDNA have 
been exploited in order to further identify other proteins associated with the nucleoids in 
HeLa cells via immunoprecipitation followed by mass spectrometry (Wang and 
Bogenhagen 2006), or by formaldehyde crosslinking, sedimentation, and fractionation, 
followed by liquid chromatography-tandem mass spectrometry (Bogenhagen, Rousseau et 
al. 2008), yielding more large-scale identification of associated proteins. From this data, 
Bogenhagen et al. have proposed a “layered” model of protein organization within the 
nucleoid, where the “core” proteins (e.g., TFAM, mtSSB, TFB1M, TFB2M, mTERF), 
which were identified via both the immunoaffinity and the harsher formaldehyde methods, 
are tightly associated with the nucleoid, and are surrounded by more loosely-associated 
nucleoid proteins which were not captured by the formaldehyde method (e.g., HSP60, 
PHB1/2, ATAD3A). 
 In addition to the proteins identified by Bogenhagen et al., a majority of which can 
be related directly to maintenance and regulation of mtDNA and its associated proteins, 
further studies of mitochondrial proteins have identified a number that colocalize to 
nucleoids by immunocytochemistry. While mtRNA polymerase, TFB1M, TFB2M, 
mTERF1, topoisomerase 1 and Twinkle, all members of the transcription machinery, were 
identified by Bogenhagen et al., mTERF2 and mTERF3 have separately been identified as 
binding to the genome (Park, Asin-Cayuela et al. 2007, Pellegrini, Asin-Cayuela et al. 
2009). Other classes of proteins, such as helicases (Wang, Shu et al. 2009, Szczesny, 
Borowski et al. 2010), RNA binding proteins (Sondheimer, Fang et al. 2010), chaperone 
proteins (Kaufman, Kolesar et al. 2003), proteases (Fu and Markovitz 1998), ribosomal 
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proteins (Rorbach, Richter et al. 2008), enzymes involved in lipid metabolism (Wang and 
Bogenhagen 2006, Bogenhagen, Rousseau et al. 2008), and even cytoskeletal attachment 
proteins (Reyes, He et al. 2011), have been identified as associating with the nucleoid. It 
requires little stretch of the imagination to postulate about the function of the localization 
some of these protein classes, such as RNA binding proteins and ribosomal proteins, to the 
nucleoid. However, the purpose of the enzymes involved in lipid metabolism and 
cytoskeletal attachment proteins, for example, is less obvious and remains an area to be 
explored. Interestingly, the proteins PHB1 (Kasashima, Sumitani et al. 2008) and 
ATAD3A (He, Mao et al. 2007, Holt, He et al. 2007), found at the periphery of the 
nucleoid, have already been implicated in mtDNA stability and nucleoid morphology, 
although the exact mechanisms still remain to be explored. 
 While the methods of protein-associated nucleoid identification described above 
have most probably identified the most common proteins found in the nucleoid, less 
abundant and more transiently associated proteins are more difficult to capture. One such 
set of proteins that has been identified as associating with mtDNA through other methods is 
the canonically nuclear transcription factors, a few of which may directly interact with 
mtDNA. The first such transcription factors identified were GR, p53, and p43, which were 
shown to localize to within mitochondria (Demonacos, Tsawdaroglou et al. 1993, Caelles, 
Helmberg et al. 1994, Wrutniak, Cassar-Malek et al. 1995). However, it was not until later, 
when new techniques for elucidating in vivo binding of proteins to DNA, that the 
mitochondrial roles of these transcription factors, independent of nuclear effect, could be 
determined. For example, CREB is present in mitochondrial fractions following subcellular 
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subfractionation, localizes to the mitochondria via immunoelectron microscopy 
(Cammarota, Paratcha et al. 1999), and has been shown to be imported into isolated rat 
liver mitochondria via the TOM translocation complex with mtHSP70 as an associated 
chaperone (Lee, Kim et al. 2005, De Rasmo, Signorile et al. 2009), providing compelling 
evidence for mitochondrial localization. Furthermore, expression of a mitochondrially 
targeted form of CREB results in increased expression of the ND2, ND4, and ND5 on the 
genome; conversely, a dominant negative form of CREB decreases expression of the 
mitochondrial genes and causes a concomitant decrease in ETC complex I activity (Lee, 
Kim et al. 2005), suggesting that CREB independently modulates expression of the 
mtDNA. Finally, in vivo ChIP and in vitro footprinting data have shown that CREB binds 
to three predicted binding sites in the D-loop (Lee, Kim et al. 2005). Similar verification of 
correct localization, independent mitochondrial modulation, and mtDNA-specific binding 
has also been shown for p43 (Wrutniak, Cassar-Malek et al. 1995, Enriquez, Fernandez-
Silva et al. 1999, Fernandez-Vizarra, Enriquez et al. 2008), ERα/β (Casas, Rochard et al. 
1999, Monje and Boland 2001, Chen, Delannoy et al. 2004, Jazbutyte, Kehl et al. 2009, 
Milanesi, Vasconsuelo et al. 2009), and p53 (Heyne, Mannebach et al. 2004, Achanta, 
Sasaki et al. 2005), with some evidence for mitochondrial-specific action by STAT3 
(Wegrzyn, Potla et al. 2009). Such modulation of both mitochondrial and nuclear genomes 
could be favorable, allowing the cell to simultaneously regulate both genomes in response 
to a single stimulus. Nonetheless, it is apparent that interactions between the mitochondrial 
genome and canonically nuclear transcription factors are not unprecedented, and are 
phenomena whose implications remain to be fully understood. 
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TFAM is a Site-Specific Mitochondrial Transcription Factor 
Of the many proteins identified to date as interacting with the mitochondrial 
genome, the HMG-box containing protein TFAM is the most abundant, best characterized, 
and arguably one of the most crucial. Because of the prokaryotic origin of mitochondria, 
TFAM is particularly important due to its role not only in its site-specific role as a 
transcription factor, but also in its nonspecific, “scaffolding” capabilities in the nucleoid. 
Clues as to the function of TFAM come from the ancestral prokaryotic and fungal systems. 
Bacterial chromosomes such as that of E. coli , which spans 4.6 million bp, lack the 
sophisticated histone-based organization of eukaryotic nuclear genomes. Instead, a class of 
proteins called NAPs, such as HU and IHF, distribute across the genome and effect an 
architectural role, performing the compacting function required to fit the genome within the 
cell and forcing DNA into a 160° turn (Rice, Yang et al. 1996, Mouw and Rice 2007, 
Dillon and Dorman 2010). The HU family of proteins, in particular, may further compact 
the genome via its ability to dimerize with itself (Rice, Yang et al. 1996). The first protein 
in eukaryotes found to have a similar function was the yeast Abf2p, an HMG box family 
protein which was found to localize to mitochondria, to be required for mtDNA integrity 
(Diffley and Stillman 1991), and to bind to DNA with a footprint of ~27bp (Diffley and 
Stillman 1992). In addition, AFM of Abf2p in conjunction with DNA has shown that 
Abf2p packages and compacts DNA (Brewer, Friddle et al. 2003). The mammalian 
ortholog of Abf2p is TFAM, which has a role not only in the packaging of mtDNA similar 
to that of the NAPs and Abf2p, but also in mitochondrial transcription. 
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TFAM, which consists of two DNA-binding HMG boxes separated by a linker 
and followed by a C-terminal tail, was first purified and identified by Fisher and Clayton 
(Fisher and Clayton 1985, Fisher and Clayton 1988, Parisi and Clayton 1991). The 
transcriptional function of TFAM relies on its binding specifically to the LSP and HSP 
promoter regions of the D-loop, where the HSP1, HSP2, and LSP transcripts originate. 
Initial DNase I footprinting experiments revealed that TFAM bound preferentially to a 
region close to the LSP transcription start site, in a part of the promoter sequences that 
was found by systemic deletional analysis to be necessary for augmented efficiency of 
transcriptional initiation (Chang and Clayton 1984). TFAM was also localized to the 
HSP1 promoter, yielding a ~20-30 bp footprint at -12 to -39 of the respective 
transcription start sites (Fisher and Clayton 1988); no footprint upstream of the HSP2 
start site has been detected to date. Interestingly, there is significant homology between 
the primary binding sites of TFAM, LSP and HSP1, only when the HSP1 sequence is 
inverted in direction, suggesting that TFAM must either act bidirectionally, or bend 
~180° to contact the polymerase at either LSP or HSP. Finally, a single, specific TFAM 
binding site has been localized in rat mtDNA upstream of the OL (Gadaleta, D'Elia et al. 
1996, Cingolani, Capaccio et al. 1997, Pierro, Capaccio et al. 1999), and is postulated to 
tie into the role of TFAM in replication. 
The classic view of the minimal mtDNA transcriptional machinery is that it 
contains three essential components: TFAM, POLRMT, and TFB2M. Although it is a 
homolog of the self-initiating prokaryotic T7 RNA polymerase, the mitochondria-specific 
POLRMT cannot initiate transcription on its own. Indeed, purified TFAM and POLRMT 
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together are also insufficient to activate transcription in in vitro experiments (Falkenberg, 
Gaspari et al. 2002). However, transcription can be reconstituted using purified TFAM 
and a partially purified mitochondrial fraction containing POLRMT, indicating that a 
protein associated with POLRMT is also required for activation (Falkenberg, Gaspari et 
al. 2002). This observation led to the identification of TFB1M and TFB2M, which have 
significant homology to the yeast essential transcription factor MTF1 as well as the 
prokaryotic rRNA dimethyltransferases. While both TFB1M and TFB2M, in the presence 
of both TFAM and POLRMT, were able to induce in vitro transcription in a run-off 
assay, TFB2M produced ~10-fold greater transcript levels (Falkenberg, Gaspari et al. 
2002, Litonin, Sologub et al. 2010). Given the stronger homology of TFB1M to the 
bacterial rRNA dimethyltransferases, it was hypothesized that while TFB1M could 
partially supplant the role of TFB2M as a transcription factor as necessary, its primary 
role is in 12S rRNA methylation needed for translation. The hypothesized far stronger 
methyltransferase activity of TFB1M would later be demonstrated to be indeed correct in 
vitro (Seidel-Rogol, McCulloch et al. 2003, Cotney and Shadel 2006) as well as in 
drosophila, mouse, and human systems (Matsushima, Garesse et al. 2004, Matsushima, 
Adan et al. 2005, Cotney, Wang et al. 2007, Cotney, McKay et al. 2009, Metodiev, Lesko 
et al. 2009).  
A commonly accepted theory of transcriptional initiation involves initial site-
specific binding of TFAM to a locus in the promoter. The sharp U-turn that TFAM 
induces in DNA aligns its C-terminal tail to the transcriptional machinery (Ngo, Kaiser et 
al. 2011, Rubio-Cosials, Sidow et al. 2011, Ngo, Lovely et al. 2014), and the 
   
 
16
POLRMT/TFB2M complex, which also maintains some site-specific recognition 
(Falkenberg, Gaspari et al. 2002, Gaspari, Larsson et al. 2004, Shi, Dierckx et al. 2012), 
is then recruited to the TFAM binding site, causing initiation of transcription. Beyond 
direct biochemical evidence discussed previously, this view of initiation is supported by 
several pieces of evidence. First, mutations to the specific TFAM binding sites leads to 
inactivation of promoter activity (Dairaghi, Shadel et al. 1995). Additionally, the C-
terminal tail of TFAM is particularly important for induction of transcription; ablation 
leads to loss of ability to initiate transcription (Kanki, Ohgaki et al. 2004), due in part to 
decreased ability to preferentially distort DNA (Malarkey, Bestwick et al. 2012), or 
perhaps due to inability to associate with TFB2M and form the complete initiation 
complex (McCulloch and Shadel 2003). Of note, more recent evidence suggests that 
TFAM may even directly interact with POLRMT to form the initiation complex 
(Yakubovskaya, Guja et al. 2014). Because of this domain-specific effect, the ~180° turn 
that TFAM imparts on DNA is crucial for initiation at LSP but not at HSP1 (Malarkey, 
Bestwick et al. 2012, Ngo, Lovely et al. 2014), where TFAM is oriented in reverse to its 
position in LSP. While TFAM bends DNA similarly at HSP1 (Ngo, Lovely et al. 2014), 
because the C-terminus is located after the proximal HMG box domain, it remains close 
to the transcriptional machinery despite the distortion. Indeed, deficits in DNA bending 
by TFAM lead to selective loss of transcription from LSP, but not from HSP1 (Ngo, 
Kaiser et al. 2011). Finally, when the distance between TFAM binding site and 
transcriptional machinery binding is lengthened, efficiency of transcription initiation is 
greatly disrupted, demonstrating the importance of the specificity of initial binding of 
TFAM for transcriptional nucleation (Dairaghi, Shadel et al. 1995). Taken together, the 
   
 
17
site- and structure-specific properties of TFAM binding at the LSP and HSP1 promoters 
appear to be essential for initiation of transcription. 
Interestingly, there has been some recent debate about whether TFAM is truly 
required for transcriptional activation. Using an in vitro system where all proteins were E. 
coli-derived and not epitope-tagged, it was demonstrated that presence of TFB2M and 
POLRMT alone were able to drive transcription from both HSP1 and LSP start sites, with 
transcription from HSP1 being just as or more efficient (Shutt, Lodeiro et al. 2010). 
Interestingly, similar results have been observed by another group as well, although they 
were not addressed in the publication (Litonin, Sologub et al. 2010). Although there is 
extensive research, discussed above, showing that the basal transcriptional machinery 
requires TFAM in addition to POLRMT and TFB2M, Shutt et al. suggest that the use of 
recombinant, non-epitope tagged proteins which were not co-expressed in insect cells, as 
per previous experiments, as well as HSP1-specific analysis of transcriptional initiation, 
contributed to the novel results. 
Given the significant implications for the field, a direct rebuttal of the Shutt et al. 
work was shortly forthcoming. Utilizing an analogous in vitro transcription system, Shi et 
al. replicate the canonically accepted results, demonstrating that specific TFAM binding 
upstream of the start site is necessary to initiate transcription, whether the protein source 
is mitochondrial extract, epitope-tagged purified proteins, or recombinant non-epitope 
tagged proteins (Shi, Dierckx et al. 2012). In addition, the authors tested parameters 
which could lead to the results produced by Shutt et al. Namely, because it is thought that 
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part of TFAM’s function is to aid in “melting” DNA in order to permit 
POLRMT/TFB2M binding, conditions that have previously been shown to allow for 
promoter breathing, e.g., decreased salt concentration (Metzler and Ambjornsson 2005) 
and negatively supercoiled templates (Parvin and Sharp 1993), were tested in the in vitro 
system. Strikingly, when NaCl levels were decreased to less than 12mM, transcription 
was increasingly enabled from both LSP and, to a greater extent, HSP1, mirroring the 
previous results. Additionally, a comparison of transcription using a linear template as 
compared to a negatively supercoiled, circular template, demonstrated that negative 
supercoiling was also transcription permissive. This effect could be abolished by 
treatment with mitochondrial topoisomerase I, which relaxes the supercoils. Similar 
permissiveness in negatively supercoiled DNA has also previously been demonstrated in 
the nuclear transcription with RNA polymerase II (Parvin and Sharp 1993). Given that 
Shi et al. performed their experiments in buffer conditions lacking NaCl, it is reasonable 
to conclude is that while TFAM is usually a necessary component of the basal 
transcriptional system, conditions in which DNA is more “melted” can result in relaxed 
requirements for TFAM binding. 
Regardless of whether TFAM is absolutely required for transcriptional activation, 
it still plays an important role in transcription, and thus in the dynamics of differential 
transcription from the transcriptional initiation site. Initial in vitro footprinting assays 
found that much higher concentrations of TFAM were required to visualize footprinting 
at HSP1 as compared to LSP (Fisher and Clayton 1988), possibly due to additional DNA-
protein contacts at LSP that do not exist when TFAM binds to either HSP1 or nonspecific 
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DNA (Ngo, Lovely et al. 2014). Subsequent work has also shown that, in the presence of 
POLRMT and TFB2M, increasing the concentration of TFAM very quickly maximizes 
transcription levels from LSP, while much higher concentrations are required to drive 
transcription from HSP1 (Falkenberg, Gaspari et al. 2002), in line with the footprinting 
results. Interestingly, binding affinity studies have consistently shown that TFAM has a 
lower KD at LSP than at HSP via FRET and SPR (Kaufman, Durisic et al. 2007, 
Malarkey, Bestwick et al. 2012). However, when TFAM concentrations rise further, 
transcript levels drop precipitously, a phenomenon that is potentially attributable to 
TFAM’s nonspecific binding properties (Dairaghi, Shadel et al. 1995, Shutt, Lodeiro et 
al. 2010). Furthermore, it is possible that under certain permissive conditions, when 
TFAM levels are extremely low, transcription progresses at a low level from both 
promoters (Shutt, Lodeiro et al. 2010); there is some in vivo evidence for this, where 
transcription levels in mice where mouse TFAM has been replaced by the largely 
transcription-incompetent human version still show low levels of transcription (Freyer, 
Park et al. 2010), although this may be attributed to any residual transcription factor 
activity on the part of human TFAM. Other in vivo experiments related to TFAM-induced 
transcription levels are mixed, with some showing that overexpression of TFAM leads to 
preferential transcription from LSP (Ekstrand, Falkenberg et al. 2004), while others see 
transcription from both promoters (Gensler, Weber et al. 2001, Garstka, Schmitt et al. 
2003). However, in vivo data is complicated by the inability to control initial 
concentrations of proteins as well as the presence of any transcriptional modulators, 
rendering such experiments difficult to interpret. Given the current evidence, however, it 
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is certainly probable that TFAM levels could in part help regulate levels of expression 
from the promoters. 
A possible model of TFAM regulation attempting to reconcile the existing 
evidence (Shutt, Bestwick et al. 2011) speculates that low levels of TFAM enable low 
levels of transcription from both LSP HSP1, allowing for sufficient gene expression for 
maintenance. Higher levels of TFAM would preferentially activate LSP, driving 
relatively higher levels of replication through creation of the requisite primer. Even 
higher levels would drive maximal transcription from both promoters for high-level 
transcription and replication, while saturating levels would lead to transcriptional 
inhibition at both primers. Such a model where TFAM modulates the genome would only 
make sense in the context of the cell’s ability to regulate TFAM levels between 
nucleoids. Indeed, there is significant evidence that this occurs. Analysis of nucleoids via 
microscopy reveals that TFAM is heterogeneously distributed across nucleoids, with 
some nucleoids containing levels below the detection limit (Wang and Bogenhagen 
2006). Additionally, measurement of replication in individual nucleoids has demonstrated 
that actively replicating nucleoids have generally less TFAM than those that were less 
active (Wai, Teoli et al. 2008). Interestingly, in the yeast transcription system, mtDNA 
became less compacted and relative Abf2p ratios decreased when yeast were placed 
under growth-permissive conditions (Kucej, Kucejova et al. 2008), further lending 
credence to the theory that TFAM modulates regulation of levels of transcription. 
However, more work needs to be performed to confirm the role of TFAM at different 
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concentrations and under different conditions, ideally with maximum physiological 
relevance, in order to elucidate the intricacies of this regulatory system. 
A third promoter, HSP2, also exists within the D-loop; however, its 
transcriptional activity is poorly characterized compared to that of LSP and HSP1. 
Indeed, although analysis of mitochondrial RNA molecules had previously identified 
HSP2 as a transcriptional start site (Montoya, Christianson et al. 1982, Montoya, Gaines 
et al. 1983), attempts at further characterization of transcription from the promoter had 
inconsistent results (Martin, Cho et al. 2005, Litonin, Sologub et al. 2010), with an in 
vitro transcription system capable of inducing transcription at LSP unable to produce an 
HSP2 transcript. However, it was found that upon isolation of HSP2 from the HSP1 
promoter, transcription could be reconstituted using both recombinant proteins and cell 
mitochondrial extracts, albeit at ~100-fold reduced levels compared to HSP1 (Lodeiro, 
Uchida et al. 2012, Zollo, Tiranti et al. 2012). Interestingly, addition of TFAM at levels 
where LSP and HSP1 are activated, even to concentrations far below a 1:1 ratio between 
TFAM and POLRMT/TFB2M, results in repression of transcription at HSP2. The 
mechanisms behind this differential response to TFAM are largely unknown, but are 
dependent on residues 220-236 of the TFAM C-terminal tail. This new knowledge about 
the function of TFAM in regulating transcription of the HSP2 promoter lends further 
credence to the hypothesis that TFAM levels within nucleoids are regulated in order to 
control expression of the mitochondrial genome. 
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Beyond its role as a transcription factor, TFAM is also essential for normal 
replication. The mechanism by which mtDNA is replicated is hotly debated, with 
competing theories postulating that replication follows the strand-asymmetric model, 
strand-symmetric model, and/or RITOLS model of replication (Kasamatsu and Vinograd 
1973, Clayton 1982, Holt, Lorimer et al. 2000, Brown, Cecconi et al. 2005, Yasukawa, 
Reyes et al. 2006). Regardless of the specific mechanism by which mtDNA replicates, 
however, it is well-accepted that the minimum in vitro replisome consists of the subunits 
of Polγ, helicase Twinkle, and mtSSB (Spelbrink, Li et al. 2001, Falkenberg, Larsson et 
al. 2007, Falkenberg and Larsson 2009, Lee, Kennedy et al. 2009, Milenkovic, Matic et 
al. 2013). However, even with the minimum machinery, replication from OH is dependent 
on the LSP transcript, and RNA primer formation is also required at OL for light strand 
replication to occur. As formation of significant amounts of RNA transcripts in 
mitochondria most probably requires TFAM, it is essential for replication (Chang and 
Clayton 1984, Chang and Clayton 1985). 
Due to its role in replication, TFAM is required for normal levels of mtDNA. 
Mice heterozygous for a knockout of TFAM exhibit not only an expected reduction of 
22% in mitochondrial transcript levels in the heart and kidney, but also a universal 34% 
reduction in mtDNA copy number across all assayed tissues. Furthermore, homozygous 
knockout mice have no detectable levels of mtDNA and die during embryogenesis 
(Larsson, Wang et al. 1998), highlighting the importance of TFAM in maintenance of 
mtDNA levels and in cellular and organismal viability. Interestingly, overexpression of 
TFAM at low levels leads to an increase in mtDNA copy number (Ekstrand, Falkenberg 
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et al. 2004), suggesting that upregulation of TFAM alone can singlehandedly enhance 
replication and thus maintenance of the genome. 
 
TFAM Functions as a Nonspecific Histone-Like Protein for mtDNA 
Beyond the role of TFAM as a transcription factor, TFAM also acts as a 
scaffolding protein for the genome in much the same way that Abf2p does in the yeast 
system, and that the NAPs do in the bacterial. Recently, the crystal structure of TFAM 
has been solved, and has been shown to indeed bind to ~22bp of DNA (Ngo, Kaiser et al. 
2011, Rubio-Cosials, Sidow et al. 2011). It also bends the DNA into a 180° turn, similar 
to that of bacterial IHF, which compacts at 160° (Rice, Yang et al. 1996). Although these 
structures were derived from binding of TFAM to its LSP binding site, an instance of 
specific binding, TFAM is also thought to organize the rest of the genome by binding 
nonspecifically in a similar manner. Beyond numerous studies colocalizing TFAM and 
nucleoids, TFAM has been shown to be able to bind to multiple DNA sequences, both by 
methylation interference studies (Fisher, Parisi et al. 1989) and by the crystal structure of 
TFAM bound to a nonspecific sequence, which has recently been solved (Ngo, Lovely et 
al. 2014). Furthermore, estimates of the average number of TFAM molecules per unit of 
mtDNA have suggested that it is sufficiently abundant to coat the genome completely 
(Alam, Kanki et al. 2003, Ekstrand, Falkenberg et al. 2004, Kaufman, Durisic et al. 
2007). Although one dissenting study does estimate that there may only be an average of 
35 TFAM molecules per mtDNA in HeLa cells (Takamatsu, Umeda et al. 2002), far less 
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than what is required to coat the genome, it is possible that this outlier datapoint may be 
due to cell growth condition and quantification differences. TFAM has also been shown 
to bind to nonspecific DNA with affinity approaching that of LSP and HSP1 (Kaufman, 
Durisic et al. 2007, Wong, Rajagopalan et al. 2009, Malarkey, Bestwick et al. 2012). 
Finally, DNase I footprinting (Fisher, Lisowsky et al. 1992), in organello footprinting 
(Ghivizzani, Madsen et al. 1994), and chromatin-immunoprecipitation data (Ohgaki, 
Kanki et al. 2007) have shown that TFAM binds to the mitochondrial genome outside of 
its promoter binding sites. Therefore, from colocalization studies, its known DNA-
binding properties, its abundance in the cell, and direct binding evidence, TFAM most 
likely binds across the mitochondrial genome. 
Although the role of TFAM in transcription and thus replication is well 
established and known to be independently required for cellular and organismal viability, 
loss of the nonspecific binding function of TFAM alone is also sufficient to cause 
mtDNA instability. Fortunately, the two functions of TFAM may be largely isolated 
thanks to the nature of the mouse form of TFAM, which, although recognizing the 
corresponding -12 to -39 bp upstream of the mouse mtDNA transcription start site, shares 
less than 50% homology with the human counterpart at DNA contact sites and is a poor 
activator of transcription in the human system despite similar binding affinities as 
assayed by EMSA (Ekstrand, Falkenberg et al. 2004, Gaspari, Larsson et al. 2004). This 
disassociation between the transcription factor and nonspecific binding properties of 
TFAM has allowed for some very interesting experiments in mouse models. In a mouse 
expressing hTFAM as well as endogenous levels of mTFAM, mtDNA copy numbers 
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increase to levels proportionate to the amount of additional hTFAM expression, despite 
poor transcriptional activation. Although levels of ND6 (from the LSP transcript) were 
elevated in the higher-expressing animals, levels of transcripts from HSP were 
unchanged. Furthermore, respiratory chain function and mitochondrial mass also remain 
constant upon expression of hTFAM. Interestingly, although hTFAM expression was 
unable to rescue the embryonic lethality of mTFAM-/- mice, mtDNA levels were at 
~30% of WT, indicating that hTFAM alone, despite its highly impaired transcriptional 
activity in the mouse system, is capable of preserving some levels of mtDNA, most 
probably due to its nonspecific binding properties. A second mouse model, a heart-
specific knockout of mTFAM, experiences rescue of mtDNA levels as well as phenotype 
when hTFAM is overexpressed despite the transcription defect, further illustrating the 
ability of TFAM to stabilize mtDNA through its nonspecific binding properties (Freyer, 
Park et al. 2010). Finally, expression of a TFAM variant lacking the C-terminal tail that is 
required for transcriptional activation but which is still competent in DNA binding in 
HeLa cells, where endogenous TFAM levels are knocked down by RNAi, results in 
prevention of mtDNA depletion (Kanki, Ohgaki et al. 2004), a result replicated in 
chicken cells as well (Wong, Rajagopalan et al. 2009). The ability of TFAM to increase 
mtDNA copy number through a non-transcriptionally active form suggests that its 
function as the mitochondrial histone may increase genomic stability by protecting 
mtDNA from turnover or deleterious damage.  
 Although TFAM is required to protect mtDNA, too much TFAM is deleterious. A 
significant increase in TFAM:mtDNA ratio has been shown to lead to decrease in 
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mtDNA copy number and transcription (Pohjoismaki, Wanrooij et al. 2006, Matsushima, 
Goto et al. 2010). Because the increased TFAM levels seem to be associated directly with 
the genome instead of elsewhere within the cell, and because transcription levels also 
seem to be perturbed, it appears that this depletion in copy number is due to TFAM 
interacting with the genome. If TFAM were exclusively a site-specific transcription 
factor, one would expect that increasing TFAM levels would result in increasing 
transcripts from LSP, resulting in proportionally increasing mtDNA levels. However, 
given that this only holds true up to a certain threshold ~2x greater than endogenous 
levels, this further validates the theory that TFAM usually nonspecifically binds to 
mtDNA, and at supersaturating levels prevents progression of transcription and thus of 
replication of the genome through structural over-compaction; indeed, as discussed 
previously, mtDNA with higher levels of TFAM have been shown to be less active in 
replication (Wai, Teoli et al. 2008). Therefore, the histone-like properties of TFAM may 
serve not only to stabilize mtDNA, but also to regulate copy number beyond the 
transcription factor capabilities. One could certainly envision a quiescent cell line 
requiring mtDNA copy number stasis utilizing such TFAM-mediated control to limit 
replication. 
 The nonspecific, architectural role of TFAM in mtDNA appears to rely on three 
main properties of the protein: its ability to bend DNA, its ability to bind cooperatively, 
and its ability to form homodimers. The ability of TFAM to bend DNA was initially 
suggested by EMSA data showing altered migration of a TFAM-DNA complex through 
the gel, suggestive of a bend in DNA (Fisher, Lisowsky et al. 1992), and by STEM data 
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showing that binding of Xenopus TFAM at LSP results in a sharp bend in the DNA 
(Antoshechkin, Bogenhagen et al. 1997). While original estimates placed the bending of 
DNA at ~100° by AFM (Kaufman, Durisic et al. 2007), the four crystal structures for 
TFAM solved to date - two while associated with LSP DNA (Ngo, Kaiser et al. 2011, 
Rubio-Cosials, Sidow et al. 2011), one while associated with HSP1, and the last while 
associated with nonspecific DNA (Ngo, Lovely et al. 2014) – all suggest a ~180° angle, 
indicating that the proximate bend is significantly greater than the observed end-to-end 
bend. FRET assays to further elucidate the bend of DNA have shown that the decrease in 
end-to-end distance for a 25-mer bound to TFAM is similar for LSP and HSP1 at ~22Å, 
which is interesting given the slightly lower binding affinity for HSP1, but smaller for 
nonspecific DNA at ~15Å (Malarkey, Bestwick et al. 2012). The site specificity and the 
level of bend are dependent on the C-terminal tail, with ablation rendering the decrease in 
end-to-end distance uniform across all templates at ~10-12Å. Thus, TFAM bends 
nonspecific DNA, albeit bending at a lower angle, with the C-terminus playing an 
important role in the degree of bend. As discussed earlier, naked mtDNA requires 
compaction because is far larger than the diameter of the mitochondrial matrix. Given 
that this feature of TFAM alone is capable of compacting DNA to a significant extent 
(Ngo, Lovely et al. 2014), it appears that one of the primary functions of TFAM’s 
bending of nonspecific DNA may be to aid in compaction of the genome into the 
nucleoid. 
 A second property of TFAM is its ability to bind DNA with positive 
cooperativity, with a single binding event nucleating that of subsequent molecules.  Such 
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cooperativity was first qualitatively identified via AFM studies where TFAM was shown 
to heterogeneously bind to DNA, preferentially localizing near loci where a previous 
binding event had occurred, leading to an estimated Hill coefficient of ~2 (Kaufman, 
Durisic et al. 2007). Other studies using fluorescence anisotropy have also shown similar 
results, with a Hill coefficient of ~2.5 (Wong, Rajagopalan et al. 2009). Additionally, 
TPM experiments using fluorescently labeled TFAM have shown that TFAM slides 
along DNA despite its bending properties, is stopped by collision, and forms patches on 
DNA in a cooperative manner, finding that TFAM is ~100x more likely to bind next to 
an extant molecular than to bare DNA (Farge, Laurens et al. 2012).  It has been suggested 
that initial binding results in template “melting” and in an increase in flexibility, 
facilitating further binding events in the area of affect. Such cooperativity has 
implications for the binding of TFAM outside of the promoters. Given the increased 
affinity for the LSP site, nucleation from LSP and HSP to the rest of the genome could be 
expected to occur.  Indeed, evidence of such “phasing” has already been observed 
(Fisher, Lisowsky et al. 1992, Ghivizzani, Madsen et al. 1994). 
The third major property of TFAM is its ability to form homodimers. There has 
been significant debate over the stoichiometry of TFAM due to conflicting evidence. 
From early immunoprecipitation studies, there was some initial evidence that TFAM 
could interact with itself, although the exact nature of the interactions was unclear 
(Antoshechkin, Bogenhagen et al. 1997). Subsequent experiments using size exclusion 
chromatography, surface plasmon resonance (Kaufman, Durisic et al. 2007), and 
analytical ultracentrifugation (Wong, Rajagopalan et al. 2009) have all furthered the 
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theory that TFAM binds as a dimer; there is even isothermal titration calorimetry 
(Malarkey, Bestwick et al. 2012), and heterogeneous subunit assay (Gangelhoff, 
Mungalachetty et al. 2009) data suggesting that a TFAM dimer binds at LSP as well as at 
HSP1 and nonspecific sequences (Malarkey, Bestwick et al. 2012) despite a DNase I 
footprint insufficient to accommodate two TFAM molecules. Further analytical 
ultracentrifugation experiments suggest that the C-terminal tail is required for 
dimerization (Wong, Rajagopalan et al. 2009). However, there is also evidence for 
TFAM binding as a monomer from size exclusion chromatography with multi-angle light 
scattering analysis (Ngo, Kaiser et al. 2011) and single molecule fluorescence 
microscopy (Farge, Laurens et al. 2012). The four recent TFAM crystal structures, while 
all depict monomeric TFAM binding to DNA, have intriguingly exhibited dimerization at 
an interface between HMG box A and HMG box B, an interesting coincidence that was 
further explored by FRET, which shows that TFAM-TFAM interactions do occur in the 
presence of DNA (Ngo, Lovely et al. 2014), although not at the C-terminus as previous 
evidence suggested. Most striking, however, is evidence from a TPM assay 
demonstrating that mutation of the novel homodimer interface leads to decreased 
compaction as compared to wild-type TFAM, while maintaining wild-type levels of 
transcriptional activation and binding affinity (Ngo, Lovely et al. 2014). This strongly 
suggests that this new interface, and not the previously identified C-terminal region, is 
the region involved in dimerization. Future work will need to be performed to elucidate 
the properties of this novel interaction, but it appears that while TFAM does not directly 
bind as a dimer to DNA, the dimerization properties do serve to increase the compaction 
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of the mitochondrial genome, possibly through a looping mechanism previously observed 
by AFM (Kaufman, Durisic et al. 2007). 
 
Dynamics of the Mitochondrial Nucleoid 
 Because mtDNA is required for production of essential components of the ETC, it 
is predicted that its regulation must be dynamic in order to meet the varying needs of the 
cell. It is clear that the mitochondrial nucleoid contains a variety of proteins involved in 
transcription, translation, replication, and regulation of mtDNA, which is essential for 
cellular and organismal viability. Central to these functions is TFAM, which is the most 
abundant, and perhaps the best-studied, protein in the mitochondrial nucleoid. TFAM’s 
function in the nucleoid involves not only its site-specific role as a transcription factor 
probably required for initiation of transcription, but also as a non-specific architectural 
histone-like protein required for protection of mtDNA stability. Therefore, many models 
of exactly how TFAM may regulate the main processes of the nucleoid via its 
biochemical properties have been proposed in order to account for these sometimes 
contradictory findings. Interestingly, in the ancestral bacterial system, the NAPs are 
involved in genome organization through not only DNA bending, but also looping and 
other higher-order structures (Dillon and Dorman 2010, Wang, Li et al. 2011), and are 
somewhat analogous in role to TFAM’s nonspecific histone-like function. Within the 
NAPs, the HU family of proteins bends prokaryotic DNA for compaction in a strikingly 
similar way to that of TFAM (Ngo, Kaiser et al. 2011). Interestingly, the expression of 
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the various NAPs varies between that of the exponential and stationary growth phases 
(Dame, Espeli et al. 2012), with some NAPs, including FIS, HU, and H-NS, expressed at 
high levels during exponential growth while others such as Dps and CbpA are expressed 
during stationary phases of growth (Ali Azam, Iwata et al. 1999). Given the differential 
binding properties of TFAM at various concentrations, there certainly exists a rationale 
for a TFAM-based system of regulation within the nucleoid. Indeed, TFAM levels are 
heterogeneous between nucleoids and correlate with different levels of replication (Wai, 
Teoli et al. 2008), suggesting some level of regulation by TFAM as well as some control 
of internucleoid protein distribution within the cell. Furthermore, semi-quantitative 
analysis of TFAM binding to mtDNA in the frontal cortex, soleus, and liver of aged rats 
reveals substantial differences in TFAM quantities and binding patterns as compared to 
young or calorie-restricted rats (Picca, Fracasso et al. 2013, Picca, Pesce et al. 2013, 
Picca, Pesce et al. 2014), suggesting that TFAM binding and levels can be modulated 
within cells. 
 Given a model of mtDNA regulation, how would TFAM itself be regulated to 
effect control?  A prime candidate is the Lon protease, which is known to degrade TFAM 
(Matsushima, Goto et al. 2010), a property especially important given that TFAM mRNA 
levels are not always tied to protein levels (King and Attardi 1996, Micol, Fernandez-
Silva et al. 1997). Overexpression of Lon protease leads to depletion of TFAM 
(Matsushima, Goto et al. 2010), while knockdown increases stability, but because Lon 
protease also degrades other proteins (Bender, Lewrenz et al. 2011), it would be both 
faster and more advantageous for more specific methods of regulation to also exist. In 
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fact, similarly to the nuclear histones, TFAM has been shown to be post-translationally 
modified by glycosylation (Suarez, Hu et al. 2008), phosphorylation (Dephoure, Zhou et 
al. 2008, Chen, Yang et al. 2009, Lu, Lee et al. 2013), acetylation (Dinardo, Musicco et 
al. 2003), and ubiquitination (Shi, Chan et al. 2011, Wagner, Beli et al. 2011). Strikingly, 
when TFAM is phosphorylated by mitochondrial cAMP-dependent protein kinase, its 
ability to bind DNA and initiate translation are impaired, and it is selectively degraded by 
Lon protease. Further studies remain to be performed to fully understand the implications 
of this and other modifications on the properties of TFAM. 
 
Conclusion 
 In the nearly 50 years since the discovery of the mitochondrial genome, much 
work has been done to characterize its organization as well as the proteins regulating its 
replication as well as its transcription and translation products, all essential for proper 
ETC function.  While many proteins have been shown to be components of the DNA-
protein nucleoid, key amongst these is TFAM, with many studies demonstrating its 
functions both as a site-specific transcription factor and as a nonspecific histone-like 
architectural protein as being essential for genome stability. However, while many 
models exist which attempt to explain the existing evidence for how TFAM interacts with 
and regulates the genome, much work remains to be done to validate and further 
understand current findings. Finally, while how TFAM binds to the genome may be well 
studied, very little is known about how these binding events are controlled between and 
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within nucleoids. Understanding the pathways that control the TFAM-mediated 
regulation of mtDNA stability will serve as a powerful tool, even with potential for 
therapeutic applications in disorders where mtDNA stability has been observed, such as 
Alzheimer’s, Parkinson’s, and aging. 
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II.  Overview of Thesis 
Chapter 2 
Mitochondria are dynamic organelles whose membranes undergo the opposing 
processes of fission and fusion. Several of the biochemical factors involved in dynamics 
have been explored and studied. The functional implications of dysfunction in dynamics 
have also been analyzed at both the cellular and whole-organism level. However, it was 
unclear how perturbation of the balance between fission and fusion cause these observed 
effects. We demonstrate in mouse embryonic fibroblasts that the outer membrane 
mitochondrial fusion proteins, Mfn1 and Mfn2, and the inner mitochondrial membrane 
fusion protein Opa1 are required for maintenance of the mitochondrial genome.  
 
Chapter 3 
The transcription factor TFAM is critical for initiation of transcription and 
replication of the genome, and is also thought to perform a packaging function. Although 
specific binding sites required for initiation of transcription have been identified in the D-
loop, little is known about the characteristics of TFAM binding in its nonspecific 
packaging state. In addition, it is unclear whether TFAM also plays a role in the 
regulation of nuclear gene expression. Therefore, to capture a high-resolution profile of 
TFAM-mtDNA interactions across the entire mitochondrial and nuclear genomes in 
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various cellular states, we performed chromatin immunoprecipitation followed by 
massively parallel sequencing (ChIP-seq) for TFAM in human HeLa cells. We directly 
localize TFAM binding to DNA in human cells, demonstrating that TFAM uniformly 
coats the whole mitochondrial genome, with no evidence of robust TFAM binding to the 
nuclear genome. One specific binding site upstream of the OL localizes to the same area 
as a previously identified site of TFAM binding to the rat mitochondrial genome. This 
represents the first direct assessment of TFAM binding on a genome-wide scale in human 
cells.  
 
Chapter 4 
While several classically nuclear transcription factors have been previously 
reported to localize to mitochondria and to bind to the D-loop to effect transcriptional 
modulation, there has been no comprehensive analysis of such transcription factors across 
the mitochondrial genome.  Here, we analyze existing ChIP-seq data from ENCODE, 
mouseENCODE and modENCODE consortia for potential interactions on human, mouse, 
and C. elegans genomes, and identify human and mouse transcription factors with strong 
localized enrichment outslide the NCR that are usually associated with the corresponding 
recognition sequence motif. We further confirm these finding by localization of the 
identified factor MafK to the mitochondria via immunocytochemistry. This represents the 
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first large-scale, genome-wide characterization of canonically nuclear transcription factors 
binding to the mitochondrial genome. 
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I. Introduction 
Proteins involved in fission and fusion 
 The transmembrane protein Fzo was first found to mediate mitochondrial 
membrane fusion in spermatozoa of D. melanogaster (Hales and Fuller 1997). In 
mammals, there are two orthologs, Mfn1 and Mfn2, which can form both homo-
oligomeric and hetero-oligomeric complexes to effect fusion between two mitochondria 
(Koshiba, Detmer et al. 2004, Meeusen, McCaffery et al. 2004). Membrane fusion in 
mammals is also mediated by the GTPase Opa1, which localizes to the intermembrane 
space and inner membrane (Cipolat, Martins de Brito et al. 2004, Chen, Chomyn et al. 
2005). Loss of Mfn1, Mfn2, or Opa1 leads to mitochondrial fragmentation and changes in 
morphology, and to loss of membrane potential, indicating impaired mitochondrial 
function (Chen, Detmer et al. 2003, Chen, Chomyn et al. 2005). 
 Mitochondrial fission is well-characterized in yeast, where it is mediated by 
several proteins: Fis1, an integral outer membrane protein, binds indirectly to the 
dynamin-related protein Dnm1 (Drp1 in mammals) through the adapter proteins Mdv1 or 
Caf4. Dnm1, in turn, is thought to form mitochondrial tubules and to effect fission 
through constriction (Smirnova, Griparic et al. 2001). While Fis1 and Dnm1 are each 
required for mitochondrial fission in yeast, either of the adaptor proteins is sufficient for a 
wild-type phenotype. No mammalian homologues have yet been found for Mdv1 or Caf4. 
 
 
 
 
69 
Pathology of dysregulation in mitochondrial dynamics 
 Defects in mitochondrial dynamics have been implicated in several human 
neurodegenerative diseases. ADOA, the most common inherited optic neuropathy, is 
directly caused by mutations in the Opa1 gene, and results in degeneration of retinal 
ganglion cells (Alexander, Votruba et al. 2000, Delettre, Lenaers et al. 2000). Loss of 
Mfn2 function is linked to CMT disease type 2a, in which the symptoms of distal motor 
and sensory impairments starting at the extremities are caused by a neuronal defect 
causing degeneration of long axons (Zuchner and Vance 2006). Moreover, there has been 
one account of a patient with a dominant negative allele of Drp1, presenting with reduced 
head growth and optic atrophy, amongst other defects, with mortality at 1 month of age 
(Waterham, Koster et al. 2007). Importantly, mice deficient in any of the fusion proteins 
die midgestation (Chen, Detmer et al. 2003, Davies, Hollins et al. 2007), indicating that 
mitochondrial fusion is essential for viability. Fission has also been shown to be essential 
in cellular processes, as downregulation results in a highly interconnected network of 
tubular mitochondria and to defects in cell division (Smirnova, Shurland et al. 1998, 
Sesaki and Jensen 1999, Smirnova, Griparic et al. 2001) and in apoptosis (Frank, Gaume 
et al. 2001, Lee, Jeong et al. 2004). Finally, PD (Van Laar and Berman 2009), AD 
(Bossy-Wetzel, Barsoum et al. 2003), HD (Bossy-Wetzel, Petrilli et al. 2008), ALS 
(Knott and Bossy-Wetzel 2008), and several other neurodegenerative diseases have been 
correlated with dysfunction in dynamics, emphasizing the importance of mitochondrial 
fission and fusion in maintenance of cellular homeostasis.  
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 There are many hypotheses addressing the cellular function of mitochondrial 
dynamics. First, dynamics may be involved in maintenance of proper mitochondrial 
function. Loss of fusion leads to defects in respiratory capacity, and morphological and 
membrane potential heterogeneity (Chen, Chomyn et al. 2005). Fusion and fission cycles 
allow for exchange of mitochondrial contents and could thus allow for rescue of 
respiratory capacity of deficient mitochondria. Such exchange of material would also 
allow for re-distribution of mtDNA-containing nucleoids, which provide the genomic 
material for transcription of essential components of the electron transport chain. In cells 
deficient in fusion, in contrast to wild-type cells, a large fraction of mitochondria lack 
nucleoids and have a lowered membrane potential (Chen, Chomyn et al. 2005), indicating 
that proper nucleoid distribution is crucial for correct mitochondrial function. 
Furthermore, maintenance of proper mitochondrial function seems to be essential for 
development, as evidenced by the embryonic lethality of fusion-deficient mice (Chen, 
Detmer et al. 2003). 
 Second, fission and fusion are important for maintaining proper distribution and 
recruitment of mitochondria in neurons. Due to the distance that neuronal processes can 
extend from the cell body, mitochondria must be transported to areas of high energy 
demand, such as pre- and post-synaptic terminals (Li, Okamoto et al. 2004, Chang, 
Honick et al. 2006). Importantly, loss of Drp1 leads to a defect in transport and a 
concomitant loss of capacity for synaptic transmission (Stowers, Megeath et al. 2002, 
Guo, Macleod et al. 2005), a phenotype that, along with loss of respiratory capacity in 
fusion-deficient cells and loss of exchange of mitochondrial material, could explain the 
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pathology of neurodegenerative diseases associated with perturbation of dynamics.  
 
Regulation of mtDNA copy number 
 Depletion of mtDNA copy number is well known to cause cellular defects in 
bioenergetics (Baron, Kudin et al. 2007). Unsurprisingly, many proteins which regulate 
mtDNA copy number exist in pathways related to the mitochondrial dNTP salvage 
pathway and to cytoplasmic de novo dNTP synthesis (Tyynismaa and Suomalainen 
2009). Interestingly, many neurodegenerative diseases, including ALS and FRDA 
(Baron, Kudin et al. 2007), as well as many mitochondrial myopathies (Alberio, Mineri et 
al. 2007), have also been associated with mtDNA copy number deficiencies. This 
suggests that loss of mtDNA has a severely negative impact on neurons and muscles, 
which have the highest energetic demand of all cells in the body. This also suggests that 
even in sporadic forms of neurodegenerative disease, dysregulation of copy number may 
lead to disease pathology. 
 Because mitochondrial dynamics is hypothesized to play an important role in 
maintenance of mitochondrial viability and in proper distribution of mitochondrial 
nucleoids, we hypothesized that it may also have a role in maintenance of mtDNA. We 
used qPCR to elucidate the role of the fusion proteins in modulating mitochondrial 
genome copy number.  
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II. Results 
Using qPCR to characterize mtDNA copy number 
It was unknown what effect loss of mitochondrial fusion had on mtDNA copy 
number. This could be characterized by determining the average mtDNA copy number 
per cell in different cell lines. I thus chose to utilize singleplex qPCR using SYBR Green 
(Brilliant SYBR Green 2X Master Mix, Agilent #929548) as the fluorescent marker for 
amplification, taking advantage of the technique’s high level of accuracy and sensitivity 
in measuring DNA copy number over a wide dynamic range. Whole DNA prep of 
cultured MEFs to maximally capture both nuclear and mitochondrial DNA was 
performed largely according to established protocols, with some modifications (Ausubel 
2002) (see Protocols section for details). Four sets of primers with no predicted 
homodimers, heterodimers, or hairpins (as predicted by the Eurofins MWG Operon oligo 
analysis tool) were designed, in the 0kb, 4kb, 5kb, and 6kb stretches of the mitochondrial 
genome and yielding 220-260bp products. Four primer sets found in a validated qPCR 
primer database (realtimeprimers.org) were tested for genomic qPCR capability, with 
primers within the PECAM1, two PCR’ing between SCN4a and mGH on chromosome 
11; and one set priming in ActB; each product was 230-235bp long. Optimization of 
qPCR conditions (Bio-Rad CFX96) using prepared WT MEF whole cell DNA resulted in 
the selection of the 4kbmt primer set for mitochondrial copy number determination and 
the PECAM1 primer set for nuclear because of their high levels of consistency (R2 = 1.00 
and 0.98, respectively) and PCR efficiency approaching 100% (100.5% and 95.7%, 
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respectively) over a wide dynamic range of a 1000-fold change in copy number 
concentration (Figure 2.1A-B). 
 
Loss of fusion leads to depleted mtDNA 
Separate whole DNA preps of Mfn1-null, Mfn2-null, Opa1-null, and Mfn-double 
null MEFs (n = 6 for each) were run using these primers, and the relative copy number 
per cell was determined using either the analysis of the difference in threshold 
amplification between mtDNA and nuclear genome, or the ΔΔC(t) method using the 
known dilution standard curve as a standard; both yielded similar results. The average 
mtDNA to nuclear genome (Shen-Li, O'Hagan et al.) ratio in MEFs was found to be 440 
mtDNA:nDNA. Strikingly, while absence of either Mfn1 or Mfn2 alone did not impact 
mtDNA copy number, absence of both Mfn’s, which leads to loss of all outer membrane 
fusion, or absence of Opa1, which leads to loss of all inner membrane fusion, results in 
dramatically depleted mtDNA (Figure 2.2A). 
To verify that this finding was due to the loss of the mitofusins in Mfn-null cells, 
and not due to other conditions which would cause different mtDNA:nDNA copy number 
in these cell lines, ds-Red (mock), Mfn1-myc, or Mfn2-myc was reintroduced into Mfn-
null cells by retroviral infection, and protein levels were monitored via Western at 2 and 
4 weeks post-infection;  mtDNA:nDNA was also simultaneously tracked. Successful 
restoration of either mitofusin to mitochondria (Figure 2.2B-C) resulted in partial rescue 
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of the fragmented mitochondrial morphology as well an increase in mtDNA:nDNA levels 
to that of WT MEFs (Figure 2.2D). This observation is corroborated by data from mouse 
studies by Hsiuchen Chen in our lab which demonstrate that mice homozygous mutant 
for both Mfn1 and Mfn2 in skeletal muscle (MLC-Cre/dm) also exhibit a severe decrease 
in mtDNA:nDNA, a phenotype not seen in Mfn1-/-,Mfn2+/- or Mfn1+/-,Mfn2-/-mice. 
 
III. Discussion 
Our lab has found (Hsiuchen Chen, Chen et al., 2011) that Mfn-null mice present 
with a phenotype strikingly similar to that found in human mitochondrial myopathies, 
unsurprising given that mtDNA levels per nuclear genome in skeletal muscle tissue were 
only 7% of that found in wild-type mice, a phenotype absent in mice heterozygous for 
either Mfn1 or Mfn2. My analysis of MEF lines confirms that mtDNA depletion occurs 
in Mfn-double null and Opa1-null cells and not in Mfn1-null and Mfn2-null MEFs; 
complete ablation of either inner mitochondrial fusion or outer membrane fusion is 
required for the phenotype. Overexpression of Mfn1 or Mfn2 is readily able to rescue the 
depletion in Mfn-double null cells, leading to the conclusion that it is loss of the fusion 
proteins that leads to the depletion phenotype. This illustrates the key role of mitofusins 
in mtDNA maintenance, and suggests the possibility that dysregulation of dynamics may 
manifest itself in the form of perturbation of mtDNA copy number, leading to cellular 
dysfunction. 
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Mitochondrial membrane fission and fusion are crucial for cellular and 
organismal viability (Chan 2006, Chan 2006). The implications of dysfunction are severe, 
as mutations in the proteins implicated in fusion and fission lead to neurodegenerative 
disease (Alexander, Votruba et al. 2000, Delettre, Lenaers et al. 2000, Zuchner and 
Vance 2006). Beyond mutations in the machinery that directly affects the machinery, 
phenotypic perturbations in mitochondrial dynamics are correlated with many of the most 
common human neurodegenerative diseases and myopathies, such as AD and PD (Knott 
and Bossy-Wetzel 2008). This implies that mitochondrial function is crucial for neuronal 
and muscular viability, and that loss of function leads to atrophy and to a devastating 
phenotype. Moreover, mtDNA depletion, which causes further mitochondrial 
dysfunction, has been implicated in several of these neurodegenerative diseases (Baron, 
Kudin et al. 2007), suggesting that depletion could contribute to the severity of the 
phenotype.. It is certainly possible that mtDNA depletion due to ablation of fusion is a 
result of loss of exchange of mitochondrial content, thus leading to heterogenous 
distribution of proteins required for proliferation of the genome and a consistent depletion 
phenotype. However, a more compelling story would be the direct or indirect regulation 
of mtDNA copy number by the fusion proteins. Further studies addressing the interplay 
between the proteins directly involved with mtDNA copy number, such as POLG, 
Twinkle, mtSSB, TFAM, POLRMT, and TFB2M, and the fusion proteins, will shed light 
on this intriguing effect. 
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IV. Methods 
Quantitative PCR of mouse mtDNA and nuclear genome 
 One set of primers, 4kbmtF/R, and one set of nuclear DNA primers, PECAMF/R, 
was optimized for mouse mtDNA: 
 
 
qPCR was performed on Bio-Rad CFX-96 machine with using Brilliant SYBR Green 2X 
Master Mix, Agilent #929548 and the following cycling conditions: 10min@95C, 
[30sec@95C, 1min@58C, 1min@72C]x40. 
 
Expression of Mfn1 and Mfn2 in MEFs 
 Viral supernatant with virus made from retroviral vector containing either Mfn1 or 
Mfn2 was applied to MEFs and incubated for 12 hours prior to replacement with normal 
growth media [DMEM (Invitrogen #11995) containing 10% fetal bovine serum, penicillin 
and streptomycin, and additional L-glutamine (2mM)]. 
 
Western Blotting of Mfn1 and Mfn2 expression 
Primer ID Sequence    Chromosome Base pairs  
4kbmtF CCTATCACCCTTGCCATCAT mt  3920 – 3939  
4kbmtR GAGGCTGTTGCTTGTGTGAC mt  4094 – 4113  
PECAMF ATGGAAAGCCTGCCATCATG 11  55425 – 55406  
PECAMR TCCTTGTTGTTCAGCATCAC 11  55190 – 55209  
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 Cells were harvested at 0, 2, and 4 weeks post-infection and run on 10% SDS-
PAGE gels. Primary antibodies were anti-Mfn1 (1:1000) and anti-Mfn2 (1:1000). 
Secondary antibodies were anti-chicken (1:10,000) and anti-rabbit (1:10,000, Jackson 
#111-035-003), respectively. Anti-actin (1:500, Imgenex #IMG-5142A) was used for 
loading control.   
 
Immunocytochemistry of Mfn1 and Mfn2 expression 
 Cells were plated onto poly-lysine coated coverslips 24 hours prior to fixation with 
10% formalin and permeabilization with acetone at -20C. Following 1hr block in PBS + 
5% FBS, incubations were as follows: 1hr with anti-myc antibody (1:10, 9E10 clone) in 
PBS + 5% FBS; 3x 10min wash in PBS; 1hr with anti-mouse AF488 (1:500, Invitrogen 
#A10680); 3x 10min wash in PBS; mounting onto glass slides. Cells were visualized using 
Zeiss LSM 710 confocal microscope with PlanApochromat 63X/14 oil objective. 
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V. Figure Legends 
Figure 2.1. Primers for quantification of relative mtDNA copy number per cell. 
Primers used for quantification of mtDNA copy number (4kbmtF and 4kbmtR) and 
nuclear genome copy number (PECAMF and PECAMR). Standard dilution curve, as 
assayed on whole cell MEF DNA prep, for 4kbmt (A) and PECAM (B) primer sets shows 
linearity through 1000-fold dilution range. 
 
Figure 2.2. Complete loss of fusion leads to mtDNA depletion. (A) Analysis of 
mtDNA:nDNA in WT MEFs and cells lacking Mfn1, Mfn2, both mitofusins, or Opa1 
demonstrate that severe loss of mtDNA only occurs with complete ablation of fusion, as 
in Mfn-null and Opa1-null cells. Infection of Mfn-null cells with either Mfn1 or Mfn2 
(C) leads to partial rescue on mitochondrial morphology and to a rapid, sustained increase 
in mtDNA copy number to that of WT MEFs. In (C), red immunostaining is HSP60 for 
labeling of mitochondria, and green is for myc, to which Mfn1 and Mfn2 are attached. I. 
WT; II. Mfn-null; III. Mfn-null + Mfn1-myc; IV. Mfn-null + Mfn2-myc. 
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Figure 2.1. 
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Figure 2.2. 
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I. Abstract 
Mitochondria contain a 16.6 kb circular genome encoding 13 proteins as well as 
mitochondrial tRNAs and rRNAs. Copies of the genome are organized into nucleoids 
containing both DNA and proteins, including the machinery required for mtDNA 
replication and transcription. The transcription factor TFAM is critical for initiation of 
transcription and replication of the genome, and is also thought to perform a packaging 
function. Although specific binding sites required for initiation of transcription have been 
identified in the D-loop, little is known about the characteristics of TFAM binding in its 
nonspecific packaging state. In addition, it is unclear whether TFAM also plays a role in 
the regulation of nuclear gene expression. Here we investigate these questions by using 
ChIP-seq to directly localize TFAM binding to DNA in human cells. Our results 
demonstrate that TFAM uniformly coats the whole mitochondrial genome, with no 
evidence of robust TFAM binding to the nuclear genome. Our study represents the first 
direct assessment of TFAM binding on a genome-wide scale in human cells. 
 
II. Introduction 
Mitochondria are essential eukaryotic organelles, serving as the epicenter of ATP 
production in the cell through oxidative phosphorylation. To perform this bioenergetic 
function, mitochondria utilize gene products encoded by the mitochondrial genome, a 
circular DNA that is 16.6 kb long. This genome is organized into DNA/protein structures 
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termed nucleoids (Bogenhagen, Rousseau et al. 2008). Mitochondrial DNA (mtDNA) 
encodes thirteen components of the electron transport chain, as well as 22 tRNAs and two 
ribosomal RNA genes. These gene products are essential for the proper function of the 
respiratory chain, and therefore maintenance of mtDNA levels and sequence fidelity is 
essential for cellular bioenergetics. In a human cell, there are hundreds to thousands of 
copies of the mtDNA genome (Bogenhagen Bogenhagen and Clayton 1974, Satoh Satoh 
and Kuroiwa 1991). Damage or depletion of mtDNA causes numerous inherited 
disorders, including Alpers’ Disease, ataxia neuropathy spectrum, and progressive 
external ophthalmoplegia (Suomalainen and Isohanni 2010, Stumpf, Saneto et al. 2013). 
Furthermore, loss and damage to mtDNA has been implicated in cardiovascular disease 
(Sugiyama, Hattori et al. 1991, Ide, Tsutsui et al. 2001, Karamanlidis, Nascimben et al. 
2010, Karamanlidis, Bautista-Hernandez et al. 2011), diabetes (Maassen, LM et al. 2004, 
Simmons, Suponitsky-Kroyter et al. 2005, Gauthier, Wiederkehr et al. 2009), 
neurodegenerative disorders such as Alzheimer’s (Coskun, Beal et al. 2004, Coskun, 
Wyrembak et al. 2012), and aging (Corral-Debrinski, Shoffner et al. 1992, Trifunovic and 
Larsson 2008). Strikingly, increasing mtDNA copy number promotes cell survival or 
function in many models of disease associated with decreased mtDNA abundance, such 
as diabetes (Suarez, Hu et al. 2008, Gauthier, Wiederkehr et al. 2009), aging (Hayashi, 
Yoshida et al. 2008), Alzheimer's (Xu, Zhong et al. 2009), and Parkinson's (Keeney, 
Quigley et al. 2009, Piao, Kim et al. 2012). Thus, it is critical to understand how mtDNA 
copy number and integrity are maintained. 
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Mitochondrial transcription factor A (TFAM) is a DNA binding protein that plays 
multiple roles in regulating mtDNA function. As a sequence-specific transcription factor, 
it binds upstream of the light strand promoter (LSP) and heavy strand promoter 1 (HSP1) 
to activate initiation of transcription. At these sites, the footprint of TFAM binding is ~22 
bp long (Fisher and Clayton 1988, Ngo, Kaiser et al. 2011). As a result, TFAM is 
essential for production of gene products from the mitochondrial genome. In addition, 
TFAM is required for normal mtDNA copy number, because RNA primers generated 
from LSP are used to prime mtDNA replication (Chang Chang and Clayton 1984, Chang 
Chang and Clayton 1985). Mice heterozygous for a knockout of TFAM exhibit not only 
an expected reduction (22%) in mitochondrial transcript levels in the heart and kidney, 
but also a universal 34% reduction in mtDNA copy number across all assayed tissues. 
Furthermore, homozygous knockout mice have no detectable levels of mtDNA and die 
during embryogenesis (Larsson, Wang et al. 1998), highlighting the importance of TFAM 
in maintenance of mtDNA levels and in cellular and organismal viability.  
 
Apart from its sequence-specific functions, TFAM is thought to organize the 
mtDNA genome by coating it in a nonspecific manner. Although how TFAM packages 
mtDNA is not well-understood, it is known to bind nonspecifically to DNA (Fisher, 
Parisi et al. 1989) and is estimated to be sufficiently abundant to coat the genome 
completely (Alam, Kanki et al. 2003, Ekstrand, Falkenberg et al. 2004, Kaufman, Durisic 
et al. 2007). One model suggests that nonspecific binding radiates from the TFAM LSP 
binding site, which acts as a nucleation site for subsequent cooperative binding in a 
phased pattern to yield an inter-genome homogeneous pattern of binding (Fisher, 
 
 
90 
Lisowsky et al. 1992, Ghivizzani, Madsen et al. 1994). The packaging function of TFAM 
appears to have important consequences for maintenance of the mtDNA genome. A 
TFAM variant that is deficient in transcriptional activation but competent in DNA 
binding is capable of preventing mtDNA depletion (Kanki, Ohgaki et al. 2004). 
Therefore, as a prominent component of mtDNA nucleoids, TFAM appears to coat the 
mitochondrial genome, perhaps protecting it from turnover or deleterious damage.  
 
Despite the importance of the associations of TFAM with mtDNA in the 
maintenance of mtDNA integrity and in cellular viability, these interactions have not 
been characterized in vivo. Therefore, to capture a high-resolution profile of TFAM-
mtDNA interactions across the entire mitochondrial genome, we performed chromatin 
immunoprecipitation followed by massively parallel sequencing (ChIP-seq) for TFAM in 
human HeLa cells. 
 
Adaptation of ChIP-Seq to mtDNA 
Canonical ChIP-seq was developed (Johnson, Mortazavi et al. 2007) in order to 
capture the in vivo interactions of transcription factors binding to the nuclear genome. This 
involves binding protein to the DNA with which it associates, shearing of DNA into 
smaller pieces in order to decrease the length of the DNA associated with the protein, 
capture of the protein via immunoprecipitation, and sequencing of the attached protein. 
Because DNA that is bound to protein is protected from shearing, this yields a series of 
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short sequences corresponding to the DNA directly adjacent to the protein of interest. 
Various computational techniques are then able to identify the regions of interest across the 
genome. As such, the general protocol for ChIP-seq is (per the Myers laboratory, 
http://myers.hudsonalpha.org/documents/Myers%20Lab%20ChIP-
seq%20Protocol%20v041610.pdf): 
1) Fixation of cells with formaldehyde to crosslink protein to DNA 
2) Resuspension of cells in Farnham buffer to selective lyse cells while 
maintaining intact nuclei 
3) Selective centrifugation of nuclei 
4) Resuspension of pellet in RIPA buffer to lyse nuclei 
5) Sonication to shear DNA to desired size 
6) Immunoprecipitation using antibody against transcription factor of interest 
7) Reversal of crosslinks and isolation of DNA 
Even when performing ChIP-seq against a new transcription factor requires 
optimization of the protocol for optimized DNA recovery. Specifically, in the case of the 
mtDNA-targeted ChIP-seq that TFAM requires, such optimization is even more of a 
requirement. Fortunately, HeLa cells have been utilized in ChIP-seq experiments 
previously and work well with the standard protocol. However, the following steps 
remained to be optimized:  
- Recovery of mtDNA in the supernatant used for IP 
- Optimization of TFAM-specific antibodies used 
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- Optimization of DNA sonication 
Each of these steps was independently optimized before the full ChIP-seq protocol 
was performed, analyzed for mtDNA content, and sent for sequencing. 
 
III. Results 
HeLa Cell mtDNA ChIP-seq Optimization 
i.  Recovery of mitochondrial fraction in cellular lysate 
 The classic protocol for ChIP-seq involves resuspension of cross-linked DNA-
protein complexes with Farnham buffer (5 mM PIPES pH 8.0, 85 mM KCl, 0.5% NP-40, 
Roche Protease Inhibitor Cocktail) first to solubilize the cellular membrane, followed by a 
2000RPM centrifugation to pellet nuclei, removal of the supernatant, and resuspension of 
the pellet in RIPA buffer (1XPBS, 1% NP-40, 0.5% sodium deoxycholate, 1% SDS) to 
solubilize the nuclear membrane. However, the soft spin is not sufficient to pellet 
mitochondria, and therefore the pellet would most likely not contain mtDNA. 
 In order to determine the best method for segregation of mitochondria during this 
procedure, Westerns were performed on three different lysates in noncrosslinked HeLa 
cells: 1) mitochondria isolated from cells using nitrogen-bomb protocol (“Mito”); 2) the 
Farnham-based supernatant of the 2000RPM spin in the classic protocol (“Farnham”); and 
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3) the resuspended pellet after removal of the Farnham supernatant, (“RIPA”). The lysates 
were assayed for H2B (nuclear), Mfn2 (outer mitochondrial membrane), Opa1 (inner 
mitochondrial membrane), TFAM (mitochondrial matrix), and GAPDH 
(cytoplasmic/mitochondrial), and β-Actin (loading control) (Figure 3.1A).  β-Actin levels 
were consistent across each sample. Unsurprisingly, GAPDH was not found in the RIPA 
sample, remaining in the Farnham fraction; GAPDH was also found in the Mito fraction, 
but this is unsurprising given that GAPDH is known to be able to localize to mitochondria 
(Tarze, Deniaud et al. 2007). Also, as expected, a large amount of H2B was recovered in 
the RIPA sample, but not in the Farnham. Where there was recovery of H2B in the 
mitochondrial prep, this may be attributed to some nuclear contamination in the 
preparation, and is seen consistently across preps. 
 In terms of the mitochondrial proteins, neither Mfn2 nor Opa1 were seen in the 
RIPA sample, although this may be attributed to the low relative amounts of these proteins 
in cells. It is unclear why Opa1 was found in the Farnham sample, as neither TFAM nor 
Mfn1 were found. In the RIPA sample, a significant amount of TFAM was recovered, 
comparable to concentrations in the Mito sample, and TFAM levels were low in the 
Farnham sample. This is possibly because whole cells, unlysed by the Farnham buffer, 
were centrifuged into the pellet used for the RIPA sample. Indeed, in some cell lines, 
douncing is required to fully break the cell membrane and release the nucleus. Because we 
sought to recover TFAM and its interactions with mtDNA, we concluded that the majority 
of TFAM can be isolated using either a mitochondrial isolation, or the RIPA pellet. 
However, due to the ambiguity of the localization of other mitochondrial proteins, and due 
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to a desire to capture a maximal number of TFAM-DNA interactions, a whole-cell RIPA 
lysate would allow for full recovery of the protein. Although mitochondrial isolation would 
also be able to do so, due to the difficulty of isolating mitochondria from crosslinked cells, 
we chose to proceed with the whole-cell RIPA buffer lysis protocol. This method of lysis 
also had another benefit: as it has been suggested that TFAM localizes to the nucleus and 
regulates nuclear expression, recovery of nuclear DNA would allow for analysis of nuclear 
binding patterns as well. 
 
ii.  Optimization of antibodies for TFAM IP 
 A crucial, rate-limiting step of ChIP-seq is identifying a high-quality antibody that 
is capable of faithfully immunoprecipitating the protein of interest in cross-linked cells. 
Our lab had used full-length TFAM in order to custom-generate antibodies in mouse 
(Susan Ou, Caltech Monoclonal Antibody Facility), and screened for ELISA effectiveness 
(Elizabeth L. Nelson). Three top candidates were identified: H101A6, 20G2C12, and 
20F8A9.  
Furthermore, two different systems of Dynabeads for immunoprecipitation were 
tested for effectiveness. The first utilized Dynabeads MyOne Streptavidin T1 (Invitrogen 
#65601), in conjunction with protein L as adapter between streptavidin and the antibody. 
Because protein L can associate with all antibodies containing a kappa chain, it can pull 
down many antibodies from many classes, such as IgG, IgM, IgA, IgE, and IgD. The 
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second utilized Dynabeads M-280 sheep anti-mouse IgG (Invitrogen #11202D), which is 
only capable of pulling down mouse IgG antibodies. In the first method, streptavidin, 
which is covalently linked onto the surface of the magnetic Dynabeads, is incubated with 
protein L, which binds to streptavidin with near-covalent strength. After washing to remove 
excess protein L, conjugated beads were then incubated with each antibody. The second 
method is the classic method of antibody conjugation to beads, where the Dynabeads, to 
which sheep anti-mouse antibodies have been covalently linked, are incubated with the 
antibody of choice. 
 Testing of the two Dynabeads methods was performed on the same two fractions of 
noncrosslinked cells as previously: the Farnham supernatant post-centrifugation, and the 
pellet resuspended in RIPA buffer. Because the 20F8A9 antibody was not available in 
sufficient quantities for experiments, only the H101A6 and 20G2C12 antibodies were 
utilized to test the two Dynabeads methods. Cell lysate was incubated with each Dynabeads 
type, already conjugated to each respective TFAM antibody, overnight with nutation. 
Beads were then washed and conjugated protein was recovered using sample buffer 
containing 2% SDS. Immunoblotting with a custom-generated anti-TFAM antibody 
optimized for Westerns, 18G102B2E11, with protein A/G as secondary, showed no 
recovery of TFAM using the streptavidin Dynabeads or using the H101A6 antibody 
(Figure 3.1B). On the other hand, immunoprecipitation using sheep anti-mouse Dynabeads 
and the 20G2C12 antibody pulled down significant amounts of TFAM. TFAM was even 
recovered, albeit in smaller quantities, in the Farnham lysate sample. Thus, antibody 
H101A6 failed to immunoprecipitate TFAM, either because it was not captured by the 
 
 
96 
sheep anti-mouse Dynabeads, or because it cannot bind to TFAM under the 
immunoprecipitation conditions utilized. 
 When sufficient quantities of the 20F8A9 antibody were available, 
immunoprecipitation using the sheep anti-mouse Dynabeads was performed on whole cell 
RIPA lysate and found to immunoprecipitate TFAM, although at lower levels than of the 
20G2C12 antibody (Figure 3.1C). TFAM was not pulled down using Dynabeads 
conjugated to an anti-Myc antibody, demonstrating the specificity of the antibody and of 
the protocol. Finally, to verify that TFAM could still be captured when cells were 
crosslinked, whole cell lysate was incubated with 20G2C12 antibody conjugated beads, 
and the decrosslinked protein positively blotted for TFAM (Figure 3.1D). Although both 
the 20G2C12 and 20F8A9 antibodies were able to pull down TFAM, subsequent 
experiments were performed with only the 20G2C12 antibody due to its stronger 
immunoprecipitation capability. 
 
iii.  Further characterization of TFAM IP antibodies  
 To further validate the two antibodies that were capable of immunoprecipitating 
TFAM, 20G2C12 and 20F8A9, they were utilized as detection antibodies for Western blot 
and for immunocytochemistry. When utilized for Western blot, the antibodies should be 
able to uniquely detect a ~23kDa band for TFAM, and immunocytochemistry should 
demonstrate binding to protein localized in a generally punctate manner to the 
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mitochondria. However, the absence of either of these qualities does not denote that the 
antibody is incapable of binding to TFAM, as some antibodies do not detect the 
corresponding protein in all uses. 
 Western blot of HeLa cell whole cell lysate with the 20G2C12 antibody (1:200) 
yielded a single, ~23kDa band, confirming its specificity (Figure 3.1E). The 20F8A9 
antibody did not detect any bands, but this is not unexpected, as discussed above. 
Immunocytochemistry using these two antibodies as primary antibody in conjunction with 
anti-PPIF for mitochondrial matrix labeling and anti-mouse AF488 and anti-rabbit AF546 
was performed, and imaging was using a Zeiss LSM 710 confocal microscope with 
PlanApochromat 63X/14 oil objective. Cells were HeLa cells plated onto poly-lysine 
coated glass coverslips 48 hours prior to fixation in formaldehyde and permeabilization 
with 0.1% Triton X-100. Cells were also stained with DAPI to visualize nuclei. 
Representative images of the immunostained cells can be seen in (Figure 3.2A). Thus, 
using both antibodies, we visualize mitochondria-specific staining which is somewhat 
punctate in morphology, as has been previously described as typical of TFAM staining. 
We also wanted to determine whether the signal detected by the antibodies 
colocalized with mtDNA nucleoid puncta.  Immunocytochemistry with the TFAM 
antibodies and an anti-DNA primary and corresponding secondary antibody was utilized. 
This particular immunostaining was performed sequentially, because both the TFAM and 
DNA antibodies are raised in mouse; no DNA antibodies raised in other species are 
currently available for purchase. Fortunately, we took advantage of the fortuitous fact that 
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our DNA antibody is an IgM, which could be of a different class than our TFAM 
antibodies, as the majority of antibodies raised against an immunogen are IgG. A protocol 
was optimized to eliminate cross-reactivity, where an IgM-specific secondary antibody was 
utilized to detect the DNA antibody. The order of antibody application was thus as follows: 
anti-TFAM antibody; anti-mouse IgG antibody; anti-DNA antibody; and anti-mouse IgM 
antibody. This lead to no detectable background (Figure 3.2C). Visualization of nucleoids 
in relation to the 20G2C12 and 20F8A9 antibody staining revealed perfect colocalization of 
signals, with the TFAM signal enveloping that of the mtDNA, as expected (Figure 3.2B). 
  
iv.  Optimization of DNA sonication 
 The precision of ChIP-seq is highly dependent on the size of DNA after it has been 
sonicated. Because ChIP-seq relies on sequencing of just the ends of DNA in a sample, 
smaller DNA fragments leads to more precise localization of interactions; size is even more 
crucial for mapping of TFAM, due to the small size of the mitochondrial genome. 
Furthermore, efficiency of sonication can vary widely between machines, even those that 
are the same model. Thus, optimization of sonication using a QSonica Sonicator 4000 was 
performed on crosslinked whole cell lysate without the immunoprecipitation step. The 
Myer lab, using a Sonics VibraCell sonicator, recommends sonicating at 30s on/30s off 
intervals, at 5W power, for a total of 6 30s on intervals as a starting point. To test multiple 
conditions, the following conditions were used: 10amp (arbitrary unit of power, device can 
be set between 0 and 100amp), for 2, 4, 6, 8, or 30 sets; and 20amp, for 2, 4, 6, 8, or 30 
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sets. After sonication, samples were decrosslinked and run on a 2.5% agarose gel to 
determine the size of the sheared DNA (Figure 3.3A). Three lanes were loaded for each 
sample, each successive lane with double the relative amount of sample; the first, second, 
and third lanes of each sample were of equal relative quantity, respectively. Unfortunately, 
the conditions were largely unsuccessful, with the exception of the conditions for each 
amplitude with 30 sets, suggesting that a higher number of sets was required to shear DNA 
to an acceptable length. 
 This hypothesis was verified, and conditions for sonication were optimized for an 
average DNA length of 150-200bp. The best conditions were assayed to be 40amp for 45 
sets with lysates of lower concentration (Figure 3.3B), and 40amp for 90 sets with lysates 
of concentration of cells required for successful ChIP-seq (Figure 3.3C). Due to the 
extremely long time-frame of sonication, however, it was imperative to find a method to 
cool the sample during this step. Sonication at such a high power also generates additional 
heat, raising concerns of damaging or denaturing the protein, inadvisable for a protocol 
reliant on immunoprecipitation. Therefore, an experimental setup was devised where the 
sample was held in a 3:1 isopropanol:water bath kept at approximately -35°C with agitation 
from a stirbar beneath the sample. This succeeded in keeping the sample below room 
temperature, although the precise temperature is not known due to the difficulty of 
obtaining an accurate measurement in such a small sample. 
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v.  Verifying capture of mtDNA in ChIP-seq samples 
 After optimization of the aforementioned steps, the full protocol performed on 150 
x 106 HeLa cells using the 20G2C12 antibody yielded 139ng of DNA for the IP (via Qubit 
Fluorometer, Invitrogen), and 2.06ug of control DNA, derived from removing a 100ul 
aliquot of the 1ml sonicated whole cell lysate before incubation with Dynabeads. However, 
it was important to verify that mtDNA had been captured before sending the sample was 
sent for sequencing. Therefore, qPCR was utilized to analyze whether was an increase in 
mtDNA copy number relative to nuclear genome. 
 Six primers sets to the LSP promoter, and four to the HSP promoter, where TFAM 
has previously been DNase footprinted, were designed. Primers in the iB5s were utilized 
for nuclear genome quantification, having previously been validated by other labs. Two 
primer sets in the LSP promoter (LSP1 and LSP2), and two in the HSP promoter (HSP3 
and HSP4) were found to have high consistency and PCR efficiency approaching over a 
wide dynamic range. These primer pairs were used to quantify the amount of enrichment of 
mtDNA sequences with TFAM immunoprecipitation. Fortunately, while there were 190-
300 copies of each of the mtDNA templates per nuclear genome in the 
nonimmunoprecipitated, sonicated sample, there were between 65,700 and 105,000 copies 
per genome in the TFAM IP DNA (Figure 3.4), an enrichment of up to ~400-fold. Of note, 
it is not surprising that the exact copy number determined by each mtDNA primer set is not 
exactly the same, as qPCR was conducted on sonicated DNA, which is subject to breakage 
bias. 
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Detection of TFAM-DNA interactions using ChIP-seq 
Given the high efficiency of 20G2C12 in immunoprecipitating TFAM, as well as 
its high specificity, we used it to capture TFAM-associated DNA fragments for ChIP-seq 
analysis. HeLa cells were cultured in DMEM (Invitrogen #11995) containing 10% bovine 
serum (Invitrogen #16170), penicillin and streptomycin, and additional L-glutamine 
(2mM). It was imperative that cells be fed 24 hours before harvest for ChIP-seq, and the 
harvest performed at 80-90% confluency, in order to capture the cells while they were 
actively growing. mtDNA copy number increases (and thus presumably the dynamics of 
protein binding to the genome changes as well) when cells reach confluency and no 
longer proliferate normally. After formaldehyde fixation and quenching, cells were 
resuspended in RIPA buffer. Lysate was sonicated prior to immunoenrichment and size-
selected prior to library building so that the average fragment length of the final library 
was centered around 200 bp (Figure 3.5), a fragment distribution allowing for high-
resolution deconvolution of binding events. Sequencing was performed using Illumina 
GAIIx and Illumina HiSeq 2000 machines. In total, we generated 3 replicates and 
matching controls. The sequencing depth of all samples was between 18 million and 48 
million mappable reads, which is generally sufficient for comprehensive identification of 
transcription factor binding sites (Landt, Marinov et al. 2012).  
A common concern with ChIP-seq datasets is the variability of enrichment for 
true binding events as compared to background. In a typical ChIP-seq experiment, a 
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minority of sequencing reads originates from binding events, with the majority 
representing random genomic DNA. Even for the same DNA binding factor, large 
variations in the strength of enrichment can be observed, and therefore it is critical to 
assess the degree of enrichment before downstream analysis. A number of ChIP-seq 
quality control metrics have been developed (Landt, Marinov et al. 2012) for nuclear 
transcription factors. However, TFAM is expected to bind to the mitochondrial genome, 
which has very different characteristics from the nuclear genome. In addition, it is 
predicted to bind both in the classical localized manner (Kharchenko, Tolstorukov et al. 
2008) as well as broadly across the mitochondrial genome. As a result, metrics for 
evaluating nuclear transcription factors are not well-suited for analysis of TFAM binding 
data. We therefore examined the fraction of sequencing reads in our libraries mapping to 
the mitochondria as a proxy for the enrichment of TFAM binding events. Strikingly, 
between 30% and 75% of TFAM ChIP-seq reads mapped to the mitochondrial genome, 
while 0.4 – 1.9% of reads mapped to the mitochondrial genome in the input samples, 
indicating that our TFAM ChIP-seq datasets are indeed highly enriched for TFAM 
binding events (Figure 3.6B). We note that 75% ChIP enrichment is extremely high (in 
fact, practically unprecedented) for any transcription factor dataset (Landt, Marinov et al. 
2012), thus underscoring the high experimental quality of our datasets. 
Because partial copies of the mitochondrial genome are also present in the nuclear 
genome, not all reads originating from mtDNA can be mapped uniquely. Therefore, we 
characterized TFAM binding to mtDNA and to the nuclear genome separately; 
computational work was performed by Georgi K. Marinov. Sequencing reads were 
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trimmed from 38 to 36 bp and then mapped to either the female set of human 
chromosomes, excluding the Y chromosome and all random chromosomes and 
haplotypes, or, separately, to the mitochondrial genome alone (Figure 3.6A). For a 
standard nuclear transcription factor, this approach may cause some reads originating 
from the nuclear genome to artificially map to the mitochondrial genome. However, 
given that TFAM is known to bind to the mitochondrial genome and the extremely high 
enrichment for TFAM binding to mtDNA in our TFAM ChIP-seq libraries, this should 
not be a significant confounding factor. The hg19 version of the human genome was used 
as the reference template and Bowtie 0.12.7 (Langmead, Trapnell et al. 2009) was used 
for read alignment. We restricted our analysis to reads mapping perfectly without any 
mismatches to further increase mapping accuracy.  
 
i. TFAM coats the mitochondrial genome 
As discussed previously, TFAM has not only been proposed to bind specifically 
to well-defined binding sites in the D-loop, but has also been suggested to play a 
nonspecific packaging role in the nucleoid that is essential for mtDNA integrity. 
However, little is known about the pattern of non-specific binding of TFAM to the 
mitochondrial genome. Localized binding at the D-loop and diffuse binding across the 
rest of the genome are expected to result in distinct ChIP-seq signal profiles. Localized, 
“point-source” binding to DNA results in an asymmetric distribution of reads mapping to 
the forward and reverse strand around the binding site of the protein (Kharchenko, 
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Tolstorukov et al. 2008, Pepke, Wold et al. 2009), while diffuse binding does not produce 
such strand asymmetry.  
To characterize TFAM binding to mtDNA, we examined the forward and reverse 
strand read distribution after mapping TFAM ChIP-seq and input library reads to the 
mitochondrial genome. Strikingly, we did not observe regions of obvious enrichment and 
strand asymmetry in the D-loop; in particular, we did not see specific binding at the 
predicted HSP1 and LSP sites. On the whole, the TFAM ChIP-seq signal was broadly 
distributed over the whole mitochondrial chromosome, and while coverage was not 
perfectly uniform, the amplitude of the non-uniformity was not significant and the signal 
profile closely tracked that of the input sample (Figure 3.7). The low level of non-
uniformity likely results from sequencing biases, which has been documented to skew 
coverage (Dohm, Lottaz et al. 2008, Ross, Russ et al. 2013). Because our libraries were 
carefully size-selected for fragments in the 200 bp range, discrete TFAM binding sites 
would be expected to yield discrete signal localizations. Therefore, we interpret these 
results as evidence for the uniform coating of the whole mitochondrial genome by 
TFAM. We observed one region of apparent localized enrichment exhibiting strand 
asymmetry in the ND2 ORF near the OL, which is discussed below. 
To further verify our results, we carried out ChIP-seq against TFAM with a 
second TFAM monoclonal antibody, 20F8A9. We obtained similar results (Figure 3.8A) 
and found significant correlation between the 20F8A9 dataset and the three datasets 
obtained from the 20G2C12 antibody datasets (Figure 3.8B, p < 0.0001). Interestingly, 
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the correlation coefficient between ChIPs and between inputs was generally higher than 
that between a ChIP and its corresponding input, suggesting that while there is high 
repudibility between like datasets, there is less uniformity when the data is compared 
against its control. 
 
ii.  TFAM localizes specifically to a locus on the mitochondrial genome 
 Attempts at utilizing available peak-calling software such as MACS and 
ERANGE were unsuccessful. In the case of ERANGE, no peaks were called, and with 
MACS, while peaks were called, they tiled the genome and visual inspection revealed 
that they were nonsignificant (Figure 3.9). We attribute this to the largely uniform 
coverage of the genome by TFAM, resulting in signal ubiquitously. Because this type of 
coverage is unprecedented in the nuclear genome, software is not designed to 
deconvolute in a situation such as this and peaks cannot be called computationally. 
 We did visually inspect the genome for evidence of strong, specific binding sites 
which were obvious above the general nonspecific binding observed across the genome. 
A single site, centered at 5175 bp, displayed the morphology typical of single binding 
events. Prediction of curvature is based on the presence and localization of A(n) and T(n) 
tracts, where n ≥ 3. A curvature score is determined based on the size and location of 
these tracts relative to each other; in essence, the longer the tract and the closer to 10.5bp 
(1 DNA turn) away from the previous tract, the more likely to cause curvature. Previous 
 
 
106 
predictions and experiments have suggested that the last half of the ND2 ORF has 
exhibits sequence-dependent DNA curvature (Welter, Dooley et al. 1989, Gadaleta, 
D'Elia et al. 1996), a characteristic of many prokaryotic origins of replication 
(Mukherjee, Patel et al. 1985, Deb, DeLucia et al. 1986). It is thought that such curvature 
acts as a “landmark” for binding of transcription-related proteins. However, 
computational analysis of the region of specific TFAM binding predicted a curvature 
score of zero within 200bp of the 5175 bp site, as compared to the threshold value of 1.5 
considered significant for intrinsic curvature (Plaskon and Wartell 1987). Although 
EMSA was utilized to characterize curvature of the region upstream of OL in human 
mtDNA, the area surveyed stopped 50 bp short of this binding site (Welter, Dooley et al. 
1989). Thus, there is no evidence for sequence-dependent DNA curvature in the vicinity 
of the peak. 
 On the other hand, TFAM has been localized just upstream of the OL in rat 
mitochondria. In fact, the locus, discovered by affinity pull-down from mitochondrial 
protein lysate using the specific mtDNA sequence as probe, resides 520 bp upstream of 
the rat OL. In comparison, our identified site is 546bp upstream, suggesting that they may 
be congruent. 
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iii.  No evidence for TFAM binding to nuclear genome 
Previous studies have suggested that TFAM can be found in the nucleus and that 
it modulates the transcription of nuclear genes. In rat neonatal cardiac myocytes, TFAM 
was found to bind to the promoter of SERCA2, the homolog of human sarco-endoplasmic 
reticulum calcium-ATPase 2 (ATP2A2), and was implicated in regulating its 
transcription (Watanabe, Arai et al. 2011). Given the extremely high degree of TFAM 
binding enrichment in our datasets, any robust nuclear TFAM binding events should be 
readily detectable. To analyze nuclear binding, we excluded all sequencing reads 
mapping to the mitochondrial genome and used the resulting set of reads to identify 
putative TFAM binding sites. We first looked for significant global read clustering using 
cross-correlation between reads mapping to the forward and the reverse DNA strands 
(Kharchenko, Tolstorukov et al. 2008, Landt, Marinov et al. 2012). Cross-correlation 
plots for input samples and for TFAM ChIP-seq datasets were indistinguishable from 
each other (Figure 3.10A-B). Next, we called putative TFAM binding sites using 
MACS2 (Zhang, Liu et al. 2008). Using default settings (corresponding to a q-value cut-
off of 10-2) we identified 72, 137 and 153 sites respectively for the three replicates 
generated with antibody 20G2C12, and a single site for the 20F8A9 antibody. However, 
manual inspection of each of the identified sites revealed that all were likely to represent 
artifacts, mostly associated with repetitive DNA sequences, as none had the expected 
strand asymmetry of read distribution around a binding site. Instead, the two strand 
profiles at each site were identical (summarized in Figure 3.10D, with the classic nuclear 
transcription factor NRSF shown for comparison in Figure 3.10C), and numerous 
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unmappable regions and repetitive elements were present in the immediate vicinity of 
many of the called sites. Inspection of the ATP2A2 gene revealed no TFAM enrichment 
neither in the promoter region nor anywhere else in the neighborhood of the gene (Figure 
3.10E). Furthermore, we do not detect nuclear localization of TFAM in our cells via 
immunocytochemistry (Fig. 1C). Therefore, in HeLa cells under normal growth 
conditions, we find no evidence for specific binding of TFAM to nuclear target genes.  
 
IV. Discussion 
ChIP-seq was originally developed to capture the in vivo interactions of nuclear 
transcription factors with DNA. However, many interesting mitochondrial transcription 
factors exist which are vital for cellular and organismal viability. Study of these 
interactions required optimization of the standard ChIP-seq protocol, due to the 
localization of mtDNA in the mitochondrial and because of the physical differences – 
nuclear DNA is long and linear, while mtDNA is short and circular. We show here 
successful recovery of mtDNA in DNA prepared via our modified ChIP-seq protocol, 
and localization of 30-75% of reads to the mitochondrial genome, highlighting the high 
experimental quality of our methods. 
Previous in vitro studies have suggested that TFAM binds specifically to LSP and 
HSP1, and that it may also bind nonspecifically in a phased manner. Furthermore, 
evidence has been presented for its nuclear localization and action as a canonical nuclear 
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transcription factor in rat neonatal cardiac myocytes. However, no direct genome-wide 
measurements of TFAM binding have been previously reported. Our TFAM ChIP-seq 
data reveal very high enrichment for reads mapping to the mitochondrial genome, but a 
binding pattern that largely mirrors the read distribution observed in the input DNA, 
suggesting broad, non-specific binding to mitochondrial genome. This pattern is highly 
reproducible, indicating that the average population-wide state of TFAM-mtDNA 
interactions is stable. We found no correlation between irregularities in TFAM signal 
distribution and characteristics of the mitochondrial genome such as GC content. Thus, 
we conclude that TFAM binds to the mitochondrial genome nonspecifically and without 
bias when cells are grown under typical culture conditions. Although we do not observe 
the synchronized phased binding seen in in-vitro studies, we cannot rule out a model 
where individual mtDNAs have such a pattern of binding initiating from a non-universal 
nucleation site.  
Strikingly, we did not observe localized enrichment of binding at the known LSP 
and HSP1 TFAM binding sites. Peak patterns mirrored that of the input in these regions, 
and no ChIP-seq peaks displaying the canonical strand asymmetry in read distribution 
were observed. This finding can be explained by a model in which the interaction of 
TFAM with the LSP and HSP1 binding sites is relatively transient and infrequent 
compared to a more stable non-specific association with the genome in its packaging 
state. 
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We did detect one site in the genome exhibiting the characteristics of a specific, 
localized ChIP-seq peak, centered at 5175 bp in the ND2 ORF. The localized nature of 
the ChIP signal at this site suggests higher occupancy of TFAM. This peak localizes to 
546 bp upstream of the OL. Strikingly, TFAM has previously been localized 520 bp 
upstream of the OL of rat mtDNA (Gadaleta, D'Elia et al. 1996, Cingolani, Capaccio et al. 
1997, Pierro, Capaccio et al. 1999). We found no sequence similarity between the rat and 
human sites, and in general this region of the mtDNA genome shows low homology 
between the two species. Further work will be required to understand the significance of 
this putative TFAM binding site. 
Finally, analysis of all datasets for TFAM binding to the nuclear genome yielded 
no hits distinguishable from common ChIP-seq artifacts. Although Watanabe et al. 
observed regulation of the SERCA2 gene in rat myocytes, we did not detect TFAM 
binding at the promoter of its ortholog in humans. Previous studies have shown nuclear 
localization of TFAM in rat hepatoma cells (Dong, Ghoshal et al. 2002), as well as an 
alternate isoform of TFAM in mouse testis nuclei (Larsson, Garman et al. 1996). We 
have thus far been unable to detect nuclear TFAM localization in HeLa cells (Figure 
3.2A), suggesting that nuclear localization and transcriptional regulation may be cell type 
or perhaps species-dependent. ChIP-seq in different cell lines may be able to detect such 
nuclear interactions. 
We demonstrate here the first in vivo ChIP-seq analysis of TFAM binding to the 
mitochondrial genome. Aside from generalized, largely non-specific binding across the 
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mitochondrial genome, we detected a putative specific binding site upstream of the origin 
of light strand replication. We do not observe the expected binding at the known HSP1 
and LSP sites, nor did we identify any nuclear binding sites. An area that remains to be 
explored is the dynamic nature of TFAM-DNA interactions with respect to both the 
nuclear and mitochondrial genomes. ChIP-chip on the yeast mitochondrial genome has 
shown that metabolic changes can lead to differential binding of the yeast TFAM 
homolog, Abf2p (Kucej, Kucejova et al. 2008). It is possible that such remodeling also 
occurs in the mammalian system, and further studies will provide insight into the 
dynamic nature of the mtDNA-protein interactions within the nucleoid that serve to 
protect its integrity. 
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V. Methods 
Cell growth and treatment 
HeLaS3 cells were cultured in Dulbecco’s modified Eagle's medium (DMEM, 
Invitrogen #11995) containing 10% bovine serum (Invitrogen #16170), penicillin and 
streptomycin, and additional L-glutamine (2mM). Cells were fed 24 hours before harvest 
for ChIP-seq, which was performed at 80-90% confluency.  
 
Antibody Production and characterization 
Antibodies were produced by the Caltech Monoclonal Antibody Facility and 
raised against the full-length TFAM protein in mouse. Immunoprecipitation with 
20G2C12 and 20F8A9 TFAM antibodies and Myc antibody (Santa Cruz #sc-40) was 
performed according to established protocols using M-280 sheep anti-mouse Dynabeads 
(Invitrogen #11201D). Immunoblotting of IP products was performed using a 
monoclonal TFAM 18G102B2E11 antibody, also custom generated, at 1:2000, with goat 
anti-mouse HRP antibody (1:10,000, Jackson ImmunoResearch #115-056-003). 
Immunoblotting of HeLa whole cell lysate with 20G2C12 was performed at a 1:200 
dilution and with goat anti-mouse HRP antibody. 
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Additional immunoblotting antibody concentrations were as follows: b-actin 
(1:500, Imgenex #IMG-5142A); H2B  (1:500, Imgenex #IMG-359); Mfn2 (1:1000, 
Sigma #128K4840), Opa1 (1:2000, in-house), GAPDH (1:2000, Imgenex #IMG5143A). 
Secondary antibodies, all at 1:10,000, included: goat anti-mouse (Jackson #115-056-003), 
and goat anti-rabbit (Jackson #111-035-003), and protein A/G. 
 
Isolation of Mitochondria 
 Isolation of mitochondrial was performed using “nitrogen bomb” method, per 
Nickie Chan. Cells were harvested by 1000rpm centrifugation for 10min, then 
subsequently washed with ice-cold PBS and pelleted at 1000rpm again. Cell pellet was 
then resuspended in isolation buffer (220mM mannitol, 70mM sucrose, 10mM HEPES-
KOH ph7.4, 1mM EGTA) and HALT protease inhibitor (Pierce #87786), and transferred 
to Parr 45ml nitrogen bomb (Parr #4639). After cell lysate was relased from bomb, it was 
centrifuged at 600g x 5min and the supernatant was collected. The pellet was dounced 
gently to break down remaining whole cells in the pellet, and recentrifuged. Supernatants 
were then pooled, and centrifuged at 650g x 5min repeatedly until no pellet was visibile 
in order to rid the lysate of any remaining whole cells and debris. The mitochondrondria 
were then pelleted at 10,000g x 10min and resuspended in RIPA buffer for future 
experiments.  
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Visualizing DNA sonication efficiency 
 Cells were formaldehyde crosslinked and quenched, and then sonicated using 
QSonica Sonicator 4000. Decrosslinking was performed by 65C incubation overnight, 
and resultant DNA was purified via phenol-chloroform extraction followed by PCR 
purification (Qiagen #28104), substituting buffer PM for buffer PB in the classic 
protocol. 4, 8, or 16ul of the 100ul lysate was then loaded onto a 2.5% agarose gel for 
visualization with EtBr incorporation. 
 
Quantitative PCR for human DNA 
 Four sets of primers, LSP1, LSP2, HSP3, and HSP4, were utilized for mtDNA 
quantification. One set of primers, iB5s, was used for nuclear DNA quantificiation. 
 
 
 
 
qPCR was performed on Bio-Rad CFX-96 machine with using Brilliant SYBR Green 2X 
Master Mix, Agilent #929548 and the following cycling conditions: 10min@95C, 
Primer ID Sequence     
LSP1F  GATCACAGGTCTATCACCCTATTAACCACT   
LSP1R  CAGCGTCTCGCAATGCTATCGC 
LSP2F  CGGGAGCTCTCCATGCATTTGGTATTTTC 
LSP2R  CAAAGACAGATACTGCGACATAGGGTGC 
HSP3F  CACTGAAAATGTTTAGACGGGCTCACATCA 
HSP3R CTGGAACGGGGATGCTTGCATG 
HSP4F  CACATCACCCCATAAACAAATAGGTTTGGTCCTAGCC 
HSP4R  TTTAGAGGGTGAACTCACTGGAACGG 
iB5sF  AGACTCCGACCCTTCCTGAC 
iB5sR  CCTCCGAGCTTGGGATAAAG 
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[30sec@95C, 1min@60.2C, 1min@72C]x40. 
 
Immunocytochemistry 
HeLa cells cultured as described above were plated onto poly-lysine coated glass 
coverslips 48 hours prior to fixation in formaldehyde and permeabilization with 0.1% 
Triton X-100. For colocalization of TFAM to mitochondria, 20G2C12 or 20F8A9 
antibodies were used at 1:10 in conjunction with PPIF at 1:200 (ProteinTech #18466-1-
AP). Secondary antibodies were goat anti-mouse AF488 (1:500, Invitrogen #A11001) 
and donkey anti-rabbit AF546 (1:500, Invitrogen #A10040). Cells were also stained with 
DAPI to visualize nuclei. Immunocytochemistry to visualize colocalization of 
mitochondrial nucleoids and TFAM was performed sequentially due to both antibodies 
being raised in mouse. Sequential immunostaining yielded no background fluorescence 
due to cross-antibody reactivity (data not shown). Order was as follows: anti-TFAM 
antibody (1:10); goat anti-mouse AF488 (1:500, Invitrogen #A11001); anti-DNA 
antibody (1:25, Millipore #CBL186); goat anti-mouse AF555 (1:500, Invitrogen 
#A21426), DAPI. Images were acquired with a Zeiss LSM 710 confocal microscope with 
PlanApochromat 63X/1.4 oil objective. Z-stack acquisitions were converted to maximum 
z-projections using ImageJ software. 
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Chromatin immunoprecipitation and sequencing 
ChIP experiments and preparation of DNA for sequencing were performed 
following standard procedures (Johnson, Mortazavi et al. 2007) with some modifications. 
Cells were fixed for 10min at RT in 1% formaldehyde, harvested using a cell scraper, 
washed once in ice-cold PBS, and resuspended in RIPA buffer with protease inhibitor. 
The sample was then sonicated using a 3.2mm microtip (QSonica Sonicator 4000) at 30s 
on/30s off intervals and 40% amplitude for 180min while in a -30°C 3:1 isopropanol and 
water bath containing dry ice. Subsequent steps were performed as per the standard 
protocol. DNA was size-selected during library building to an average fragment size of 
200bp. Libraries were sequenced using Illumina GAIIx and Illumina HiSeq 2000. 
Sequencing data is available under GEO accession record GSE48176. 
 
Sequencing data processing and analysis 
Sequencing reads were trimmed down to 36 bp and then mapped against either 
the female set of human chromosomes (excluding the Y chromosome and all random 
chromosomes and haplotypes) or the mitochondrial genome alone, using the hg19 version 
of the human genome as a reference. Bowtie 0.12.7 (Langmead, Trapnell et al. 2009) was 
used for aligning reads, not allowing for any mismatches between the reads and the 
reference. ChIP-seq peaks were called using MACS2 (Zhang, Liu et al. 2008) with 
default settings except for the mfold parameter, which was lowered to (2,30). Circos plots 
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were generated using Circos version 0.60 (Krzywinski, Schein et al. 2009). Additional 
data processing was carried out using custom-written python scripts. ENCODE data was 
downloaded from the UCSC browser (http://hgdownload-
test.cse.ucsc.edu/goldenPath/hg19/encodeDCC/wgEncodeHaibTfbs) and its use here 
complies with its terms of usage. Pearson correlation coefficient, t-test, and p values were 
calculated using embedded and custom Microsoft Excel functions. 
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VI. Figure Legends 
Figure 3.1. Localizing mitochondria in cellular fractions. A) Mitochondrial prep [1], 
RIPA-buffer solubilized pellet [2], and Farnham buffer solubilized supernatant [3] were 
immunoblotted for actin, H2B, Mfn2, TFAM, Opa1, and GAPDH. TFAM localized to [1] 
and [2], but not [3]. B) Antibodies H101A6 and 20G2C12 were tested for ability to 
immunoprecipitate TFAM using either streptavidin- or sheep anti-mouse-conjugated 
Dynabeads. Western is anti-TFAM with protein A/G secondary. Two types of lysate were 
used: Farnham supernatant (“Farnham”) and pellet resuspended in RIPA buffer. 
Conditions as follows: [1] 20G2C12 RIPA; [2] 20G2C12 Farnham; [3] H101A6 RIPA; 
[4] H101A6 RIPA; [5] Myc Farnham;  [6] 20G2C12 RIPA; [7] 20G2C12 Farnham; [8] 
H101A6 RIPA; [9] H101A6 RIPA; [10] Myc RIPA; [11] Myc Farnham; [12] RIPA 
lysate alone. 1-5 are using streptavidin-conjugated beads, and 6-11 are using sheep-anti-
mouse conjugated beads. Red arrow indicates TFAM band. No TFAM was capture by 
any condition with streptavidin beads. 20G2C12 antibodies captures the most TFAM in 
RIPA lysate, with some captured in Farnham lysate. H101A6 does not capture any 
TFAM, nor does Myc antibody. RIPA lysate shown as control. Note that ~26 kDa band is 
light chain, and ~50 kDa band is heavy chain. C) Immunoprecipitation of TFAM from 
noncrosslinked whole cell lysate. HeLa cell lysate was applied to sheep anti-mouse 
Dynabeads conjugated to anti-Myc [1], 20G2C12 TFAM antibody [2], 20F8A9 TFAM 
antibody [3], or a 50/50 mixture of 20G2C12 and 20F8A9 TFAM antibodies [4]. The 
labeled bands are: I. Antibody heavy chain; II. antibody light chain; III. TFAM. D) 
20G2C12 antibody successfully immunoprecipitates TFAM that has been crosslinked to 
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DNA. Cells were fixed by formaldehyde, sonicated, and then incubated with sheep-anti-
mouse antibodies conjugated to 20G2C12 antibody. After immunoprecipitation, 
decrosslinking of DNA and protein was performed and protein lysate was assayed by 
anti-TFAM immunoblotting. [1] Immunoprecipitated lysate; [2] immunoprecipitated 
lysate with 2x beads; [3] supernatant of immunoprecipitation (after removal of beads); [4] 
supernatant of immunoprecipitation, 2x beads (after removal of beads). Same % of each 
sample is loaded in each lane. Not all TFAM from lysate is captured; use of twice the 
concentration of beads yielded poorer results. E) Western blot of whole cell HeLa lysate 
using the 20G2C12 antibody detects only a ~23kDa band. 
 
Figure 3.2.  Characterization of TFAM monoclonal antibodies. A)  
Immunocytochemistry showing TFAM localization in HeLa cells. Mitochondria were 
identified by PPIF staining; B) mtDNA was identified by anti-DNA staining. There was 
no evidence for nuclear localization of TFAM using either antibody. C) sequential 
immunostaining of cells with TFAM and DNA antibodies yielded no cross-reactivity 
when either the DNA or TFAM antibody was not used; respective secondary antibodies 
were utilized. 
 
Figure 3.3. Optimization of DNA sonication.  HeLa whole cell lysate was sonicated 
using either 10amp or 20amp power, and either 2,4, 6, or 30 replicates of 30s on/30s off 
 
 
120 
sonication. Only 10/20amp x 30 was successful in yielding DNA near the size desired, 
indicating that a larger number of cycles was required. B) 30am x 45 and 40amp x 45 are 
able to successfully shear DNA to an average length of 150-200bp in small samples of 
cell lysate. In larger samples C), 45amp x 90 was sufficient to effect shearing. 50amp x 
90 yielded no benefit over 40amp, so the lower power value was selected due to it being 
less damaging to sample. 
 
Figure 3.4. ChIP-seq against TFAM yields high ratio of mtDNA:nDNA. DNA was 
collected either before immunoprecipitation (Sonicated DNA), or after 
immunoprecipitation (TFAM ChIP), and was assayed by qPCR using four different 
primer sets for mtDNA content. While mtDNA:nDNA ratio was 190-300 in pre-
immunoprecipitated cells, it was 65,700-105000/genome after, indicating a very high 
enrichment for mtDNA, as expected with a successful ChIP. 
 
Figure 3.5. Bioanalyzer of TFAM ChIP-seq shows majority of DNA centered at 
~200bp. Analysis of ChIP-seq DNA sent for sequencing shows that the majority was 
sheared to ~ 222bp. 
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Figure 3.6. ChIP-seq analysis of genome-wide TFAM binding. (A) Overview of 
computational processing of data. Reads were trimmed to 36 bp and then either mapped 
against the mitochondrial genome (ChrM), or the complete hg19 version of the genome. 
After removing multireads and alignments to the mitochondrial genome, peaks in the 
nuclear genome were called using MACS2. (B) The proportion of sequencing reads 
mapping to chrM in ChIP and input datasets. All replicates of the ChIP-seq resulted in at 
least 30% of reads mapping to the mitochondrial genome, much greater than the 0.4-1.9% 
of reads mapping to mtDNA in the input datasets. Replicates 1-3 were performed using 
the 20G2C12 antibody, while Replicate 4 was performed using the 20F8A9 antibody. 
 
Figure 3.7. Coating of the mitochondrial genome by TFAM in HeLa cells. Circos plot 
of plus strand and minus strand TFAM ChIP-seq and input read density signal over chrM. 
(A, E) Annotation of protein coding (green on forward/heavy strand, red on reverse/light 
strand), ribosomal RNA (blue) and tRNA (blue on forward/heavy strand, grey on 
reverse/light strand) transcripts. (B) D-loop (black), LSP promoter (large red tile), known 
LSP TFAM binding site (small red tile), HSP promoter (large blue tile), known HSP1 
TFAM binding site (small blue tile), and origins of heavy strand replication (Ori-b, 
orange tile; OH, yellow tile). (C) TFAM ChIP-seq signal on forward (red) and reverse 
(blue) strands. (D) Input signal on forward (red) and reverse (blue) strands. (F) Origin of 
light strand replication (yellow tile). Note that the input signal is exaggerated 60-fold 
relative to the ChIP-seq signal in order to visualize coverage irregularities. The signal 
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from the TFAM ChIP-seq largely follows that of the input, indicating generalized binding 
across the mitochondrial genome. 
 
Figure 3.8: Comparison of profiles of TFAM binding to mitochondrial genome. (A) 
Circos plots of TFAM ChIP-seq experiments: (1) 20F8A9 antibody ChIP-Seq; (Shen-Li, 
O'Hagan et al.) 20G2C12 replicate 1; (Gerstein, Lu et al.) 20G2C12 replicate 2; (4) 
20G2C12 replicate 3. Read profiles are very similar across replicates and antibodies. (B) 
R2 coefficient of determination values for dataset pairs: rep to rep – TFAM ChIP pairs; 
rep to input – TFAM ChIP to corresponding input; input to input – input pairs. 
 
Figure 3.9. MACS calls along the mitochondrial genome. MACS was utilized to call 
peaks on the mitochondrial genome (first replicate). 1) Called peaks tile the genome. 2) 
Plus-strand read distribution; 3) minus-strand read distribution. 
 
Figure 3.10. Absence of TFAM binding to the nuclear genome. (A) Cross-correlation 
plot of input DNA computed over the nuclear genome. (B) Cross-correlation plot of 
TFAM ChIP-seq computed over the nuclear genome. (C) Distribution of ChIP-seq reads 
mapping to the plus and minus strand around called binding sites in a ChIP-seq dataset 
for the NRSF transcription factor (Schoenherr and Anderson 1995) [51] in HeLa cells, 
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generated by the ENCODE consortium. (D) Distribution of TFAM ChIP-seq reads 
mapping to the plus and minus strand around called binding sites indicates lack of real 
binding sites. (E) No ChIP-seq enrichment around the promoter of the SERCA2/ATP2A2 
gene, previously suggested to be a TFAM target. 
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VII. Figures 
Figure 3.1. 
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Figure 3.2. 
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Figure 3.3. 
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Figure 3.4. 
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Figure 3.5. 
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Figure 3.6. 
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Figure 3.7. 
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Figure 3.8. 
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Figure 3.9. 
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Figure 3.10. 
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I. Abstract 
Mitochondria contain their own circular genome, with mitochondria-specific 
transcription and replication systems and corresponding regulatory proteins. All of these 
proteins are encoded in the nuclear genome and are post-translationally imported into 
mitochondria. While several classically nuclear transcription factors have been reported 
to act in mitochondria and to bind to the D-loop, there has been no comprehensive 
mapping of their occupancy patterns across the genome. Furthermore, it is not clear how 
many other nuclear TFs may also be found in mitochondria. By using ChIP-seq data from 
the ENCODE, mouseENCODE and modENCODE consortia for 151 human, 31 mouse 
and 35 C. elegans factors, we were able to identify 8 human and 3 mouse transcription 
factors with strong localized enrichment over the mitochondrial genome that was usually 
associated with the corresponding recognition sequence motif. Notably, these sites of 
occupancy are often the sites with highest ChIP-seq signal intensity within both the 
nuclear and mitochondrial genomes and are thus best explained as true binding events to 
mitochondrial DNA, which exist in high copy number in each cell.  We corroborated 
these findings by immunocytochemical staining evidence for mitochondrial localization. 
However, we were unable to find clear evidence for mitochondrial binding in ENCODE 
and other publicly available ChIP-seq data for most factors previously reported to 
localize there. As the first global analysis of nuclear transcription factors binding in 
mitochondria, this work opens the door to future studies that probe the functional 
significance of the phenomenon. 
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II. Introduction 
Mitochondria are the primary site of ATP production through oxidative 
phosphorylation and are therefore critical to eukaryotic cells. It is widely accepted that 
they arose as the result of an endosymbiotic event (Sagan 1967) between the ancestor of 
modern eukaryotes and a member of the α-proteobacteria clade (Yang, Oyaizu et al. 
1985). Reflective of the organelle's prokaryotic ancestry, mitochondria retain their own 
circular genome (Nass, Nass et al. 1965), although its size has been greatly reduced in 
many eukaryotes through transfer of genes to the eukaryotic nucleus. After transcription 
and translation of nuclear components of the separate mitochondrial transcription, 
replication and regulatory machineries, a number of which retain evidence of their 
prokaryotic origin (Szklarczyk and Huynen 2010), the protein products are then imported 
back into the mitochondria to modulate organellar function. 
The mitochondrial genome in mammals encodes 13 proteins, all of which are 
components of the electron transport chain, as well as 22 tRNAs and two rRNAs 
(Anderson, Bankier et al. 1981, Bibb, Van Etten et al. 1981). Mitochondrial DNA 
(mtDNA) is organized in cells as macromolecular DNA-protein complexes called 
nucleoids. Mitochondrial genes are densely packed along the genome, with the notable 
exception of the D-loop regulatory region (Shadel and Clayton 1997), which is located 
within the NCR. Transcription initiates in the D-loop, is carried out by the mitochondrial-
specific RNA polymerase POLRMT, and results in long polycistronic transcripts from 
each strand (called the Heavy- or H-strand and the Light- or L-strand), from the light 
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strand promoter (LSP) and the two Heavy strand promoters (HSP1 and HSP2) (Cantatore 
and Attardi 1980, Montoya, Christianson et al. 1982). In addition, the transcription 
factors TFAM (Fisher and Clayton 1985, Fisher and Clayton 1988, Fisher, Lisowsky et 
al. 1992), and TFB2M as well as the methyltransferase TFB1M (Falkenberg, Gaspari et 
al. 2002, Gaspari, Larsson et al. 2004, Metodiev, Lesko et al. 2009) are required for 
initiation and regulation of transcription (Shutt, Bestwick et al. 2011). Unlike many of the 
proteins involved in regulation of the mitochondrial genome, these transcription factors 
are generally accepted as not being of prokaryotic origin. Instead, they are genes of 
eukaryotic ancestry, appropriated for their function through co-evolution of the organellar 
and cellular genomes and imported into mitochondria to regulate mtDNA transcription.  
In addition to these well-characterized regulators of mitochondrial transcription, 
previous studies on a few transcription factors have suggested that certain ones which 
normally effect regulation of the nuclear genome may have an indirect or even direct 
effect on mitochondrial transcription (Achanta, Sasaki et al. 2005, Ryu, Lee et al. 2005, 
Leigh-Brown, Enriquez et al. 2010). The glucocorticoid receptor was the first such factor 
reported to localize to mitochondria and to interact with mtDNA (Demonacos, 
Tsawdaroglou et al. 1993, Demonacos, Djordjevic-Markovic et al. 1995, Koufali, 
Moutsatsou et al. 2003, Psarra, Solakidi et al. 2006). A 43kDa isoform of the thyroid 
hormone T3R α receptor, p43, has been found to directly control mitochondrial 
transcription (Wrutniak, Cassar-Malek et al. 1995, Casas, Rochard et al. 1999, Enriquez, 
Fernandez-Silva et al. 1999, Enriquez, Fernandez-Silva et al. 1999). CREB has been 
shown to localize to mitochondria, and ChIP followed by SACO on select 21-bp CRE-
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like sites on the genome suggests that it binds to the D-loop (Cammarota, Paratcha et al. 
1999, Lee, Kim et al. 2005, Ryu, Lee et al. 2005). The tumor suppressor transcription 
factor p53 has been implicated in mtDNA repair and regulation of gene expression 
through interactions with TFAM (Marchenko, Zaika et al. 2000, Yoshida, Izumi et al. 
2003, Heyne, Mannebach et al. 2004, Achanta, Sasaki et al. 2005). The mitochondrial 
localization of the estrogen receptor is also well established, for both its ERα and ERβ 
isoforms, and it too has been suggested to bind to the D-loop (Monje and Boland 2001, 
Chen, Delannoy et al. 2004). NFκB and IκBα have been found in mitochondria and have 
been proposed to regulate mitochondrial gene expression (Cogswell, Kashatus et al. 
2003, Johnson, Witzel et al. 2011). The AP-1 and PPARγ2 transcription factors have 
been proposed to localize to mitochondria and bind to the genome (Casas, Domenjoud et 
al. 2000, Ogita, Okuda et al. 2002, Ogita, Fujinami et al. 2003), and the MEF2D 
transcription factor was found to regulate the expression of the ND6 gene by binding to a 
consensus sequence recognition motif within it (She, Yang et al. 2011). Finally, the 
presence of STAT3 in mitochondria has been found to be important for the function of 
the electron transport chain and also to be necessary for TNF-induced necroptosis 
(Gough, Corlett et al. 2009, Wegrzyn, Potla et al. 2009, Szczepanek, Chen et al. 2011, 
Shulga and Pastorino 2012, Szczepanek, Chen et al. 2012), although direct mtDNA 
binding has not been established. Mitochondrial localization has also been reported for 
STAT1 and STAT5 (Boengler, Hilfiker-Kleiner et al. 2010, Chueh, Leong et al. 2010). 
Despite the evidence for nuclear transcription factors localizing to mtDNA, direct 
in vivo immunoprecipitation evidence for the binding of these factors to the genome 
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exists only for CREB (Lee, Kim et al. 2005), p53 (Achanta, Sasaki et al. 2005), and 
MEF2D (She, Yang et al. 2011), and with the exception of MEF2D characterization, is 
limited to the D-loop region. No prior studies have assayed transcription factor 
occupancy across the entire mitochondrial genome in vivo with modern high-resolution 
techniques such as ChIP-seq (Chromatin Immunoprecipitation coupled with deep 
sequencing (Johnson, Mortazavi et al. 2007)). As a result, the precise nature, and in many 
instances the existence, of the proposed binding events remains unknown. The limited 
sampling of transcription factors in previous studies also leaves uncertain how common 
or rare localization to mitochondria and binding to mtDNA is for nuclear transcription 
factors in general. 
Here we survey the large compendium of ChIP-seq and other functional genomic 
data made publicly available by the ENCODE, mouseENCODE and modENCODE 
Consortia (Gerstein, Lu et al. 2010, mod, Roy et al. 2010, Consortium 2011, Consortium, 
Bernstein et al. 2012, Mouse, Stamatoyannopoulos et al. 2012)  to identify transcription 
factors that associate directly with mtDNA and to characterize the nature of these 
interactions. We identify eight human and three mouse transcription factors for which 
robust evidence of site-specific occupancy in the mitochondrial genome exists. These 
sites exhibit the strand asymmetry typical of nuclear transcription factor binding sites, 
usually contain the recognition motifs for the factors in question, and are typically the 
strongest (as measured by ChIP-seq signal strength) binding sites found in both the 
nuclear and mitochondrial genome by a wide margin. Notably, these interactions are all 
found outside of the non-coding D-loop region. The D-loop region itself exhibits 
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widespread sequencing read enrichment for dozens of transcription factors. However, it 
does not show the aforementioned feature characteristics of true binding events. Though 
not observed in control datasets generated from sonicated input DNA, the high ChIP-seq 
signal over the D-loop is frequently seen in control datasets generated using mock 
immunoprecipitation, suggesting that it is likely to represent an experimental artifact. 
Examination of available ChIP-seq data for the transcription factors previously proposed 
to play a role in mitochondria (GR, ERα, CREB, STAT3, p53) revealed no robust 
binding sites except for enrichment in the D-loop. Resolving the functional significance 
of the identified occupancy sites in future studies should provide exciting insights into the 
biology of both mitochondrial and nuclear transcriptional regulation. 
 
III. Results 
In the course of our study of TFAM occupancy in the mitochondrial and nuclear 
genomes (Wang, Marinov et al. 2013), we noticed that a number of nuclear transcription 
factors exhibit localized enrichment in certain areas of the mitochondrial genome in 
ChIP-seq data (Figure 4.1). These events could be divided in two classes: high ChIP-seq 
signal over the NCR, and localized high read density over regions outside of it. Given 
prior reports suggesting that nuclear transcription factors might act in mitochondria, the 
potential of exploiting the power and resolution of existing ChIP-seq data to shed light on 
this phenomenon is significant. Thus, we surveyed available functional genomics data to 
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characterize the general prevalence of the phenomenon among transcription factors and 
investigate evidence of occupancy in detail. We took advantage of the wide compendium 
of human, mouse, fly and worm functional genomics data generated by the ENCODE, 
mouseENCODE, and modENCODE cortoria (Gerstein, Lu et al. 2010, mod, Roy et al. 
2010, Consortium 2011, Consortium, Bernstein et al. 2012, Mouse, Stamatoyannopoulos 
et al. 2012) and analyzed it for mitochondrial binding events. 
In collaboration with Georgi K. Marinov, we found: 
1) The human, mouse, and C. elegans mitochondrial genomes are largely 
mappable 
2) The signal intensity of mtDNA-mapping peaks is dependent on cell type  
3) Eight human transcription factors and three mouse transcription factors have 
strong localized enrichment over the mitochondrial genome 
4) Mitochondrial peaks rank in top three peaks in intensity across the genomes 
5) Transcription factor cellular localization for identified TFs is mitochondrial 
despite the lack of a recognized MTS 
Computation was performed by Georgi Marinov.  
Identifying transcription factor binding events in the mitochondrial genome 
Publicly available ENCODE and mouseENCODE ChIP-seq and control data from 
the UCSC Genome Browser and modENCODE data, were downloaded from 
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ftp://ftp.modencode.org, which included ChIP-seq data for 151 transcription factors in 
human cell lines (Wang, Zhuang et al. 2012), 31 in mouse, and 35 in C.elegans. We also 
downloaded DNase hypersensitvity (both DNase-seq (Thurman, Rynes et al. 2012) and 
DGF (Neph, Vierstra et al. 2012)), FAIRE-seq (Song, Zhang et al. 2011) and MNase-seq 
data as these datasets provide valuable orthogonal information about potentially 
artifactual patterns of read enrichment over the mitochondrial genome.  
It is well known that the nuclear genome contains partial copies of the 
mitochondrial genome (NUMTs) (du Buy and Riley 1967, Hazkani-Covo, Zeller et al. 
2010). Depending on their levels of divergence from the mitochondrial sequence, they 
can present an informatics challenge for distinguishing binding events to the true 
mitochondrial genome from binding events to NUMTs. For this reason, we aligned reads 
simultaneously against the nuclear and mitochondrial genomes, and retained only reads 
that map uniquely, and with no mismatches, relative to the reference. Although this 
removed some regions of the genome from analysis, we felt it was a necessary to use the 
most stringent set of putative mitochondrial binding events.  
Fortunately, while the human mitochondrial genome contains numerous small 
islands of unmappable sequence, no large completely unmappable segments were present 
(Figure 4.2A). The mouse genome contains a large unmappable stretch between the CO1 
and ND4 genes (Figure 4.2B). The C. elegans mitochondrial genome is almost 
completely uniquely mappable (Figure 4.2C). In contrast, the D. melanogaster genome 
is almost completely unmappable (Figure 4.2D), that some NUMTs were of very high 
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sequence similarity. We therefore excluded fly datasets from further analysis and focused 
on human, mouse and worm data. 
 
Mitochondrial read recovery is proportional to cell type mtDNA copy number 
Mammalian cells typically contain hundreds to thousands of copies of mtDNA, 
with the precise number varying depending on the metabolic needs of the particular cell 
type (Bogenhagen and Clayton 1974, Williams 1986, Satoh and Kuroiwa 1991). This 
variation is relevant to our analysis because the relative read density over the 
mitochondrial genome is expected to scale with the mtDNA:nuclear DNA ratio for a 
given cell. Thus, cell types with very high mtDNA copy number are expected to display 
correspondingly elevated background read density over the mitochondrial genome. 
Several types of ENCODE data provide a rough proxy for the relative mitochondrial 
genome copy number per cell. In particular, the fraction of reads originating from the 
mitochondrial genome in DNase hypersensitivity and ChIP control datasets is expected to 
scale accordingly. We examined the distribution of this fraction in ENCODE and 
mouseENCODE DGF datasets and observed very large differences between different cell 
lines and tissues (Figure 4.3). For example, about half of reads in K562 DGF data 
originated from mitochondria, while the fraction was less than 2% in CD20+ B-cells 
(Figure 4.3A). Notably, these differences are in many cases (though not always) 
consistent with what is known about the cell lines, with certain cancer cell lines (such as 
K562 and A549) and muscle cells (LHCN) showing the largest number of mitochondrial 
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reads, while primary cells with small volumes of cytoplasm such as B-cells showed the 
least. 
Mouse DGF data was available mostly for tissues, and the fraction of 
mitochondrial reads in these was much smaller compared to both the human cell lines and 
the few mouse cell lines assayed (Figure 4.3B). This is consistent with a significant 
proportion of cells in tissues being in a less active metabolic state than cell lines in 
culture. Still, we observed expected differences between tissues. For example, one of the 
tissues that was most enriched for reads mapping to the mitochondrial genome was the 
heart. This cell and tissue-dependent difference was observed in ChIP control datasets as 
well. We observed similarly large differences in ChIP control datasets (Figure 4.3C-D), 
although the absolute number of reads was much lower than it was in DGF data. Again, 
the mouse tissues with the highest number of mitochondrial reads were the more 
metabolically active ones, such as brown adipose tissue, cortex, and heart. 
These large differences in background read coverage between different cells 
lines/tissues have two consequences for the analysis of putative transcription factor 
binding to the mitochondrial genome. First, peak calling algorithms usually used to 
identify transcription factor binding sites from ChIP-seq data may not work equally well 
in different cell lines due to the highly variable background read density. Second, these 
differences render comparing the strength of binding across cell lines difficult. 
To address the technical challenges that the difference in fraction of reads posed, 
we devised a normalization procedure to convert read coverage to signal intensity z-
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scores reflecting how strongly regions of enrichment stand out compared to the average 
background read density along the mitochondrial genome for each dataset. We then used 
the maximum z-scores for each dataset to identify datasets with very strong such 
enrichment, which we then examined manually in detail, as traditional peak-calling 
software does not adapt well to peak calling on the small, read-dense mitochondrial 
genome. 
 
D-Loop ChIP-seq signal is likely artifactual 
The distribution of read density z-scores for transcription factor ChIP-seq and 
control datasets in seven ENCODE human cell lines (GM1278, K562, HepG2, HeLa, H1-
hESC, IMR90 and A549) is shown in Figures 4.4, 4.5 and 4.6. A wide range in the 
values of the maximum z-score is observed, from less than 5, to more than 100. 
Strikingly, most factors exhibit high read density in the NCR. One obvious explanation 
for this observation is that it represents an experimental artifact. This is likely, as the 
NCR contains the D-loop (Sebastian, Faralli et al. 2013), the unique triple-strand 
structure of which could conceivably either cause overrepresentation of DNA fragments 
originating from it in sequencing libraries or it could be non-specifically bound by 
antibodies during the immunoprecipitation process. To distinguish between these 
possibilities, we carried out the same analysis on DNase, FAIRE and MNase data. As 
these assays do not involve an immunoprecipitation step, they are a proper control for 
sequencing artifacts. We did not observe significant localized read enrichment in these 
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datasets (Figure 4.7), suggesting that the observed read enrichment over the D-loop is 
not due to sequencing biases or overrepresentation of D-loop fragments in ChIP libraries. 
Similarly, we did not observe enrichment in the matched sonicated input ChIP-seq 
control datasets. However, a number of mock-immunoprecipitation  [IgG] control 
datasets did exhibit high z-scores (up to >50 in K562 cells) and closely matched the 
signal profile over the D-loop of ChIP-seq datasets (Figure 4.8B). We also examined the 
forward and reverse strand read distribution in the NCR (Figure 4.8). Site-specific 
transcription factor binding events display a characteristic asymmetry in the distribution 
of reads mapping to the forward and reverse strands, with reads on the forward strand 
showing a peak to the left of the binding site and reads on the reverse strand showing a 
peak to the right of it (Figure 4.8C). Such read asymmetry was not observed in the D-
loop region (average profile shown in Figure 4.8A, individual dataset profile shown 
in Figure 4.1). 
These results suggest that while immunoprecipitation is necessary for high 
enrichment over the D-loop, the enrichment might not be mediated by the proteins 
targeted by the primary antibody. This does not explain why a large number of factors 
show little enrichment over the D-loop (Figures 4.4, 4.5 and 4.6) and why some factors 
show enrichment that is much higher than that observed in K562 IgG controls, with z-
scores of up to 300 (compared to a maximum of 50 for the most highly enriched IgG 
controls). Still, given the lack of clear hallmarks of site-specific occupancy, and the IgG 
control results, enrichment over the D-loop has to be provisionally considered to be 
primarily the result of an experimental artifact, even if it cannot be ruled that at least in 
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some cases it is the result of real biochemical association with nuclear transcriptional 
regulators. 
 
Identification of mtDNA peaks in 8 human transcription factors 
In contrast to the widespread, but likely artifactual, read enrichment over the D-
loop, we observed strong enrichment, exhibiting the canonical characteristics of a ChIP-
seq peak over a true transcription factor binding site, in other regions of the human 
mitochondrial genome for eight of the examined transcription factors using a minimum z-
score threshold of 20: CEBPβ, c-Jun, JunD, MafF, MafK, Max, NFE2 and Rfx5. Figures 
4.9 and 4.10 show the forward and reverse strand read distribution for representative 
replicates of each factor in each assayed cell line, as well as the occurrences of the 
corresponding explanatory motifs (identified from the top 500 ChIP-seq peaks in the 
nuclear genome, see Methods for details). The putative binding sites outside of the D-
loop are characterized by an asymmetric forward and reverse strand read distribution, and 
in most cases, the presence of the explanatory motif in a position consistent with binding 
by the factor. We identified multiple binding sites for CEBPβ: a strong site of enrichment 
around the 5′ end of the CYB gene, what seems to be two closely clustered sites in the 
ND4 gene, a weaker site in the ND4L gene, and two other regions of enrichment over 
CO2 and CO1 (Figure 4.9D). A single very strong binding site over the ND3 gene was 
observed for c-Jun, as well as two weaker sites, one coinciding with the ND4 
CEBPβ sites and one near the 5′ end of ATP6 (Figure 4.9B); the strong ND3 site was 
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also observed for JunD in HepG2 cells. Max exhibited two putative binding sites: one in 
the middle of the 16S rRNA gene, containing a cluster of Max motifs, and another one 
around the 5′ end of CO3, which also contains a cluster of Max motifs but is in a region 
of poor mappability. Strikingly, a common and very strong MafK and MafF binding site 
is present near the 3′ end of ND5, though it does not contain the common explanatory 
motif for both factors (Figure 4.10A-B). MafK and MafF act as a complex in conjunction 
with MafG, so colocalization in the ChIP-seq data argues for a true binding event. 
Several putative binding sites were identified for NFE2: one close to the CEBPβ site in 
the 5′end of CYB, one over the tRNA cluster between ND4 and ND5, one in the 5′ end of 
ATP6 and one in the 16S rRNA gene (Figure 4.10C). Finally, two putative binding sites 
are observed for Rfx5, at the 5′ end of ND5 and in the middle of CO2 (Figure 4.10D). 
Intriguingly, these binding events are not always present in all cell lines. For example, 
CEBPβ binding around CYB was absent in K562, A549 and H1-hESC cells, while the 
MafK ND5 binding site was absent in GM18278 and H1-hESC cells, but present in the 
other cell lines for which data is available. 
 
Identification of mtDNA peaks in 3 mouse and 1 C. elegans transcription factor 
The same analysis as described above was carried out for both mouse and C. 
elegans datasets. We saw that three transcription factors (Max, MafK, and USF2) also 
exhibiting strong enrichment elsewhere in the mouse mitochondrial genome (Figure 
4.12). We observe a single MafK binding site, containing the explanatory motif and 
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situated over the tRNA cluster between the ND2 and CO1 genes (Figure 4.12A). Max 
displayed a strong set of binding sites in the ND4 gene, and a weaker binding site near 
the 5' end of ND5; both sites contained the explanatory motif (Figure 4.12B). Finally, a 
single site, also containing the explanatory motif for the factor and situated near the ND5 
Max site, was present in CH12 USF2 datasets (but not in MEL cells) (Figure 4.12C). 
MafK and Max were also assayed in human cells, and, as discussed above, putative 
mitochondrial sites were identified for both, though not at obviously orthologous 
positions in the genome to those found in the mouse data. We also analyzed available 
ChIP-seq data for the mouse orthologs of c-Jun and JunD, which in human cells exhibited 
putative mitochondrial binding sites. In contrast to observation in human, we did not 
detect strong sites for either protein in mouse. 
Most C. elegans ChIP-seq datasets did not show very strong enrichment over the 
mitochondrial genome (Figure 4.13A), with the exception of DPY-27 and W03F9.2. Of 
these, only W03F9.2 exhibited regions of enrichment with the characteristics of 
transcription factor binding sites (Figure 4.13B). However, very little is known about this 
protein and the significance of its binding to the mitochondrial genome is unclear. 
 
Mitochondrial peaks rank in top three peaks in intensity 
The occupancy observations reported above for human and mouse mitochondria 
do not formally rule out the possibility that there are unannotated NUMTs in the genomes 
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of the cell lines in which binding is detected in our analysis and the observed binding is 
in fact nuclear. Such an explanation is superficially likely, given that binding to the 
mitochondrial genome was observed in some cell lines and not in others. However, closer 
examination reveals that this hypothesis would require different NUMTs in different cell 
lines as the cell lines that lack binding are not the same for all factors. For example, MafF 
and MafK binding is very prominent in K562 cells but CEBPβ and c-Jun seem not to 
bind to mtDNA in those cells. While still possible, we consider the independent insertion 
of multiple partial NUMTs in different cell lines to be an unlikely explanation for the 
observed binding patterns. 
Each chromosome in the nuclear genome exists as only two copies in diploid 
cells, as compared to the hundreds of mitochondria, each of which may contain multiple 
copies of the mitochondrial genome (Bogenhagen and Clayton 1974, Williams 1986, 
Satoh and Kuroiwa 1991). Thus, higher read density over mitochondrial transcription 
factor binding sites than over nuclear ones is expected, assuming similar occupancy rates. 
We compared the peak height (in RPM) of the top 10 nuclear peaks (peak calls generated 
by the ENCODE consortium were downloaded from the UCSC Genome Browser) with 
that of the putatively mitochondrial binding sites (Figure 4.14). We found that the 
mitochondrial binding sites are usually the strongest binding sites by a wide margin, or at 
least within the top three of all peaks. For example, while the strongest nuclear MafK 
peak in mouse CH12 cells has a peak height of 14.5 RPM, the mitochondrial binding site 
has a peak height of 290 RPM. These observations are difficult to explain as being the 
result of binding to unannotated NUMTs in the nuclear genome, but are entirely 
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consistent with the hypothesis that these factors indeed bind to the large number of copies 
of the mitochondrial genome present in each cell. 
 
No mitochondrial targeting sequence in identified transcription factors 
 Algorithms for prediction of mitochondrial targeting sequences on proteins have 
previously been developed (Claros and Vincens 1996, Emanuelsson, Brunak et al. 2007). 
To test whether these sequences existed in our identified transcription factors, we ran 
TargetP and MitoProt analysis for all known isoforms (Table 1). Unfortunately, no MTS 
was identified in any isoform using a threshold value of 80% probability. However, it is 
not unusual that mitochondrial proteins have no identified MTS. 
Evidence for localization of transcription factors to mitochondria 
If the observed binding sites in ChIP-seq data are the result of actual association 
of nuclear transcription factors with mtDNA, then these transcription factors should 
exhibit mitochondrial localization. We tested this directly by performing 
immunocytochemistry for MafK in HepG2 cells (Figure 4.15).  Strikingly, even though 
we did not find a predicted MTS, we observe clear colocalization of MafK to 
mitochondria in 60% of cells (n = 124). These observations provide independent 
corroboration for the mtDNA binding events identified through ChIP-seq. 
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No robust mitochondrial occupancy in ChIP-seq data for previously reported 
mitochondrially targeted nuclear factors 
We note that none of the factors previously reported to be localized to 
mitochondria and to bind to mtDNA was retrieved by our analysis, even though CREB, 
GR, ERα, IRF3, NFκB, STAT1, STAT5A and STAT3 were assayed by the ENCODE 
Consortium. This failure could be attributed to the use of too stringent a z-score threshold 
when selecting datasets with significant enrichment. We therefore examined available 
ChIP-seq data against these factors more carefully (Figure 4.16, Figure 4.17). We also 
performed the same analysis on published mouse and human p53 ChIP-seq data (Aksoy, 
Chicas et al. 2012, Li, He et al. 2012, Kenzelmann Broz, Spano Mello et al. 2013) 
(Figure 4.18). Again, we did not observe any major sites of enrichment outside of the D-
loop. For these factors, the D-loop region exhibits the same putatively artifactual pattern 
discussed previously. And for STAT3 and p53, even the enrichment over the D-loop was 
low. The one factor for which binding to mtDNA is confirmed by ChIP-seq is MEF2D, 
data for two of the isoforms of which in mouse C2C12 myoblasts was recently published 
(Sebastian, Faralli et al. 2013) (Figure 4.19). It exhibits a very complex binding pattern 
over large portions of the mouse mitochondrial genome, which is not straightforward to 
interpret, but nevertheless a number of locations exhibit strand asymmetry and contain 
the MEF2 sequence recognition motif. Notably, most of these are outside the ND6 gene. 
It is at present not clear how to interpret these discrepancies. It is not surprising 
that some of these factors do not exhibit binding to mtDNA, as they were reported to play 
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a role in mitochondrial biology through mechanisms other than regulating gene 
expression (for example, IRF3 and STAT3). However, this is not the case for all of them. 
One possibility is that many prior studies reporting physical association of transcription 
factors with the D-loop suffered from the same artifactual read enrichment over that 
region that we observe, but this would not have been noticeable using the methods of the 
time. This would not be surprising, as it is only apparent that D-loop enrichment is likely 
to be artifactual when the high spatial resolution of ChIP-seq is combined with the joint 
analysis of input and mock immunoprecipitation controls. However, the mitochondrial 
localization of these factors has been carefully documented in a number of 
cases (Cammarota, Paratcha et al. 1999, Casas, Domenjoud et al. 2000, De Rasmo, 
Signorile et al. 2009). Another possibility is that binding to mtDNA only occurs under 
certain physiological conditions and the factors were assayed using ChIP-seq only in 
cellular states not matching those. Further analysis of ChIP-seq data collected over a wide 
range of conditions should help resolve these issues. 
 
IV. Discussion 
We report here the first large-scale characterization of the association of nuclear 
transcription factors along the entire mitochondrial genome by utilizing the vast ChIP-seq 
data resource made publicly available by the ENCODE and modENCODE consortia. We 
find two classes of signal enrichment events, neither of which is detected in high-
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throughput sequencing datasets that do not involve immunoprecipitation and therefore 
they are not due to sequencing biases. First, the majority of factors for which we detect 
strong read enrichment over the mitochondrial genome display high ChIP-seq signal only 
over the D-loop non-coding region in both human and mouse datasets. However, these 
signals do not have the characteristics of sequence specific occupancy and are present in 
a number of mock-immunoprecipitation control datasets. They are thus best explained as 
experimental artifacts, although it remains possible that they represent real non-canonical 
association with the D-loop for some factors. Second, for a subset of factors, specific 
ChIP-seq peaks are observed outside of the D-loop, and these display the additional 
hallmark characteristics of sequence specific occupancy. 
Nuclear transcription factors previously reported to localize to mitochondria 
either did not exhibit significant enrichment in the available ChIP-seq datasets or, when 
they did, it was over the D-loop region with similar non-specific read distribution shape 
as other factors. In contrast, applying conservative thresholds we found eight human and 
three mouse transcription factors (two in common between the two species) that strongly 
occupy sites outside of the D-loop. They display the strand asymmetry pattern around the 
putative binding site that typifies true nuclear ChIP-seq peaks. Even more convincing is 
the fact that the explanatory motif for the factor is usually found under the observed 
enrichment peaks, further suggesting that they correspond to true in vivo biochemical 
events. 
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There are three main explanations for our observations. First, it is possible that 
despite our considerable bioinformatic precautions the observed binding events are in fact 
nuclear, originating from NUMTs present in the genomes of the cell lines assayed, but 
absent from the reference genome sequence. We believe that this is very unlikely. An 
experimental argument against unknown NUMTs comes from the strength of the ChIP-
seq signal we see in the mitochondrial genome. These signals are much higher than even 
the strongest peaks in the nuclear genome for the same factor in the same dataset. This is 
expected for true mitochondrial genome binding because of the presence of many copies 
of the mitochondrial genome per cell, in contrast to the presence of only two copies of the 
nuclear genome. Second, it is possible that mitochondria are sometimes lysed in vivo, 
with mitochondrial DNA spilling into the cytoplasm where transcription factors could 
then bind. This cannot be ruled out based on the ChIP-seq data alone, but we consider it 
unlikely, as this would need to happen with a sufficient frequency to explain the 
remarkable strength of mitochondrial occupancy sites. The third, and most plausible, 
interpretation is that these nuclear transcription factors indeed translocate to the 
mitochondria and interact with the genome, as has been observed for the D-loop in some 
previous studies for other factors. Indeed, immunocytochemistry experiments in our 
study confirm the presence of MafK in mitochondria in a majority of HepG2 cells. 
Several major questions are raised by our results. First, it is not clear how these 
nuclear transcription factors are targeted to the mitochondria. Mitochondrial proteins are 
typically imported into the mitochondrial matrix through the TIM/TOM protein 
translocator complex, and are targeted to the organelle by a mitochondrial localization 
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sequence, which is cleaved upon import. We scanned both human and mouse versions of 
our factors for mitochondrial target sequences (MTS) with both Mitoprot (Claros and 
Vincens 1996) and TargetP (Emanuelsson, Brunak et al. 2007) (using default settings), 
but we were unable to identify significant matches using either. This seems to be a 
common feature of nuclear transcription factors previously found to localize to 
mitochondria, most of which lack import sequences and are instead imported through 
other means (Casas, Domenjoud et al. 2000, Szczepanek, Chen et al. 2012). 
Posttranslational modifications may be important for import, as has been demonstrated 
for STAT3 in TNF-induced necroptosis (Shulga and Pastorino 2012). 
Second, it is unclear why the same factor binds detectably to the mitochondrial 
genome in some cell types but not in others. It is certainly possible that different splice 
isoforms or post-translationally modified proteins are present in different cell types, with 
only some capable of being imported into mitochondria, or that import into mitochondria 
only happens under certain physiological conditions only met in some cell lines. 
Third, the question of the biochemical reality of transcription factor binding at the 
D-loop remains open. Previous studies understandably focused on the D-loop, given its 
well-appreciated importance in regulating mitochondrial transcription. As a consequence, 
the literature supporting a role for some nuclear factors in mitochondria suggests that 
they do so through binding to the D-loop. Our analysis of ChIP-seq data, which was 
carried out in an agnostic manner, revealed that dozens of transcription factors – many 
more than had been studied locally at the D-loop alone – also show high level of 
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enrichment over the D-loop. However, the observed enrichment has characteristics 
suggesting that these signals are mainly due to experimental artifacts. In support of this 
judgment, the explanatory motifs for most of these factors were generally not found 
under the area of strongest enrichment in the D-loop. Therefore a conservative 
interpretation is that enrichment over the D-loop is an artifact in most cases. 
Finally, and most importantly, the functional significance of factor occupancy 
observed by ChIP-seq remains unknown. It is entirely possible that it represents 
biochemical noise, with transcription factors entering the mitochondria because they have 
the right biochemical properties necessary to be imported, then binding to mtDNA but 
with little functional consequence. Alternatively, nuclear transcription factors may in fact 
be playing a regulatory role in mtDNA. It is difficult to imagine the exact mechanisms 
through which they might be acting, aside from interactions with the regulatory D-loop. 
While we do observe pairs of related factor such as c-Jun and JunD, and MafK and MafF 
binding to the same sites, binding events are overall widely dispersed over the 
mitochondrial genome and are found outside of the known regulatory regions. Plausible 
regulatory relationships are therefore not obvious and our results suggest that biological 
noise should be the working null hypothesis explaining the data. The functional 
regulatory role of these nuclear transcription factors in mitochondria is a very exciting 
possibility but it will have to be demonstrated in subsequent studies. Direct functional 
tests are the golden standard for establishing regulatory relationships, using gain and loss 
of function experiments and genetic manipulation of putative regulatory sites. The latter 
is at present not possible for mitochondria while the former are difficult to interpret in the 
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case of the role of nuclear transcription factors in mitochondrial gene regulation, as it is 
not easy to separate the direct effects of binding to mtDNA from the indirect effects of 
transcriptional changes in the nucleus. Thus, it may be some time before definitive 
answers to these questions are obtained. In the meantime, larger compendia of 
transcription factor ChIP-seq data such as those expected to be generated by the next 
phase of the ENCODE project will be a primary source of further insight by providing 
binding data for additional nuclear transcription factors that will clarify allowed or 
preferred occupancy patterns across the mitochondrial genome. 
This analysis is the large-scale characterization of the association of nuclear 
transcription factors along the entire mitochondrial genome by utilizing the vast ChIP-seq 
data resource made publicly available by the ENCODE and modENCODE consortia. We 
find two classes of signal enrichment events, neither of which is detected in high-
throughput sequencing datasets that do not involve immunoprecipitation, and therefore 
they are not due to sequencing biases. While the majority of factors for which we detect 
strong read enrichment over the mitochondrial genome display high ChIP-seq signal only 
over the D-loop non-coding region in both human and mouse datasets, these signals do 
not have the characteristics of sequence specific occupancy and are present in a number 
of mock-immunoprecipitation control datasets. They are thus best explained as 
experimental artifacts, although it remains possible that they represent real non-canonical 
association with the D-loop for some factors. Second, for a subset of factors, specific 
ChIP-seq peaks are observed outside of the D-loop, and these display the additional 
hallmark characteristics of sequence specific occupancy. 
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Previously identified nuclear transcription factors were not detected in our 
analysis of non-D-loop binding. One possibility for this is that many prior studies 
reporting physical association of transcription factors with the D-loop suffered from the 
same artifactual read enrichment over that region. This would not be surprising, as it is 
only apparent that D-loop enrichment is likely to be artifactual when the high spatial 
resolution of ChIP-seq is combined with the joint analysis of input and mock 
immunoprecipitation controls. However, the mitochondrial localization of these factors 
has been carefully documented in a number of cases (Cammarota, Paratcha et al. 1999, 
Casas, Rochard et al. 1999). The specific binding sites of these transcription factors 
remains to be studied in greater depth. 
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V. Methods 
Except for where indicated otherwise, all analysis was carried out using custom-
written python scripts by Georgi Marinov. 
 
Sequencing read alignment 
Raw sequencing reads were downloaded from the UCSC genome browser for 
ENCODE and mouseENCODE data (Mouse, Stamatoyannopoulos et al. 2012), and from 
ftp://ftp.modencode.org for modENCODE data (data current as of February 2012). ChIP-
seq data for p53 was obtained from GEO series GSE26361 (Li, He et al. 2012), 
GSE46240 (Kenzelmann Broz, Spano Mello et al. 2013) and GSE42728 (Aksoy, Chicas 
et al. 2012). Reads were aligned using Bowtie (Langmead, Trapnell et al. 2009), version 
0.12.7. Human data was mapped against either the female or the male set of human 
chromosomes (excluding the Y chromosome and/or all random chromosomes and 
haplotypes) depending on the sex of the cell line (where the sex was known, otherwise 
the Y chromosome was included), genome version hg19. Mouse data was mapped against 
the mm9 version of the mouse genome. modENCODE D. melanogaster data was mapped 
against the dm3 version of the fly genome. modENCODE data for C. elegans was 
mapped against the ce10 version of the worm genome. Reads were mapped with the 
following settings: “-v 2 -k 2 -m 1 -t --best –strata”, which allow for two mismatches 
relative to the reference, however for all downstream analysis only reads mapping 
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uniquely and with zero mismatches were considered, to eliminate any possible mapping 
artifacts.  
 
Mappability track generation 
Mappability was assessed as follows. Sequences of length N bases were generated 
starting at each position in the mitochondrial genome. The resulting set of “reads” was 
then mapped against the same bowtie index used for mapping real data. Positions covered 
by N reads were considered fully mappable. In this case, N = 36 as this is the read length 
for most of the sequencing data analyzed in this study. 
 
Signal normalization of ChIP-seq data over the mitochondrial genome 
Because the number of mitochondria per cell varies from one cell line/tissue to another, 
direct comparisons between datasets based on the absolute magnitude of the signal in 
RPM are not entirely valid. For this reason, we normalized the signal as follows. For each 
dataset, we fit a Gamma distribution over the RPM coverage scores for the bottom Fb 
percentile of fully mappable position on the mitochondrial chromosome. The estimated 
parameters were then used to rescale the raw signal over all position to a z-score. This 
results in datasets with strong peaks receiving low z-scores over most of the mappable 
mitochondrial genome, and very high z-scores over the regions with highly localized 
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enrichment. We used F=0.8 for our analysis. As this procedure is sensitive to datasets 
with very low total read coverage over the mitochondrial genome, we restricted our 
analysis to datasets with at least 5000 uniquely mappable reads (and with no mismatches 
to the reference), or more than 10x coverage. We used a z-score cutoff of 20 to select 
datasets with high enrichment over the mitochondrial genome, as it was the highest z-
score observed in sonicated input samples. 
 
Motif analysis 
The peak calls for human and mouse ENCODE data available from the USCS 
Genome Browser were used to find de novo motifs for transcription factors from ChIP-
seq data. The sequence around the peak summit (using a 50bp radius) was retrieved for 
the top 500 called peaks for each factor in each cell line and motifs were called using the 
MEME program in the MEME SUITE, version 4.6.1 (Bailey, Boden et al. 2009). The 
MEME-defined position weight matrix was then used to scan the mitochondrial genome 
for motif matches following the approach described in (Mortazavi, Leeper Thompson et 
al. 2006). 
 
 
Cell growth and immunocytochemistry 
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HepG2 cells were grown following the standard ENCODE protocol [DMEM 
media, 4mM L-glutamine, 4.5g/L glucose, without sodium pyruvate, with 10% FBS 
(Invitrogen 10091-148) and penicillin-streptomycin]. Cells were fixed in 10% formalin 
(Sigma-Aldrich HT501128-4L) for 10 min, permeabilized with 0.1% Triton X-100, and 
blocked in 5% FBS. Primary antibodies used were MafK (1:100, Abcam, ab50322) and 
Hsp60 (1:125, Santa Cruz, sc-1052). Secondary antibodies used were donkey anti-goat 
AF488 (Invitrogen A11055) and donkey anti-rabbit AF546 (Invitrogen A10040). 
Imaging on a Zeiss LSM 710 confocal microscope with PlanApochromat 63X/1.4 oil 
objective, and 0.7µm optical sections were acquired. 
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VI. Figure Legends 
Figure 4.1. Representative USCS Genome Browser snapshots of nuclear 
transcription factor ChIP-seq datasets exhibiting strong enrichment in the 
mitochondrial genome. (A) GM12878 GCN5 shows high signal intensity in the D-loop 
(the region between coordinates 16030 and 580, i.e. the non-coding regions on the left 
and right ends of the snapshot) representative of the D-loop enrichment observed for a 
large number of transcription factors (B) In contrast, a large MafK peak is observed in a 
coding region outside of the D-loop in HepG2 cells. Upper track (black) shows reads 
aligning to the forward strand, lower track (gray) shows read aligning to the reverse 
strand. 
 
Figure 4.2. Unique mappability of the mitochondrial genome in ENCODE and 
modENCODE species. (A) human; (B) mouse; (C) C. elegans; (D) D. melanogaster. 
The 36 bp mappability track (see Methods for details) is shown. The annotated protein 
coding and rRNA and tRNA genes are shown in the inner circles as follows: forward-
strand genes are shown as green lines, while reverse-strand genes are shown as red lines, 
with the exception of mouse and human rRNA and tRNAs (blue). The D-loop region in 
human is shown in black. Gene annotations were obtained from ENSEMBL (version 66). 
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Figure 4.3. Variation in mitochondrial DNA copy number in cell lines and tissues. 
The fraction of reads mapping to the mitochondrial genome (chrM) is shown. (A,B) UW 
human (A) and mouse (B) UW ENCODE digital genomic footprinting (DGF) data; (C) 
UW human ChIP input datasets; (D) LICR mouse ChIP input datasets. “UW” and 
“LICR” refers to the ENCODE production groups that generated the data. Inputs from the 
UW and LICR groups were chosen because they are the largest ENCODE sets in terms of 
number of cell lines/tissues assayed by the same production groups, thus avoiding 
possible variation between different laboratories. A general positive correlation between 
the expected metabolic demand of the tissue type and the relative amount of reads 
mapping to chrM is observed. 
 
Figure 4.4. Signal distribution over the mitochondrial genome in human ChIP-seq 
datasets. The maximum z-score for each individual TF ChIP-seq replicate in each cell 
line is shown on the left (factors are sorted by average z-score, with control datasets 
always shown on the bottom in red, below the red horizontal line). The z-score profile 
along the mitochondrial chromosome for the replicate with the highest z-score is shown 
on the right. “SYDH” and “HA” refer to the ENCODE production groups which 
generated the data. Z-scores ≥100 are shown as equal to 100. (A) GM12878 cells; (B) 
K562 cells. 
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Figure 4.5. Signal distribution over the mitochondrial genome in human ChIP-seq 
datasets. The maximum z-score for each individual TF ChIP-seq replicate in each cell 
line is shown on the left (factors are sorted by average z-score, with control datasets 
always shown on the bottom in red, below the red horizontal line). The z-score profile 
along the mitochondrial chromosome for the replicate with the highest z-score is shown 
on the right. “SYDH” and “HA” refer to the ENCODE production groups which 
generated the data. Z-scores ≥100 are shown as equal to 100. (A) HepG2 cells; (B) HeLa 
cells; (C) A549 cells. 
 
Figure 4.6. Signal distribution over the mitochondrial genome in human ChIP-seq 
datasets. The maximum z-score for each individual TF ChIP-seq replicate in each cell 
line is shown on the left (factors are sorted by average z-score, with control datasets 
always shown on the bottom in red, below the red horizontal line). The z-score profile 
along the mitochondrial chromosome for the replicate with the highest z-score is shown 
on the right. “SYDH” and “HA” refer to the ENCODE production groups which 
generated the data. Z-scores ≥100 are shown as equal to 100. (A) H1-hESC cells; (B) 
IMR90. 
 
Figure 4.7. Signal distribution over the mitochondrial genome in human FAIRE-
seq, DNAse-seq and MNAse-seq datasets. Shown is the maximum z-score for each 
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individual replicate for each cell line (left) and the z-score profile along the mitochondrial 
chromosome for the replicate with the highest z-score (right). (A) FAIRE data; (B) 
DNAse data; (C) MNAse data. “UNC”, “UW” and “SYDH” refer to the ENCODE 
production groups which generated the data. Z-scores larger than 100 are shown as 100. 
No read enrichment over the D-loop is observed, suggesting that the D-loop signal found 
in TF ChIP-seq datasets is not due to sequencing biases but is a result of the 
immunoprecipitation process. 
 
Figure 4.8. Combined signal distribution profile for the forward and reverse strand 
in the D-loop region. Shown is the average signal (in RPM) for each strand in human 
ChIP-seq datasets with z-scores ≥20 (A) and human IgG controls (B). Also shown for 
comparison is the plus and minus strand read distribution around nuclear CTCF binding 
sites in H1-hESC cells (C). 
 
Figure 4.9. Human transcription factors with canonical ChIP-seq peaks (displaying 
the typical strand asymmetry in read distribution around the putative binding site) 
outside of the D-loop. Reads mapping to the forward strand are represented in black, 
reads mapping to the reverse strand are represented in yellow. The unique mappability 
track for the mitochondrial genome is shown in red in the outside track (see Methods for 
details). Protein-coding, rRNA and tRNA genes are shown as colored bars. The 
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innermost circle shows the motif occurrences in the mitochondrial genome for each factor 
as black vertical bars. (A) JunD (B) c-Jun; (C) Max; (D) CEBPβ. The reads per million 
(RPM) tracks are shown, scaled to the maximum signal level (for both strands) for each 
dataset.  
 
Figure 4.10. Human transcription factors with canonical ChIP-seq peaks (displaying 
the typical strand asymmetry in read distribution around the putative binding site) 
outside of the D-loop. Reads mapping to the forward strand are represented in black, 
reads mapping to the reverse strand are represented in yellow. The unique mappability 
track for the mitochondrial genome is shown in red in the outside track (see Methods for 
details). Protein-coding, rRNA and tRNA genes are shown as colored bars. The 
innermost circle shows the motif occurrences in the mitochondrial genome for each factor 
as black vertical bars. (A) MafF; (B) MafK (note that MafK has been assayed using two 
different antibodies in HepG2, both of which are shown); (C) NFE2; (D) Rfx5. The reads 
per million (RPM) tracks are shown, scaled to the maximum signal level (for both 
strands) for each dataset.  
 
Figure 4.11. Signal distribution over the mitochondrial genome in mouse ChIP-seq 
datasets. Shown is the maximum z-score for each individual replicate for each cell line 
(left) and the z-score profile along the mitochondrial chromosome for the replicate with 
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the highest z-score (right). Control datasets are shown in red on the bottom, below the red 
horizontal line. (A) CH12 cells; (B) MEL cells. 
 
Figure 4.12. Mouse transcription factors with canonical ChIP-seq peaks (displaying 
the typical strand asymmetry in read distribution around the putative binding site) 
outside of the D-loop. Reads mapping to the forward strand are represented in black, 
reads mapping to the reverse strand are represented in yellow. The unique mappability 
track for the mitochondrial genome is shown in red in the outside track (see Methods for 
details). Protein-coding, rRNA and tRNA genes are shown as colored bars. The 
innermost circle shows the motif occurrences in the mitochondrial genome for each factor 
as black vertical bars. (A) MafK (note that the putative binding site is found in a region 
that is not completely mappable, thus the read profiles loses the canonical shape but the 
strand asymmetry is nevertheless apparent and a motif is present); (B) Max; (C) USF2. 
The reads per million (RPM) tracks are shown, scaled to the maximum signal level (for 
both strands) for each dataset.  
 
Figure 4.13. Signal distribution over the mitochondrial genome in C.elegans ChIP-
seq datasets. (A) Shown is the maximum z-score for each individual replicate for each 
cell line (left) and the z-score profile along the mitochondrial chromosome for the 
replicate with the highest z-score (right). Control datasets are shown in red on the bottom, 
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below the red horizontal line; (B) Forward and reverse strand read distribution over the 
C.elegans mitochondrial genome for W03F9.2 (“Young Adult” stage). Reads mapping to 
the forward strand are represented in black, reads mapping to the reverse strand are 
represented in yellow. The unique mappability track for the mitochondrial genome is 
shown in red in the outside track (see Methods for details).  
 
Figure 4.14. Mitochondrial ChIP-seq peaks are generally significantly stronger than 
nuclear peaks. Shown is the maximum signal (in RPM) for the top 10 nuclear peaks 
(“N”, smaller black dots), and the maximum signal intensity (also in RPM) in the 
mitochondrial genome (“M”, larger red dot) for representative ChIP-seq datasets for each 
factor. (A) Mouse datasets (B) Human datasets. 
 
Figure 4.15. Localization of MafK to the mitochondria. (A) Immunocytochemistry 
showing MafK localization in HepG2 cells. Mitochondria were identified by HSP60 
staining. Shown are two representative images of cells showing that MAFK localizes 
strongly to the nucleus and mitochondria, and exhibits diffuse staining in the cytoplasm. 
In 60% of cells (C), there is colocalization of HSP60 with MAFK staining at an intensity 
higher than that of the surrounding cytoplasm. (B) An example of a cell exhibiting only 
nuclear and cytoplasmic MAFK localization. 
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Figure 4.16. Distribution of reads over the human mitochondrial genome for factors 
previously reported to bind to mitochondria in ENCODE ChIP-seq data. Reads 
mapping to the forward strand are represented in black, reads mapping to the reverse 
strand are represented in yellow. The unique mappability track for the mitochondrial 
genome is shown in red in the outside track (see Methods for details). Protein-coding, 
rRNA and tRNA genes are shown as colored bars. The innermost circle shows the motif 
occurrences in the mitochondrial genome for each factor as black vertical bars. (A) 
CREB; (B) STAT3; (C) GR in A549 cells treated with different concentrations of 
dexamethasone (Dex) (Reddy, Pauli et al. 2009, Reddy, Gertz et al. 2012); (D) ERα in 
untreated (DMSO) ECC1 cells and ECC1 cells treated with bisphenol A (BPA), genistein 
(Gen) or 17β-estradiol (E2) (Gertz, Reddy et al. 2012); (E) IRF3; (F) NFκB in GM12878 
cells treated with TNFα (Kasowski, Grubert et al. 2010). The reads per million (RPM) 
tracks are shown, scaled to the maximum signal level (for both strands) for each dataset.  
 
Figure 4.17. Distribution of reads over the human and mouse mitochondrial genome 
for p53 in publicly available ChIP-seq datasets. Reads mapping to the forward strand 
are represented in black, reads mapping to the reverse strand are represented in yellow. 
The unique mappability track for the mitochondrial genome is shown in red in the outside 
track. Protein-coding, rRNA and tRNA genes are shown as colored bars. The innermost 
circle shows the motif occurrences in the mitochondrial genome for each factor as black 
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vertical bars. (A) p53 in mouse embryionic fibroblasts (MEFs), data from (Kenzelmann 
Broz, Spano Mello et al. 2013), GSE46240. (B) p53 in mouse embryonic stem cells 
(mESC), data from (Li, He et al. 2012), GSE26361; (C) p53 in human IMR90 cells, data 
from (Aksoy, Chicas et al. 2012), GSE42728. The reads per million (RPM) tracks are 
shown, scaled to the maximum signal level (for both strands) for each dataset.  
 
Figure 4.18. Distribution of reads over the mouse mitochondrial genome for MEF2D 
isoforms MEF2Da1 and MEF2Da2 in C2C12 myoblasts. Reads mapping to the 
forward strand are represented in black, reads mapping to the reverse strand are 
represented in yellow. The unique mappability track for the mitochondrial genome is 
shown in red in the outside track (see Methods for details). Protein-coding, rRNA and 
tRNA genes are shown as colored bars. The innermost circle shows the MEF2D motif 
occurrences in the mitochondrial genome as black vertical bars. Data was obtained from 
(Sebastian, Faralli et al. 2013), GSE43223.  
 
Figure 4.19. Distribution of reads over the human mitochondrial genome for STAT1 
and STAT5A in ENCODE ChIP-seq data. Reads mapping to the forward strand are 
represented in black, reads mapping to the reverse strand are represented in yellow. The 
unique mappability track for the mitochondrial genome is shown in red in the outside 
track (see Methods for details). Protein-coding rRNA and tRNA genes are shown as 
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colored bars. The innermost circle shows the motif occurrences in the mitochondrial 
genome for each factor as black vertical bars. (A) STAT1; (B) STAT5A; the RPM tracks 
are shown, scaled to the maximum signal level (for both strands) for each dataset.  
 
Table 4.1. No mitochondrial targeting sites are predicted in positive mouse and 
human TFs. Analysis of all variants of the eight human transcription factors and three 
mouse transcription factors resulted in generally low predicted MTS values by TargetP 
and MitoProt. No predicted probability exceeded the threshold of 0.80. Criteria for 
TargetP: non-plant organism, no cutoffs. 
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VII. Figures 
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Figure 4.2. 
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Figure 4.3. 
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Figure 4.4.  
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Figure 4.5. 
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Figure 4.6. 
 
	   	   	   190	  
 
Figure 4.7. 
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Figure 4.8. 
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Figure 4.9. 
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Figure 4.10. 
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Figure 4.11. 
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Figure 4.12. 
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Figure 4.13. 
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Figure 4.14. 
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Figure 4.15. 
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Figure 4.16. 
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Figure 4.17. 
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Figure 4.18. 
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Figure 4.19. 
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Table 4.1. 
Gene Variant TargetP Probability MitoProt Probability 
Human 
CEBPb  0.091 0.0413 
c-Jun  0.056 0.1973 
JunD  0.147 0.0258 
MafK  0.108 0.0167 
MafF 
1 0.112 0.0574 
2 0.112 0.0574 
3 0.112 0.0574 
4 0.112 0.0574 
5 0.635 0.1132 
Max 
1 0.066 0.0041 
2 0.064 0.0112 
3 0.064 0.0019 
4 0.055 0.0017 
5 0.068 0.0044 
6 0.057 0.0088 
7 0.071 0.0251 
NFE2 1/2/3 0.282 0.1996 
RFX5 
1 0.092 0.0185 
2 0.092 0.0185 
Mouse 
MafK  0.108 0.0124 
MAX  0.064 0.0167 
USF2 
1 0.059 0.0484 
2 0.056 0.0563 
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C h a p t e r  5  
FUTURE DIRECTIONS 
 Maintenance of mtDNA stability is required for cellular and organismal viability; 
mutations in the genome lead to cellular respiratory defects, resulting in neuromuscular 
impairment, movement disorders, myopathy, and eye disorders (Zeviani and Di Donato 
2004). Furthermore, loss of mtDNA is known to cause Alpers’ Disease, ataxia 
neuropathy spectrum, progressive external ophthalmoplegia, and mitochondrial depletion 
syndrome (Suomalainen and Isohanni 2010, Stumpf, Saneto et al. 2013). mtDNA 
instability has also been implicated in cardiovascular disease (Sugiyama, Hattori et al. 
1991, Ide, Tsutsui et al. 2001, Karamanlidis, Nascimben et al. 2010, Karamanlidis, 
Bautista-Hernandez et al. 2011), diabetes (Maassen, LM et al. 2004, Simmons, 
Suponitsky-Kroyter et al. 2005, Gauthier, Wiederkehr et al. 2009), neurodegenerative 
disorders such as Alzheimer’s (Coskun, Beal et al. 2004, Coskun, Wyrembak et al. 2012, 
Rice, Keeney et al. 2014), and aging (Corral-Debrinski, Shoffner et al. 1992, Trifunovic 
and Larsson 2008). Therefore, it is essential to understand the mechanisms of mtDNA 
maintenance. 
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Mitochondrial Dynamics and mtDNA Copy Number  
 Work in our lab (Chen, Vermulst et al. 2010) has demonstrated that loss of 
mitochondrial fusion leads to not only loss of mtDNA copy number, but also of its 
integrity, with mutations and deletions accumulating in affected skeletal muscle. A recent 
study has tied the mitochondrial fission protein Drp1 to nucleoid morphology, where 
knockdown causes aggregation and misdistribution of the nucleoids (Ban-Ishihara, 
Ishihara et al. 2013). Although mtDNA copy number does not change, it is unclear if the 
incomplete loss of fission seen here is the reason for this. However, it is evident that 
mitochondrial fission and fusion proteins play an important role in the regulation of the 
genome. Further understanding of the pathways initiated when fusion and fission are 
abrogated will provide necessary insight into understanding how control of mtDNA 
maintenance is tied into the proteins regulating fusion and fission. One amenable 
approach is through proteomics analysis of cells with deleted fusion proteins via SILAC 
analysis, and comparison of the labeled mitochondrial proteome to that found in wildtype 
counterparts. The technique has previously been utilized effectively by our own lab 
(Chan, Salazar et al. 2011) to characterize changes in mitochondrial protein content upon 
CCCP treatment. If significant differential import or export of protein levels exists, 
SILAC will be able to detect this. An alternative, and perhaps more directed, method of 
identifying changes in the proteome specifically at the nucleoid, possibly with greater 
sensitivity given the lower number of targets, would be an approach analogous to that 
described by Bogenhagen et al., who have used both immunoaffinity purification using 
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anti-TFAM and anti-mtSSB antibodies, as well as purification of formaldehyde-
crosslinked nucleoids exposed to harsh ionic detergents to decrease nonspecific binding 
in order to selectively isolate mtDNA-associated proteins for identification (Wang and 
Bogenhagen 2006, Bogenhagen, Rousseau et al. 2008). Proteins within the nucleoids 
isolated by either means can then be sequenced for identification. Although this method 
is more specific to the proteins directly involved with the nucleoid, it is certainly less 
quantitative and does not allow for accurate elucidation of changes in protein levels 
within the nucleoid. Furthermore, it is more susceptible to experimental variation; 
because of the need to compare two independent samples, this method requires additional 
attention to consistency of procedure. A comparison between wild-type and knockout 
cells is not ideal due to potential proteasomal differences between cell lines, and an RNAi 
– based assay would be more preferable in order to abrogate inter-cell line variability, 
and also allow for a time-course study to follow changes in the mitochondrial proteome 
as fusion proteins are depleted. Unfortunately, because levels of the fusion proteins must 
be extremely low before defects are seen, a knockdown-based model could be difficult to 
attain.  
 SILAC analysis of fusion protein-deficient cells, especially if performed as a time 
course after successful RNAi knockdown, could prove extremely informative in itself to 
understand how loss of fusion shifts protein levels. However, another potential result of 
these studies is the identification of novel proteins associated with the nucleoid, imported 
into the mitochondria, or absent from each upon fusion protein depletion that could then 
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be further characterized. Immunocytochemical analysis could confirm such proteomic 
results via localization studies, and subcellular fractionation followed by western blotting 
could confirm differential levels of each target within the mitochondria. Furthermore, 
because it is thought that some level of defect in fusion-deficient cells could be due to 
loss of distribution of mitochondrial contents and thus inter-mitochondrial protein 
heterogeneity (Chen, Vermulst et al. 2010), immunocytochemical analysis should be able 
to determine the level of this heterogeneity for each target. Finally, over-expression and 
knockdown studies of the target followed by rt-qPCR, qPCR, or western blotting could 
then elucidate the effect of the target on transcription, replication, or translation of 
mtDNA products. 
 
Dynamics of the Mitochondrial Nucleoid 
 The mitochondrial nucleoid is normally composed of many proteins (Wang and 
Bogenhagen 2006, Bogenhagen, Rousseau et al. 2008). Of those, the transcriptional and 
replication machineries are perhaps best characterized (Falkenberg, Gaspari et al. 2002, 
Korhonen, Pham et al. 2004, Falkenberg, Larsson et al. 2007). We focused our analysis 
on TFAM, which is essential for mtDNA copy number maintenance. Our ChIP-seq data 
reveals the nonspecific binding nature of TFAM across the genome under resting 
conditions in HeLa cells, as well as a specific binding site upstream of the origin of light 
strand replication, previously unidentified in human mtDNA. Strikingly, we did not 
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observe increased read intensity in the known binding sites in LSP and HSP. These 
unexpected observations call for a revision of the known model of TFAM; under these 
cellular conditions, TFAM does appear not bind to its sites of transcriptional activation, 
or if it does, that it is a transient or low-probability event. Furthermore, a novel site with 
higher TFAM occupancy has been identified, one whose function is thus far unknown. 
Currently, TFAM is tied to replication of the genome through the requirement for an 
RNA primer for initiation (Lee and Clayton 1998). Due to its proximity to the origin of 
light strand replication, it can be postulated that this specific binding locus may play a 
direct role in replication. Further analysis of this site will be required to understand its 
significance. Specifically, biochemical assays may be performed to understand the 
function of TFAM binding to this site. FRET and SPR studies could be performed to 
understand the binding affinity and level of DNA bending by TFAM at this locus as 
compared to that for nonspecific sequences. Replication run-off assays may also be 
utilized to understand the role of TFAM in replication at this locus, although 
interpretation of results from such an experiment could be difficult due to the role of 
TFAM in transcription in facilitating the RNA primers required for replication, and the 
dependence of initiation of light strand replication on heavy strand synthesis (Holt and 
Reyes 2012). There are widely used cell-free replication assays utilizing cell lysate that 
appear to work for the mitochondrial system (Jui and Wong 1991, Rizwani and 
Chellappan 2009, Svitin and Chesnokov 2010), and which could be leveraged to study 
the effect of TFAM in the context of a relatively complete cellular system. Because 
TFAM knockout cells are not viable, wild-type lysate cannot be compared to that of a 
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knockout for replication activity. Instead, TFAM from wild-type mitochondrial lysate 
could be removed via immunoaffinity pull-down. Because it has been shown that 
POLRMT is sufficient for RNA primer formation at OL (Wanrooij, Fuste et al. 2008), 
POLRMT would also need to be removed from the lysate and the lagging strand primer 
added to drive continued replication. Levels of replication, as measured by qPCR, in the 
absence of POLMRT, presence of the RNA primer, and presence or absence of TFAM 
should inform whether TFAM has a direct effect on replication from OL. 
Mitochondrial in vitro replication assays have also previously been utilized to 
characterize the minimum replisome (Wong and Clayton 1985, Korhonen, Pham et al. 
2004), and could also be used to understand the role of TFAM at the OL. Testing the role 
of TFAM in transcription at the OL locus could be performed using well-known in vitro 
transcription assays. Decoupling TFAM’s potential role in direct modulation of 
replication from its role in transcription of the primer may then be performed in an 
experiment where the RNA primer is provided along with the minimum replisome and 
the presence or absence of TFAM, similarly to the experiments using cell lysate. While 
the true in vitro replication system may yield “cleaner” experimental data, lack of other 
components of the mitochondrial proteome could preclude potential protein-protein 
interactions necessary for direct modulation of replication by TFAM. Thus, lack of effect 
in the in vitro system will not rule out the possibility that TFAM modulates replication 
through protein adapters. 
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 Although we have identified a cell state where TFAM binds across the entire 
mitochondrial genome (Wang, Marinov et al. 2013), it is possible that under different 
conditions, the nucleoid could undergo remodeling, with differential TFAM binding 
patterns. Indeed, such remodeling is observed with the yeast homolog, Abf2p (Kucej, 
Kucejova et al. 2008), under different metabolic conditions. Given the homologous 
systems, it is reasonable to postulate that similar remodeling would occur if human cells 
were placed under different metabolic conditions. This could be tested via growth of cells 
in galactose-containing media as opposed to glucose-containing media, which drives cells 
towards reliance on oxidative phosphorylation because no net ATP is created when 
pyruvate is produced via glycolytic metabolism of galactose (Reitzer, Wice et al. 1979, 
Robinson, Petrova-Benedict et al. 1992, Marroquin, Hynes et al. 2007). Another state in 
which mtDNA-TFAM interactions could be altered is when active transcription and 
replication are occurring. While these activities generally occur continuously throughout 
the cell cycle (Bogenhagen and Clayton 1977, Magnusson, Orth et al. 2003) with some 
variation from nucleoid to nucleoid (Wai, Teoli et al. 2008), general upregulation of 
replication may be achieved by first depleting mtDNA and then allowing for recovery, 
presumably driving the mtDNA population towards a more uniform, actively replicative 
state. Such experiments were attempted in our lab using EtBr, which is well-established 
to cause mtDNA depletion (King and Attardi 1996), followed by recovery during which 
TFAM levels recover more slowly than mtDNA levels (Seidel-Rogol and Shadel 2002), 
implying differential binding characteristics. Treatment of HeLa cells resulted in rapid 
mtDNA and TFAM depletion and striking changes in nucleoid morphology, with 
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nucleoids consolidating into extremely large super-nucleoids, suggesting differential 
nucleoid structure. However, evidence that TFAM-DNA interactions were modified 
during the recovery phase were inconsistent, with some experiments showed a strong, 
highly specific binding of TFAM at distinct loci, and others demonstrated nonspecific 
binding across the entire genome as seen under normal conditions. It is possible that the 
state of TFAM-DNA interactions is highly sensitive to cellular growth conditions and is 
highly transient, thus rendering capture of any differential state more difficult. Further 
ChIP-seq studies will need to be performed to fully elucidate the dynamics of binding 
under highly replicative conditions. 
 It has recently been shown that TFAM may bind differentially in aged rat frontal 
cortex, soleus muscle, and liver as compared to young and calorie-restricted aged rats 
(Picca, Fracasso et al. 2013, Picca, Pesce et al. 2013, Picca, Pesce et al. 2014) via analysis 
of 5 specific regions of the genome. However, the far more powerful tool is our ChIP-seq 
analysis, which allows for much greater resolution across the entire genome, and such an 
experiment could readily be performed using rat tissue samples. Interestingly, Picca et al. 
assayed an area proximal to the OL and found decreased occupancy in cortex but 
increased occupancy in the soleus and liver in aged rats. Relative amounts of TFAM were 
increased, in contrast to the decreased TFAM amounts in soleus and liver. Thus, it 
appears that there is some dynamics of binding at OL as well as elsewhere in the genome 
that could be further characterized with ChIP-seq analysis. In addition, similar ChIP-seq 
experiments may be performed to understand differential TFAM binding in other 
	  	  	   	   	   	  	  	  	  	  	  	  	  228	  
pathologies where mtDNA instability has been implicated previously, such as 
mammalian models of cardiovascular disease, diabetes, and Alzheimer’s disease. 
Although TFAM has not been directly implicated in causing any of these pathologies, 
that TFAM is capable of rescuing phenotypic defects upon overexpression suggests that 
mis-regulation of TFAM could be a phenotype of the diseases. 
 Beyond the current TFAM ChIP-seq analysis, it is evident that such experiments 
will be an important tool for understanding how other proteins interact with the 
mitochondrial genome. ChIP-seq analysis such as that described in Chapter 2 could be 
utilized for many of the core components of the nucleoid in order to better understand 
binding patterns during many cell states. Key targets of interest include: Opa1, for which 
there is some evidence that it acts as an anchor for the mitochondrial nucleoid to the inner 
mitochondrial membrane (Elachouri, Vidoni et al. 2011); ATAD3, which has been 
implicated in regulation of nucleoid morphology and may bind to the D-loop (He, Mao et 
al. 2007); the prohibitins, which have also been implicated in nucleoid morphology and 
genome stabilization (Merkwirth, Martinelli et al. 2012); the Lon protease, which is 
known to bind to the D-loop, hypothetically to remain close to TFAM to effect rapid 
degradation as needed (Liu, Lu et al. 2004, Lu, Yadav et al. 2007); mTERF1, to extend 
our current understanding of transcriptional termination beyond its already-known site of 
high occupancy (Kruse, Narasimhan et al. 1989) toward additional sites (Hyvarinen, 
Pohjoismaki et al. 2007); mTERF2 and mTERF3, which have been shown to bind to the 
D-loop and appear to modulate transcription  (Wenz, Luca et al. 2009); TFB1M, TFB2M, 
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RNA polymerase, Twinkle, and DNA polymerase, in order to understand potentially 
novel start sites as well as pause sites across the genome to better understand the 
dynamics of transcription and replication. While there are other core nucleoid proteins 
that may also be of interest (Bogenhagen, Rousseau et al. 2008), ChIP-seq data for 
binding by these targets is likely to lead to better understanding of the regulation of the 
genome, supplementing existing biochemical characterization studies. 
Finally, there is some evidence for localization of classically nuclear transcription 
factors to mitochondria and associating with mtDNA (Leigh-Brown, Enriquez et al. 
2010). We identified both human and mouse transcription factors exhibiting canonical 
ChIP-seq peaks. None of these peaks had previously been identified as areas of protein 
localization by the transcriptional machinery; however, further ChIP-seq analysis of the 
transcriptional machinery, as mentioned above, could aid in determining the underlying 
rationale for the noncanonical localization of these TFs outside of the NCR. The main 
mitochondrial transcripts were first identified using guanylyltransferase capping followed 
by S1 nuclease protection experiments, identifying the 3 main transcripts from LSP, 
HSP1, and HSP2. However, it is possible that lower-abundance transcripts exist, not 
captured by these methods. Due to the polycistronic nature of the mitochondrial 
transcripts, identification of true transcription initiation from sequencing methods can be 
difficult (Ojala, Montoya et al. 1981, Temperley, Wydro et al. 2010). Previous 
experiments have relied on pulse-chase labeling of nascent RNA transcripts (Cantatore 
and Attardi 1980), and could potentially be utilized for identification of the potential 
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lower-occurrence sites of transcriptional initiation. Such identification of novel origins of 
transcription by nascent transcript characterization, in conjunction with analysis of 
existing knowledge of the transcriptome and novel pause sites for POLRMT through 
ChIP-seq, could aid in identifying novel transcriptional start sites or stop sites coinciding 
with the non-D-loop binding sites of the identified nuclear transcription factors, 
forwarding understanding of their function. 
Interestingly, several of the nuclear transcription factors we identified as binding 
to mtDNA have been previously identified as affecting mitochondrial function. It is well-
known that MafF and MafK, part of the Maf family of proteins, effect function as a 
heterodimer with NRF-2 (Dhakshinamoorthy and Jaiswal 2000), a transcription factor 
which is a key activator of the oxidative stress response and modulates expression of 
cytochrome oxidase (Igarashi, Kataoka et al. 1994, Itoh, Chiba et al. 1997). Indeed, an 
NRF-2 consensus sequence has been identified in the promoters of TFAM, TBFIM, and 
TBFIIM (Rantanen, Jansson et al. 2001, Falkenberg, Gaspari et al. 2002, McCulloch, 
Seidel-Rogol et al. 2002). The proteins are somewhat redundant, leading to only a minor 
defect when a single gene is knocked out, with a moderate neurological defect in MafG 
knockout mice, perhaps due to its more ubiquitous expression pattern. Strikingly, a 
MafK/MafG double knockout displays severe motor ataxia and spastic hind legs (Kotkow 
and Orkin 1996, Shavit, Motohashi et al. 1998, Onodera, Shavit et al. 1999, Onodera, 
Shavit et al. 2000), while the triple knockout is embryonic lethal (Yamazaki, Katsuoka et 
al. 2012). Although the neurological defects have been currently attributed to reduction in 
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glycine receptor A1 expression, it is possible that the role of Maf proteins modulating 
mitochondrial function may also play a role, whether it be nuclear- or mitochondrial- 
genome driven. Interestingly, NFE2, also identified in our analysis, is a CNC family 
protein as well, forming a dimer with MafF to effect transcriptional regulation in 
erythrocytes (Blank, Kim et al. 1997). However, loss of NFE2 leads only to a mild 
erythropoietic effect, unsurprising given that its expression is limited to erythrocytes, and 
no mitochondrial-related phenotype is known (Shivdasani and Orkin 1995).  
Two other nuclear transcription factors identified, c-Jun and JunD, are members 
of the JUN family of proteins and are components of the AP1 transcription factor 
(Mechta-Grigoriou, Gerald et al. 2001).  Both of these transcription factors have been 
shown to dimerize with NRF-1 and NRF-2, driving induction of response to antioxidants 
and xenobiotics (Novotny, Prieschl et al. 1998, Venugopal and Jaiswal 1998). NRF-1 has 
been linked to expression of genes in all five subunits of the respiratory complexes 
(Virbasius, Virbasius et al. 1993, Tiranti, Rossi et al. 1995, Scarpulla 2002, Scarpulla 
2002, Kelly and Scarpulla 2004), and also drives expression of TFAM, TFBIM, and 
TFB2M (Virbasius and Scarpulla 1994, Gleyzer, Vercauteren et al. 2005). Furthermore, 
AP-1, a Jun/Fos protein family complex, has been shown to translocate to mitochondria 
and bind to mtDNA (Ogita, Okuda et al. 2002, Ogita, Fujinami et al. 2003). c-Jun-lacking 
mice are embryonic lethal due to hematopoietic and hepatic apoptosis that does not 
appear to be related to hepatopathies seen in some patients with mitochondrial disease 
(Eferl, Sibilia et al. 1999).  Interestingly, a JunD-/- mouse exhibits accelerated aging-
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induced endothelial dysfunction, increased mitochondrial superoxide formation, 
increased mtDNA fragmentation, and swelling of the mitochondria (Paneni, Osto et al. 
2013). Although these phenotypic effects could be due to nuclear effect alone, it is clear 
that c-Jun and JunD function in mitochondrial maintenance. 
CEBPβ, a bZIP transcription factor, has been implicated in increasing 
mitochondrial biogenesis and expression of ETC components through elevated 
expression of the G protein α subunit in white adipose tissue of mice where CEBPα has 
been replaced by CEBPβ (Chiu, Lin et al. 2004). Interestingly, expression of Complex I, 
II, COX3, and NDUFS3 proteins was elevated in a CEBPβ knockout mouse (Rahman, 
Choudhury et al. 2013). While expression levels of the individual components of 
Complexes I and II, which contain mitochondrially encoded proteins, was not probed, 
COX3 expression levels were elevated in the knockout mouse. Because COX3 is 
mitochondrially encoded, this implies that CEBPβ knockout has an effect on transcription 
from the mitochondrial genome. 
There is limited evidence for regulation of mitochondrial function by the other 
identified nuclear transcription factors. Max is required for almost all functions of Myc 
family proteins and is a member of the E2F6 complex, which is involved in gene 
repression via histone modification. A Max-/- knockout mouse exhibits embryonic 
lethality due to general developmental arrest (Shen-Li, O'Hagan et al. 2000). USF2, also 
a Myc family protein, has been linked to glucose-mediated induction of hepatic gene 
expression. Although USF2 has been implicated in transcription of some mitochondrial 
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genes (Breen and Jordan 1999), no mitochondrial defect has been identified in USF2 
knockout mice, where the main defects are in altered kinetics of glucose response upon 
administration of a high carbohydrate diet and iron accumulation due to hepcidin 
deficiency (Vallet, Henrion et al. 1997, Nicolas, Bennoun et al. 2001). Finally, RFX5, a 
subunit of the RFX complex, has largely been implicated in regulation of the MHC class 
II molecules (Clausen, Waldburger et al. 1998, Gobin, Peijnenburg et al. 1998). Of all the 
nuclear transcription factors identified to have mitochondrial binding sites, none have 
been implicated in human diseases with phenotypes similar to that of mitochondrial 
diseases. 
 Several of the identified nuclear transcription factors have been identified as 
modulating mitochondrial gene expression from at least the nuclear genome. 
Interestingly, CEBPβ has been shown to regulate levels of COX3 transcripts, which 
originate from the mitochondrial genome. However, it is not clear whether these 
transcription factors act directly on mtDNA, and can only be decoupled from the nuclear 
effects through further biochemical characterization Although we were able to 
demonstrate mitochondrial localization of MafK to mitochondria using 
immunofluorescence, the other transcription factors we also identified in our analysis also 
require evidence of mitochondrial localization. Of note, we were able to localize c-Jun to 
mitochondria, but significant background fluorescence of the antibody used prevented 
inclusion of the results in our publication. Other methods of demonstrating localization to 
mitochondria have also previously included subcellular fractionation followed by 
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Western blot (Cammarota, Paratcha et al. 1999, Milanesi, Vasconsuelo et al. 2009), 
immunoelectron microscopy (Cammarota, Paratcha et al. 1999), and evidence for import 
of radiolabeled protein into the mitochondria (Casas, Rochard et al. 1999). And, of course 
– the mitochondrial effect of the transcription factors must be separated from the nuclear. 
This has previously been shown by observation of isolated mitochondria when exposed to 
the ligand which activates the TF in question (Enriquez, Fernandez-Silva et al. 1999), or 
by  overexpression of mitochondrially-targeted protein (Lee, Kim et al. 2005, Casas, 
Pessemesse et al. 2008) in conjunction with monitoring of mtDNA and nuclear transcript 
levels. The addition of these two pieces of evidence – localization to the mitochondria 
and mtDNA-specific regulation agnostic of the nuclear genome – will confirm the 
identified transcription factors as acting on the mitochondrial genome directly. 
The first utilization of ChIP-seq in the mitochondrial setting has clearly 
demonstrated that it is a powerful tool for visualizing binding of mitochondrial proteins, 
with great potential for use in understanding regulation within the mitochondrial 
nucleoid, especially given the unique size of the mitochondrial genome, which allows for 
coverage many fold above that of similar experiments in the nuclear genome. While the 
experiments detailed here demonstrate the power of the tool, its uses extend beyond 
simply understanding where transcription factors bind and into understanding the 
dynamics of binding. Future studies will surely further our understanding of not only how 
the many components of the nucleoid interact with the genome, but also how the 
dynamics of nucleoid as driven changes in cell state, whether they be metabolic or 
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pathological. Given the importance of mitochondrial function in cellular and organismal 
viability, understanding and optimizing these dynamics of the nucleoid could certainly 
have future therapeutic implications that remain to be explored. 
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